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I 
 
 Abstract 
 
Pharmaceuticals and their metabolites are known to enter the environment from the 
effluent of wastewater treatment plants. From statistical analysis on the usage of 
pharmaceuticals, and their effects on the environment, five pharmaceuticals were 
selected for this study (Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol and Ranitidine). Trace concentrations of pharmaceuticals were 
determined using a sensitive analytical method, comprising solid phase extraction 
(SPE) and liquid chromatography with a mass spectrometry detector (LC-
MS),operating in selected ion monitoring (SIM) mode. It was found that 
Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine were 
detected at the highest levels in the wastewater entering the Sulaibiya WWTP Kuwait, 
with concentrations of up to 58 ng.L
-1
, 1814 ng.L
-1
, 1669 ng.L
-1
, 2086 ng.L
-1
 and 2009 
ng.L
-1
, respectively. High removal efficiencies of these pharmaceuticals were found in 
the Sulaibiya WWTP. One year study was conducted to investigate the occurrence, 
persistence and fate of a range of these pharmaceuticals at different sampling points at 
the Sulaibiya WWTP. The treatment processes consisted of screening, grit removal 
and diffused air activated sludge treatment (primary and secondary treatment), 
followed by microfiltration (MF), reverse osmosis (RO), and chlorine oxidation 
(tertiary treatment). During primary and secondary treatment, Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine were removed 
efficiently with average removals efficiencies of 83.4%, 86.1%, 77.5%, 97.5% and 
77.5%, respectively. The RO system lowered these pharmaceuticals further, giving 
overall removal efficiencies of 97%, 99%, 99%, 100% and 100% for Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine, respectively. All 
selected pharmaceuticals were tested in laboratory scale reactors to assess their 
removal by chlorination and ozonation, and results showed that 10 mg.L
-1 
of chlorine 
removed these pharmaceuticals better than 15 mg.L
-1
 of ozone. 
 
Lab-scale aerobic reactors (2 L), seeded with activated sludge inoculum from the 
Sulaibiya WWTP and fed with different concentrations of pharmaceuticals (0.1, 1 and 
10 mg.L
-1
), spiked individually into a synthetic wastewater showed that the TOC 
could be removed efficiently without inhibition by these pharmaceuticals. 
 
II 
 
The fate of Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol and 
Ranitidine was investigated in a membrane bioreactors (MBR), and a sequencing 
batch reactors (SBR), operating under strictly aerobic, and anoxic/aerobic conditions 
at different concentrations of a pharmaceutical mixture (PM) of the same 
pharmaceuticals (1 µg.L
-1
, 1 mg.L
-1
 and 10 mg.L
-1
). The COD and TOC removal 
efficiency decreased when the PM concentration was increased to 10 mg.L
-1
. The 
removal of Metronidazole and Trimethoprim was moderately effective, and similar in 
all the reactors. Sulphamethoxazole and Paracetamol were removed efficiently, but 
this decreased when the PM was increased to 10 mg.L
-1 
for most of the reactors, 
whilst Ranitidine experienced high removal rates at all concentrations in all the 
reactors.  
Analysis of the microbial diversity in laboratory reactors treating pharmaceuticals 
wastewater showed decreases in microbial community diversity when the PM 
concentration was increased. Pure cultures of bacteria isolated on selected 
pharmaceutical growth media were also detected in the microbial communities of 
reactor sludge by performing polymerase chain reaction–denaturing gradient gel 
electrophoresis (PCR-DGGE). 
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1. Introduction 
 
During the last three decades, traces amount of different pharmaceutical have been 
discovered in the natural environment, primarily through anthropogenic sources 
(Kummerer, 2001; Kummerer, 2009). Pharmaceuticals have been released to the 
environment either as the parent compounds or their metabolites (Ternes et al., 2001; 
Celiz et al., 2009). They affect ecosystems through changes to physical and chemical 
behaviour which can cause a biological effect by interruption of the food chain 
(Halling-Sørensen et al., 1998; Liu et al., 2009). Pharmaceutical wastes eventually 
find their way into the aquatic environment such as rivers, lakes, seas and ground 
water, that may have an adverse effect on human health (Webb et al., 2003; 
Cunningham et al., 2010). Expired pharmaceuticals may transform into toxic 
compounds that may also affect human health. Thus, pharmaceutical wastes disposal 
has become an increasing concern over recent years as it is released into the 
environment following ingestion, subsequent excretion, and transport through the 
wastewater treatment network. Furthermore, the disposal of unused or expired 
pharmaceuticals can also contribute to the problem, because there are few rules for 
their collection disposal and treatment, as the amount of pharmaceutical waste 
disposed in the sewer systems is unknown. Veterinary pharmaceuticals for livestock 
treatment, aquaculture and fisheries are another source of pharmaceutical waste in the 
environment. 
 
Modern wastewater treatment technologies are efficient biological and chemical 
systems for removal of the majority of organic compounds (BOD) and providing 
enhanced nutrient removal, thus preventing de-oxygenation and eutrophication of 
receiving water bodies (Jones et al., 1998; Randall and Sen, 1996; Rogalla et al., 
2006; Sriwiriyarat and Randall, 2005; Tocchi et al., 2012). However these treatment 
systems face a greater modern challenge with the threat of new and persistent 
compounds entering our wastewaters through a number of different sources. Many 
trace compounds, such as pharmaceuticals and endocrine disrupting chemicals 
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(EDCs) are being increasingly used to reduce disease in humans and life stock, but 
their ability to be removed from these systems is poorly understood or optimised 
leading to their discharge into the aquatic environment with potential serious 
consequences on the health of the receiving biota, and further up the food chain 
including humans (Giger et al., 2003; Hirsch et al., 1999; Sacher et al., 2001; Luo et 
al., 2014). 
 
Over the past decade water companies and regulators have grown increasingly 
concerned about reports of high concentrations of pharmaceuticals in wastewater, 
appearing in the aquatic environment, on a large scale, e.g.in streams, rivers, 
groundwater and drinking water (Ayscough et al., 2000; Hilton et al., 2004; Kanda et 
al., 2003; Thompson et al., 2005; Luo et al., 2014) and the potential implications of 
these chemicals. This has led to additional tertiary wastewater treatments, such as 
ozonation, granular activated carbon and chlorine dioxide treatment, designed and 
installed to provide an improved effluent quality free from these emerging 
contaminants. However, these systems come with additional burdens in that they are 
expensive to install and operate reducing the desire to implement these technologies. 
Subsequently, the optimisation of existing primary and secondary treatment 
technologies and assets is preferred to maximize the removal of pharmaceuticals and 
potential EDCs while minimising capital costs or increasing running/energy costs.  
Secondary biological treatment processes have the most potential for optimisation as 
these have previously shown to have the most capacity for pharmaceutical removal 
from previous studies (Boyd et al., 2005; Carballa et al., 2005; Jones et al., 2005; 
Miao et al., 2005; Nakada et al., 2006; Perez et al., 2005; Ternes et al., 2004; 
Verenitch et al., 2006; Verlicchi et al., 2012). 
 
Globally, the number and size of wastewater treatment plants (WWTP) has been 
increasing over the past two decades, and now widely use reverse osmosis (RO) 
technology to produce high quality recycled water (Ng et al., 2008). As the RO water 
production increases, the disposal also increases in the environment. Therefore, it is 
3 
 
essential that the fate of these micropollutants is more fully understood so that human 
health and the environment can be protected. 
 
1.1 Aim and Objectives 
 
The aim of this study was to investigate and detect the fate of five common 
pharmaceutical compounds in a full scale treatment at Sulaibiya wastewater treatment 
plant Kuwait, and to identify and optimise which treatment processes were most 
effective for the removal of pharmaceuticals using laboratory-scale simulations.  
The objectives of the research were: 
1. Develop analytical methods to analyse five selected pharmaceuticals in real and 
synthetic wastewaters at low concentrations. 
2. Evaluate the removal of these pharmaceuticals from the different wastewater 
treatment processes at Sulaibiya WWTP. 
3. Evaluate the capability of natural bacterial strains isolated from the biomass of the 
Sulaibiya WWTP to biodegrade the selected pharmaceutical compounds aerobically 
in laboratory-scale batch reactors. 
4. Carry onto laboratory-scale experiments to evaluate the optimal conditions to 
enhance pharmaceutical degradation processes of full-scale WWTP. 
5.  Evaluate the relative effectiveness of two different designs of bioreactors, the 
sequencing batch reactor (SBR) and the membrane bioreactor (MBR), for 
pharmaceutical degradation efficiency using laboratory-scale reactors. 
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1.2 Thesis plan 
The main aim of this study was to assess the removal of pharmaceuticals in Sulaibiya 
wastewater treatment plant, through investigations into the occurrence and fate of five 
major pharmaceuticals (Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol and Ranitidine). These compounds were selected based on their previous 
detection in wastewater, combined with their anticipated health and environmental 
effects or bioaccumulation potential. The thesis has been divided into the following 
sections: 
Chapter 2: a review of earlier literature exploring pharmaceutical wastes in the 
environment, the quantities of these pharmaceuticals present in the environment, and 
their removal mechanism and removal efficiency.  
Chapter 3: a review the analytical methods used to detect those pharmaceuticals in 
previous research and developing analytical methods. 
Chapter 4: Full details of experimental and analytical methods used in this research. 
Chapter 5: a presentation of all results and discussion of the research under the 
following sections: 
     a. Investigation of the removal efficiency of the target pharmaceuticals during their 
treatment at Sulaibiya WWTP throughout one complete year of operation. 
     b. Evaluation of the removal efficiency of target pharmaceuticals using chemical 
oxidation processes (chlorination and ozonation) in laboratory experiments. 
c. Evaluation of pharmaceutical removal efficiency, and the effect of pharmaceutical 
concentrations, in laboratory-scale stirrer tank bioreactors (CSTR). 
     d. Evaluation of pharmaceutical removal efficiency, and effect of pharmaceutical 
concentrations, in laboratory-scale continuous bioreactors: 
i. Membrane bioreactors (MBR) 
ii. Sequencing batch reactors (SBR)  
e. Investigate changes in the microbial diversity of bacterial populations in the 
biomass of a laboratory-scale bioreactors operating under different pharmaceutical 
loading. 
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2. Literature Review 
 
The presence of trace organic pollutants is of growing environmental concern 
(Halling-Sørensen et al., 1998; Kummerer, 2009). Pharmaceuticals are one such 
pollutant that has received great focus due to increasing use, with many routes to the 
environment, and the ability to treat these pollutants prior to reaching the environment 
is highly variable. These are becoming a major focus for environmental engineers for 
the next century.  
 
2.1 Fate of pharmaceutical wastes in the environment 
 
To date there has been significant research on the detection and fate of different 
pharmaceutical wastes in the environment. The occurrence of pharmaceutical residues 
in the environment are affected by the following main factors, the amount of 
pharmaceuticals and the fate of each compound in both the sewage treatment plants 
and the aquatic environment. The fate of the pharmaceutical waste in the environment 
may be related to the following three factors:  
1- It may ultimately mineralise to carbon dioxide and water. 
2-  It may be retained in the sludge because is lipophilic and not readily 
degradable.  
3- It may metabolise to a more persistent hydrophilic compound and pass 
through the WWTP, then discharge to water bodies and may affect the 
organisms if it is biologically active. 
 
A first report about pharmaceutical in environment was done by Fielding et al. (1981) 
who discovered some pharmaceuticals and related compounds in a river and drinking 
water. Tetracycline and theophylline were the first reported pharmaceuticals in the 
environment; these were antibiotics found in a river in 1983 (Watts et. al, 1983) which 
were used to treat infection in fish farms. Fish farms expose the receiving waters to a 
large proportion of drugs because most of the antibiotics and chemotherapeutics used 
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are not consumed by the fish but fall through the cages and accumulate on the sea bed 
(Jacobsen & Berglind, 1988;  Labella et al., 2013).Then they may affect the aquatic 
organisms on the sea bed, and subsequently bioaccumulate up the food chain. A study 
has shown that 80% of drugs used in a fish farms end up in the environment, and 
found drug concentrations with antibacterial activity in the sediment directly 
underneath the fish farms (Samuelsenet al., 1992; Snow et al., 2013). 
 
Steroids have been discovered in the sewage effluent (Daughton & Ternes, 1999). 
Steroids are a physiologically active compounds such as dietary fat cholesterol, the 
sex hormones estradiol and testosterone and the anti-inflammatory drug 
dexamethasone.17a-ethynylestradiol for example detected in sewage effluent at low 
concentration (< 7 ng l
-1
) (Ternes et al., 2002).In addition, the analgesic drug 
acetaminophen, the stimulant caffeine, and the non-steroidal anti-inflammatory agents 
ibuprofen and aspirin, have been found in municipal wastewater (Metcalfe et al., 
2003; Boyd et al., 2003). The presence of pharmaceuticals in sewage is due to the 
drugs not being completely degraded in the human body and thus excreted from the 
human body either without any change in their chemical structure or transformed into 
more active compounds. It is has been found in European sewage effluents at 
concentrations up to 6 μg.L−1 (Ternes, 1998) and up to 10 μg.L−1 in USA natural 
waters (Kolpin, 2002). Metformin is an oral anti-diabetic drug for the treatment of 
type 2 diabetes. It is the most popular anti-diabetic drug in the world and one of the 
most prescribed drugs in the country overall. It is detected in surface water and 
ground water in the USA at maximum concentration of 0.15 µg.L
-1
 (Kolpin et al., 
2002).  
Although the primary route for pharmaceuticals to enter the environment is through 
excretion and wastewater treatment, there are other routes that could potentially 
contribute significant quantities of pharmaceuticals to the environment. 
The discovery of pharmaceuticals in wastewater is largely due to the excretion of 
pharmaceuticals by the human body into wastewater. However, there is also another 
source of pharmaceutical waste in the environment - disposal in landfill. Holm et al. 
(1995) report finding organic compounds from pharmaceutical industry waste at the 
7 
 
bottom of a landfill; wastes such as sulphonamides, propylphenazone and 5,5-
Diallylbarbituric acid may have entered the surrounding aquifers (Holm et al., 1995). 
 
A study on a landfill in Florida that received wastes between the period 1968 and 
1969 from the naval base hospital, show the presence and persistence of pentobarbital, 
meprobamate and phensuximide in a nearby shallow ground water source (Eckel et 
al., 1993; Karthikeyan & Meyer, 2006). Study in Germany reported that tap water in 
Berlin is contaminated by clofibric acid which is a metabolite of a blood lipid 
regulator in human medical care (Stan et al., 1994). The study shows that all samples 
from tap water, surface water and several rivers in Germany are contaminated by 
clofibric acid in concentrations between 10 and 165 ng.L
-1
.  
 
Other sources of pharmaceuticals are from agricultural sources. Modern intensive 
agriculture for higher productivity has led to widespread use of different 
pharmaceuticals and there applications. This increase in usage has led to 
contamination of the natural environment.  Chlortetracycline used in agricultural 
applications have been detected in soil surrounding these farms, when combined with 
poultry manure, antibiotics resistant bacteria (microorganisms) may develop (Warman 
& Thomas, 1981; Zielezny et al., 2006; Schauss et al., 2009). As a consequence, the 
pharmaceuticals used for animals as growth promoters may affect micro-organisms, 
and it may also be mineralized and reach the groundwater. 
Pharmaceuticals consumption may change depending on the season. During the 
winter season the antibiotics load in the WWTP were twice as high as in the summer 
months, due either to the lower removal efficiency of pharmaceuticals in the WWTP; 
to lower biological activity during transport through the sewage system as being less 
efficient in winter, or because the input in winter is higher (McArdell et al., 2003). 
 
 
 
 
 
8 
 
2.2 Toxicology of pharmaceutical in the environment 
 
The presence of these pharmaceutical in environment is a matter of major concern 
with largely unknown consequences (Daughton, 2005; Kümmerer, 2009). Usually 
concentrations of pharmaceuticals found in the environment are in the levels ng.L
-1
 to 
mg.L
-1
. Toxicology studies report that even at low concentrations may be cause for 
concern in certain tested mixtures (Parrott and Bennie, 2009; Pomati et al., 2006, 
2008). Many antibiotics have been reported to have acute or chronic toxicity to the 
environment and the development of antibiotic resistance in pathogens which show a 
potential danger to human health.  
 
Researchers reported that triclosan effect algal growth and develop bacterial 
resistance, where they observed that photodegradation of triclosan can form dioxin 
by-products which would increase dioxin-like activity (Orvos et al., 2002; Mezcua et 
al., 2004). Roh et al. (2009) speculated that Nitrosomonas europaea inactivation in 
the presence of the antimicrobials was either a result of toxic product formation or the 
antimicrobial effect of triclosan. 
 
Study showed that levofloxacin and clarithromycin have high toxicity to microalgae 
as well as chronic toxicity to crustaceans (Yamashita et al. 2006). In another study, 
sulphamethoxazole hazard quotient, derived from the acute toxicity concentration on 
Daphnia magna and its predicted environment concentration (PEC) was reported to 
be 6.3 µg.L
-1
, which suggests potential environmental concerns (Kim et al. 2007). 
This is in agreement with previous studies, which demonstrated that the 
photodegradation of some pharmaceuticals increases toxicity. Trovo et al. (2009) 
found that sulphamethoxazole irradiation increases Daphnia magna toxicity from 
60% to 100%. 
 
Pharmaceutical mixtures containing carbamazepine, ibuprofen, and clofibric acid 
have toxic effect on algae, which shows a correlation with their Log Dlipw (Cleuvers, 
2003; Caminada et al., 2006; Escher et al., 2005). In a test using membrane vesicles 
isolated from a photosynthetic bacterium, Rhodobacter sphaeroides, seven 
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pharmaceutical (i.e. clofibrate, acetaminophen, propranolol, diazepam, diclofenac, 
ethinyletradiol and ibuprofen) clearly exhibited baseline toxicity (Escher et al., 2002). 
 
Furthermore, researchers found that Ranitidine and Lincomycin inhibited the 
ammonia degradation up to 78% in activated sludge wastewater lab-scale sequencing 
batch reactor (Carucci et al., 2006). Also naproxen mixed with non-steroidal anti-
inflammatory drugs showed significant effect in both the Daphnia and algal tests 
(Cleuvers, 2004). Quinn et al. (2009) also observed an additive effect in Hydra 
attenuata following exposure to pharmaceutical mixtures (ibuprofen, naproxen, 
gemfibrozil, bezafibrate, carbamazepine, sulphapyridine, oxytetracycline, novobiocin, 
trimethoprim, sulphamethoxazole and caffeine) from various therapeutic classes.  
 
Estrogenicity has been verified for many contaminants such as natural and synthetic 
hormones and alkylphenols commonly detected in wastewaters (Dagnino et al., 2010). 
Endocrine disruptors such as diethylstilbestrol and 17-α ethinylestradiol has been 
shown to have profound ecological impacts as they mimic a natural hormone, fooling 
the body or blocking the effects of a hormone from certain receptors. Study reported 
that a single dose of 2 ng.L
-1
 17-α ethinylestradiol in water can retard testes growth 
and development by 50% in maturing male trout (Tyler et al., 1998; Palace et al., 
2009, Kidd et al., 2007). In other study, exposure to 50 ng.L
-1
 of either 17-β 
ethinylestradiol or estrone in wastewater for 21 days induced vitellogenin (an egg 
yolk precursor protein that is normally produced only byadult females) synthesis and 
abnormal testicular growth in male fathead minnows (Pimephales promelas) (Panter 
et al., 2000; Martinovic et al., 2007). 
 
2.3 Source of pharmaceuticals in the environment 
 
Pharmaceuticals are released into the environment as a result of their use, alongside 
their use, any unused or expired pharmaceuticals that are incorrectly disposed off. The 
quantity and type of pharmaceuticals that are introduced into the environment is 
related to the quantity of pharmaceuticals produced, the dosage amount, the 
metabolism excretion efficiency and the biological transformation capability in the 
transferring or receiving environment. Figure 2.1 shows the primary routes of 
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pharmaceuticals entering into wastewaters and the aquatic environment.  Studies have 
shown that humans are the main source of pharmaceuticals entering the aquatic 
environment via discharges from WWTPs (Alder et al., 2006). 
 
Figure 2.1 Overview of exposure routes of pharmaceuticals into wastewaters and 
the aquatic environment (Alder et al., 2006) 
 
 
2.3.1 Pharmaceutical Industry 
 
The pharmaceuticals industry can be considered a potential source of pharmaceuticals 
in the environment, where it may be present in solid waste or in wastewater effluent.  
Solid pharmaceuticals waste may be destroyed by incineration, whereas disposal in 
landfills may provide pharmaceuticals with access to aquifers through landfill 
leachate or in water drained from the landfill.  
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2.3.2 Household 
 
Unwanted or unused pharmaceuticals are disposed of by incineration by most 
pharmaceutical companies and pharmacists following a regulated pathway. However, 
large quantities of pharmaceuticals which are not consumed are eventually disposed 
of through domestic household sewage (Daughton and Ternes, 1999; Ruhoy and 
Daughton, 2008). A study conducted in the Southeast of England indicates that 66% 
of people dispose of unwanted pharmaceuticals via their domestic municipal waste, 
12% empty dispose of them via the toilet and 22% of people returned them to the 
pharmacy (Bound and Voulvoulis, 2005).  
 
2.3.3 Hospital wastewater 
 
Hospital wastewater also a major source of pharmaceuticals such as antibiotics, anti-
cancer agents and iodinated contrast media containing individual pharmaceuticals at 
high concentrations (Alder et al., 2006). Several pharmaceuticals have been found in 
hospital wastewater effluent in relatively large concentrations (Table 2.1) (Kümmerer, 
2001; Gómez et al., 2006). Hartmann et al. (1998) detected ciprofloxacin 
concentrations in the range of 3-87μg.L-1 in hospital effluent. Heberer and Feldman 
(2005) found that 10% of the diclofenac and 15% of carbamazepine detected in 
wastewater treatment plants in Berlin, Germany was derived from local hospital 
wastewater. Typically most hospital effluent is directly connected to the municipal 
sewerage system without any additional treatment prior to the hospital discharge. 
 
 
 
 
 
 
12 
 
Table 2.1: Maximum pharmaceutical concentrations detected in hospital wastewater 
effluent (Gomez et al., 2006; McArdell et al., 2011).   
Pharmaceutical Product group Concentration µg.L
-1 
Paracetamol Analgesic  29  
Atenolol  Beta-blocker 122  
Carbamazepine  Antiepileptic  0.07 
Codeine  Analgesic 5.7 
Diclofenac Anti-inflammatory  1.9 
Erythromycin  Antibiotic  0.03  
Ibuprofen  Analgesic 151  
Ketorolac  Anti-inflammatory 59.5       
Metronidazole  Antibacterial 9.4  
Propranolol  Beta-blocker 6.5  
Ranitidine  H2 antagonist  1.7  
Trimethoprim  Antibiotic 0.037 
Azithromycin  Antibiotic 0.11  
Clarithromycin Antibiotic 1.28 
Sulfamethoxazole Antibiotic 3.23 
Sulfadiazine Antibiotic 2.33 
Sulfapyridine Antibacterial 0.251  
Ciprofloxacin Antibiotic 15.7  
Norfloxacin Antibacterial 3.14 
Clindamycin Antibiotic 1.16 
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2.3.4 Wastewater Treatment plants (WWTP) 
 
Wastewater treatment plant effluent is the main source of pharmaceuticals in the 
environment (Daughton and Ternes, 1999). In WWTPs there are wide ranges of 
processes such as primary screening and biological treatment, which may remove 
pharmaceuticals. Biodegradation (aerobic and anaerobic) and sorption of hydrophobic 
pharmaceuticals to activated sludge are examples of processes that may reduce 
concentrations present in the WWTP effluent. Sludge biosolids have a high organic 
content. The less polar or non-polar components of sludge are likely to sink, whereas 
polar substances are more likely to remain in aqueous phase. Some pharmaceuticals 
may be excreted as conjugates that will be broken down in wastewater treatment to 
release a less soluble compound. Other pharmaceuticals are not biodegradable and are 
hydrophilic, so there is incomplete elimination of these pharmaceuticals in WWTPs 
(Bendz et al., 2005). 
Pharmaceuticals that are removed from wastewater by adsorption into sludge solids 
may enter the aquatic environment through sewage sludge when disposed of in 
landfill or agricultural application (Jones et al, 2005).  
 
2.3.5 Leachate from Landfill 
 
Landfills are the sources of a wide range of contaminate compounds that may effect 
the environmental, wildlife and human health (Eggen et al., 2012). Municipal landfills 
may generate leachate which contains significant amounts of dissolved organic 
matter, heavy metal and pharmaceutical (Li et al., 2009). Several kinds of 
contaminants such as hormones, pharmaceuticals and fire retardants detected in down 
gradient from the landfill (Buszka et al., 2009). Another study found similar 
observation that landfill in U.S has high concentration of pharmaceuticals and it is 
persistent in the groundwater (Barnes et al., 2004). Leachate contamination of the 
groundwater may occur by seepage of water from landfill. Three pharmaceuticals, 
namely propyphenazone, ibuprofen, and clofibric acid, were identified by 
Schwarzbauer et al. (2002) when they analyzed contaminated groundwater from 
seepage water of a domestic waste landfill in Germany. 
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2.3.6 Sewage Sludge Disposal 
 
Sewage sludge is a by-product of the wastewater treatment process and it consists of 
organic and inorganic solids present in the influent as well significant quantities of the 
biomassformed during aerobic, anoxic, or anaerobic degradation processes, this 
biomass constitutes 40-80% of the total organic materials dependent on process 
(Schowanek et al., 2004). Typically sludge is used as an agricultural fertilizer and 
after concentration and pathogen treatment (typically with lime) is spread on the soil 
surface. It is spread for only a short time before cultivation as to avoid potential 
problems of odour, pest attraction and surface run-off.  In EU countries the maximum 
allowable sludge disposal rate is 5 tonnes of dry matter/ha annually (Lucid et al., 
2013). Soluble pharmaceuticals or metabolites of these pharmaceuticals have the 
potential to leach through the soil structure and enter the groundwater, especially 
problematic when rainfall occurs. Göbel et al. (2005) found five sulphonamides or 
macrolide antimicrobial’s containing trimethoprim in samples of activated sludge 
taken from WWTPs in Germany and Switzerland. Kinney et al. (2006) detected 19 
different pharmaceuticals in the sludge samples in nine different sludge products 
produced by WWTPs in seven different states in the USA.  
 
2.4 Treatment of pharmaceuticals in wastewater treatment plants 
Wastewater is water discharged from domestic homes, commercial properties, 
industry, and agriculture and can include a wide range of potential contaminants and 
concentrations. Wastewater is derived from human waste such as faeces, urine, 
washing water, and manufactured liquids from domestic sources such as drinks, 
cooking oil, pesticides, lubricating oil, paint, and cleaning liquids. Industrial effluent 
such as cooling waters which contain silt, sand, alkali, oil, and chemical residues; 
organic biodegradable waste from abattoirs, creameries, and ice cream manufacture; 
and organic non-biodegradable or difficult to treat waste such as that from 
pharmaceutical and pesticide manufacturing are also found in wastewater.  
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Most applications used in wastewater treatment plants, by removal the residual 
particulate matter in secondary treatment (e.g. activated sludge, trickling filter and 
membrane bioreactor) and even in tertiary treatment (filter technologies such as depth, 
surface and membrane filtrations), comply with the quality requirements for reuse of 
water.  
 
Sorption of pharmaceuticals by the sludge in the treatment process can be present in 
two mechanisms, absorption and adsorption. Absorption is the hydrophobic 
interaction of the aliphatic or aromatics groups with the lipophilic cell membrane or 
with the lipid fraction of the sludge. Adsorption is the electrostatic interactions of 
positively charged groups of pharmaceuticals with negatively charged surfaces of the 
biomass (Schwarzenbach et al., 2003).  
 
Stripping is an important removal mechanism for low molecular weight compounds 
and depends on the aeration intensity and the Henry’s coefficient of a given 
compound. Stripping is not likely to be a practical removal mechanism for 
pharmaceuticals because the majority have a molecular mass above 250 mg.mol
-1
 
with a Henry coefficient below 0.005 (Larsen et al., 2004). 
 
Water treatment plants for domestic and industrial consumption use unit processes 
such as coagulation, flocculation, sedimentation, filtration and disinfection. The 
objective of these processes are to provide drinking water free from pathogens, 
organic matter, neutralise taste compounds and remove any other chemical 
contaminants. Previously, focus has been primarily on pathogens, but with increasing 
concern over other chemical contaminants advanced processes are becoming more 
widespread. 
 
Most pharmaceuticals in the aqueous phase are expected to be partially degraded and 
transformed by photo-transformative, physicochemical and biological degradation 
reactions. Removal of pharmaceuticals via adsorption processes typically uses 
activated carbon to adsorb the chemical in question. Activated carbon will adsorb a 
wide range of compounds, and so pharmaceutical adsorption has to compete with 
natural organic matter or other larger compounds present in the water. Snyder et al. 
(2003) found that when 10 to 20 mg.L
-1
 of powdered activated carbon (PAC) is added 
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to distilled water containing seven antibiotics the removal efficiency was 50 to 99%, 
while in river water it decreased (10 to 20%). The removal efficiency of 
sulphonamides, trimethoprim, and carbadox in surface water samples containing 10.7 
mg.L
-1
 of dissolved organic matter by using 10 and 20 mg.L
-1 
of PAC ranged from 49 
to 73% and 65 to 100%, respectively (Adams et al., 2002). Westerhoff et al. (2005) 
conducted a batch study on sulphamethoxazole, trimethoprim, and erythromycin-H2O 
at concentrations from 30 to 150 ng.L
-1
 in natural water containing dissolved organic 
matter at 3.5 mg.L
-1
 with PAC dose of 4 mg.L
-1
 and a contact time of 4 h, finding that 
removal efficiency of sulphamethoxazole, trimethoprim, and erythromycin-H2O to be 
21%, 93%, and 65%, respectively. 
 
Membrane filtration for water treatment is primarily undertaken for industrial 
applications when a high (chemical and microbiological) water quality is required. 
Processes such as reverse osmosis, nano filtration and ultrafiltration have been 
previously demonstrated to remove different pharmaceuticals efficiently (Kim et al., 
2007 and Yoon et al., 2006).  Although filtration processes provide a high quality 
pharmaceutical free effluent there are significant drawbacks to the process including 
cost, energy usage and importantly, the lack of degradation of these chemicals. 
Filtration removes the target chemicals, but in doing so produces a concentrated 
effluent high in suspended and dissolved constituents that still requires treatment 
before disposal (USEPA, 2005). 
 
Chlorine is typically used in disinfectant a process which is primarily designed for the 
removal of pathogens. Chlorine disinfection takes place using a variety of different 
forms of chlorine; free chlorine and chloramines (Mono, di, tri), designed to provide 
effective bacterial kill and maintain a residual within the distribution network. 
Dissolving chlorine gas or hypochlorite into water produces free aqueous chlorine 
(HOCl/OCl
–
), which reacts with ammonia to form chloramines. It is a strong oxidant, 
which reacts with many organic pollutants and produces chlorination by-products 
such as disinfection by-products (DBP) including harmful halogenated organics, 
mainly trihalomethanes (THM) and haloacetic acids (HAA). Chloramines are 
relatively weaker oxidants, which are expected to react much more slowly with 
organics (Rice & Gomez-Taylor, 1986). Rapid reactions happen when aliphatic 
amines react with HOCl to produce N-chloramines and reaction rates with chlorine 
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depend on the degree of nucleophilicity of amines (Abia et al., 1998). Further reaction 
present the N-chloro compounds with a hydrogen atom on the carbon α- to the amine 
to produce an imide, which subsequently hydrolyses, resulting in bond cleavage 
between the nitrogen and carbon atoms and removal of the α-carbon side-chain 
(Armesto et al., 1998). Aromatic amines tend to produce ring-substituted rather than 
N-chlorinated products (O'Connell et al., 2006). Phenol compounds react with free 
chlorine through a typical electrophilic substitution pathway (Doborde & Gunten, 
2008). The phenolate anion reacts quite rapidly with HOCl because it has a higher 
electron density.  In antibiotics, sulphonamides are subject to free chlorine attack 
because they contain an aromatic amine group. Fluoroquinolones, tetracyclines and 
macrolide antibiotics follow a different degradation pathway. These antibiotics 
contain aliphatic amine groups, which are likely to react with free chlorine to produce 
N-chloroamines that can then further degrade. 
 
A study was conducted on the kinetics and reaction mechanisms of 
sulphamethoxazole, trimethoprim, and fluoroquinolone with free chlorine and 
chloramines at a lower disinfectant to analyte ratio (~10) (Dodd et al., 2005). It was 
shown that these antibiotics react slowly with chloramines and more rapidly with free 
chlorine. Sulphamethoxazole yields a N-chlorinated adduct, which rearranges to a ring 
chlorination product or leads to a break of the sulphonamide moiety to produce the 
main product N-chloro-p-benzoquinoneimine. The primary reaction of trimethoprim 
occurs on the molecule’s trimethoxybenzyl moiety at a pH of less than 5, while a N-
chlorinated intermediate is generated at a pH greater than or equal to 5. This may 
react further or rearrange to a number of stable substitution products. Free chlorine 
reacts very rapidly with Ciprofloxacin to produce a chloramine intermediate that 
spontaneously decays in water by piperazine fragmentation, whereas it reacts 
relatively slowly with enrofloxacin to produce a chlorammonium intermediate that 
can catalytically halogenate the parent compound in an aqueous solution. The 
oxidation processes of fluoroquinolones are not complete, which means they may not 
eliminate completely the biological effect of these compounds (Dodd et al., 2005). 
 
However, the reaction of sulphamethoxazole with free chlorine produces substantial 
structures that may reduce the antimicrobial activities of sulphamethoxazole (Dodd & 
Huang, 2004). This is not such an issue in reality as sulphonamides have been shown 
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to be easily removed from drinking water at neutral pH, despite the proximity of 
barely affected by monochloramine (Chamberlain & Adams, 2006). Chlorination is 
unlikely to reduce the antimicrobial activities for trimethoprim because the reaction 
produces primarily stable and multiple-substituted compounds such as 
monochlorinated 3,4,5-trimethoxytolyl and dichlorinated 3,4,5-trimethoxytolyl(Dodd 
& Huang, 2004). Trimethoprim antibacterial activity is derived from its 2,4-diamino-
5-methylpyrimidine moiety which blocks bacterial folate synthesis by occupying 
available dihydrofolate reductase enzymes (Walsh, 2003). 
 
 
Ozone (O3) is a strong oxidising agent, which oxidizes some organic compounds 
quicker than both chlorine and chlorine dioxide. It is used for disinfection in drinking 
water treatment plants to control colour, odour, iron and manganese concentrations, 
aid the deterioration of colloidal material to improve flocculation, remove disinfection 
by products precursors through oxidation, and further eliminate organic compounds 
(Haas, 1990). Ozone oxidation is a highly selective reaction and will interact with the 
double bonds, activated aromatic compounds, and amine groups, while the hydroxyl 
(OH) radicals generated from ozonation interact with the components of most of the 
water with nearly diffusion controlled rates (von Gunten, 2003). 
 
A batch study was conducted to determine the degradation rate constants of several 
pharmaceuticals (carbamazepine, diclofenac, 17α-ethinylestradiol, 
sulphamethoxazole, and roxithromycin) with ozone and OH
-
 radicals. It was shown 
that under ozonation all three chemical were completely degraded (Huber et al., 
2005). Removal of carbamazepine and sulphamethoxazole in a full-scale ozonation 
plant at a concentration of 2.4 and 9.7 ng.L
-1
, were observed to below the detection 
limit (<1 ng.L
-1
) (Snyder et al., 2003). 
 
The mechanism for carbamazepine degradation under ozone involves the ozone 
reacting rapidly with the double bond in carbamazepine, with the formation of by-
products containing quinazoline-based functional groups that can then be further 
oxidized by reaction with OH radicals (McDowell et al., 2005). In a pilot-scale study, 
when ozone was introduced to carbamazepine in the plant’s source water, 66 to 96% 
reduction was observed (Hua et al., 2006). 
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The degradability of the pharmaceuticals by OH radical mediated reactions of 
advanced oxidation processes were observed, where 5 mg.L
-1
 ozone and 1.8 mg.L
-1
 
hydrogen peroxide in river water was almost quantitatively degraded to 2.1% 
(clofibric acid), 0.6% (ibuprofen) and 0.1% (diclofenac) of the initial concentration of 
clofibric acid, ibuprofen and diclofenac, respectively (Zwiener & Frimmel, 2000). On 
the other hand, 2.5 mg.L
-1
of ozone achieved greater than 70% removal of each in a 
pilot-scale plant (Snyder et al., 2003).  
 
The reaction mechanisms of oxidation during ozonation have been widely studied 
(Deborde et al., 2005; Huber et al., 2005). During ozonation, micro-pollutants are 
oxidised through attack by either the ozone molecule itself or the creation of a 
hydroxyl radical, derived from direct ozone decomposition. Von Gunten (2003) 
hypothesised that ozone molecules react selectively with certain functional groups, 
but oxidation with hydroxyl radicals is indiscriminate. However, Nakada et al. (2007) 
suggests that molecular ozone attacks structures with high electron density, such as 
C=C bonds, activated aromatic systems, and non-protonated amines, but not aromatic 
rings with ethylene, amide or carboxylic groups. Currently, exact mechanisms on 
transformation products are still poorly understood. 
 
 
 
The UV radiation process is widely used to disinfect and purify drinking water to 
remove biological pathogens. A small number of studies focusing on the degradation 
of pharmaceuticals through the process of UV treatment, in conjunction with 
hydrogen peroxide or ozone, found this process may actually transform these 
pharmaceuticals. In the United States, this technique is currently gaining greater 
importance because its use can reduce the dosage of chlorine to purify the final 
application and, thus, reduce the levels of disinfection by-products formed (Sharpless 
& Linden, 2001). UV can be used in advanced oxidation processes as an alternative to 
O3 to remove disinfection by-product precursors and its use is attractive due to lower 
cost and lower potential for producing alternative chemical by-products. 
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Furthermore, degradation of pharmaceuticals can be obtained using direct photolysis 
and advanced oxidation processes. Accordingly, the absorption of light will cause the 
chemical to undergo transformation (Schwarzenbach et al., 1993).UV radiation can be 
generated using medium pressure (MP) lamps that emit a broadband ranging 
wavelength from 205 to above 500 nm, which was found to achieve a more effective 
degradation of bisphenol A, ethinylestradiol, and estradiol than direct photolysis using 
low pressure (LP) lamps that emit monochromatic light at 254 nm (Sharpless & 
Linden, 2003; Rosenfeldt & Linden, 2004). 
 
A study on the kinetic degradation constant of carbamazepine and reaction 
intermediates formed using LP UV/H2O2 revealed an effective removal, whereas it 
leads to negligible degradation through direct photolysis in the absence of H2O2 
(Vogna et al., 2004). 
 
Degradation of paracetamol and diclofenac using ozonation and LP UV/H2O2 
processes was found to be effective and achieved degrees of mineralization of 
approximately 30 and 40% for ozonation and H2O2 photolysis, respectively 
(Andreozzi et al., 2003; Vogna et al., 2004) . 
 
Batch reactor experiments were conducted to evaluate LP and MP ultraviolet systems 
and to investigate the UV photolysis and UV/H2O2 oxidation of pharmaceuticals 
(carbamazepine, clofibric acid, iohexol, ciprofloxacin, naproxen, and ketoprofen) in 
the aquatic environment (Pereira et al., 2007). Pharmaceuticals' removal was very 
high under MP-UV photolysis and the MP-UV/H2O2 oxidation process, whereas it 
was well under LP-UV and was underestimated in the LP-UV/ H2O2. In general, MP 
lamps proved to be more degradation efficient in both UV photolysis and UV/H2O2 
oxidation in the bench-scale experiments conducted.  
 
A controlled laboratory scale photo-catalysis experiment achieved the reduction of 
carbamazepine, clofibric acid, iomeprol, and iopromide (Doll & Frimmel, 2005). This 
was accompanied by high photo-catalytic degradation of carbamazepine and clofibric 
acid with elimination of the model solution’s dissolved organic carbon showing that 
the xenobiotics were mineralized to some extent. On the other hand, the photo-
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catalytic degradation of iomeprol was accompanied by formation of iodide as 
degradation products and intermediates.  
 
 
2.5 Bioreactor 
 
2.5.1 Sequencing Batch Reactor 
 
A sequencing batch reactor (SBR) system consists of a wastewater fill-and-draw 
process. SBR is different to a conventional activated sludge system, because the 
processes of equalization, aeration and clarification are all achieved in the same tank 
at the same time (Morgenorth and Wilderer, 2000). SBR consists of five process steps 
carried out in sequence: (1) fill, (2) react (aeration), (3) settle 
(sedimentation/clarification), (4) draw (the effluent is decanted), and (5) idle (see 
Figure 2.2). Wastewater fills the tank, is treated and then discharged. Treated 
wastewater is usually drawn after the settling phase. 
 
Figure 2.2: The processes operation of SBR during one cycle 
(http://www.lifesciences.napier.ac.uk/smaefiles/kinneil/kinneil.htm).   
 
SBR has good characteristics, by combining the reactor and the settling tank in the 
same container, which can easily control the performance of the reactor with respect 
to reaction time and sludge solids maintenance. The SBR process saves more than 
60% of the expenses compared to the conventional activated sludge process (Chang et 
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al., 2000). SBR is an effective biological treatment system for the treatment of 
domestic wastewater, and for different industrial wastewaters such as landfill 
leachate, pulp and paper industry wastewater, dairy wastewater and chemical complex 
wastewater (Mace and Mata-Alvarez, 2002; Mohan et al., 2005; Tsang et al., 2007; 
Neczajet al., 2008; Elmolla and Chaudhuri, 2011). 
 
2.5.2 Aerobic Membrane Bioreactor 
 
A membrane bioreactor (MBR) is a combination of activated sludge processes and 
membrane filtration in one treatment process. Activated sludge is filtrated from the 
effluent by using an ultrafiltration or microfiltration membrane, which can be applied 
within the bioreactor by submergence or externally through recirculation. By using a 
membrane for separation of the suspended solid and colloidal material such as micro 
contaminants, bacteria and viruses from the effluent, the sludge concentration in the 
aeration tanks can be higher than in conventional systems (Ujang and Anderson, 
2000; Trussell et al., 2005). Biological processes in a MBR are better than in 
conventional activated sludge systems, due to the long sludge ages, and nitrogen 
removal is more efficient because of the slow growing autotrophic bacteria (Ujang et. 
al., 2005).   
 
A membrane is a barrier that separates two phases and restricts the transport of 
various particles in a selective manner (Paul and Yampol, 1994). The principle is that 
the semi-permeable membrane acts as a very specific filter that permits water to flow 
through permeate, while it retains suspended solids and other substances (retentate) 
(see Figure 2.3). A MBR is an integrated system consisting of the biological 
degradation of waste products and membrane filtration, where microorganisms 
responsible for biodegradation and suspended solids get separated from the treated 
water by membrane filtration (Jacques et al., 1996; Cicek, 2003).  
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Feed Permeate
Retentate
 
Figure 2.3. Scheme of membrane removal process   
 
The MBR system can be classified according to the design (the separation principle 
employed and the aggregation state of the fluids contacting the membrane) and pore 
size (the largest particles that can permeate a membrane) of membrane modules. 
There are many membrane types according to whether the design is tubular, hollow 
fibre, rotary disk, plate and frame. The tubular membrane is commonly used to 
improve turbulent flow and mechanical cleaning. Hollow fibre has the highest 
membrane surface area of all the membrane module types and is considered as a self-
supporting membrane, whereas the rotary disk membrane has an acceptable 
membrane surface area (Seung, 2004). The plate and frame shaped membranes are 
usually disposable and inexpensive. According to the pore sizes, there are four types 
of membrane, namely Microfiltration (MF), Ultrafiltration (UF), Nanofiltration (NF) 
and Reverse Osmosis (RO). MF removes particulate contaminants such as clay, algae, 
bacteria and microorganisms with less energy consumption than other types of 
membranes (Meier-Haack et al., 2003; Ujang et al., 2002).  
 
Hydrophilicity refers to the chemical characteristics of the membranes which have the 
tendency to wet the membrane and form a water film or coating on their surface. 
24 
 
Hydrophobic means that the membranes have no tendency to absorb water, and water 
tends to stay on their surface. Many natural products are negatively charged, due to 
dipole or multiple chemical bonds in their structure, while particulates in aqueous 
media are hydrophobic and will attach to any material that is less hydrophilic than 
water. The precipitation of the particles on the membrane surface can be achieved by 
less exposure to hydrophobic particles. Hydrophobic membrane filtration tends to 
have more fouling than hydrophilic filtration, so membranes should preferably be 
hydrophilic for wastewater treatment (Fane et al., 1991; Belfort et al., 1994; Chang et 
al., 1999; Judd and Till, 2000; Choi et al., 2002; Hadidi & Zydney, 2014). 
 
Membranes can be made from organics such as polyethylene, polyethersulfone, 
polysulfone, polyolefin, etc. and inorganic (ceramic) or metallic substances. 
Membrane materials should be inert and non-biodegradable, easily cleaned and able 
to withstand cleaning chemicals and high temperature and pressure. The surface 
charge of a membrane can attract or repel charged species in water. Moreover, the 
surface charge of the membrane should be neutral or negatively charged to avoid 
adsorption of microorganisms (Seung, 2004). The negative or neutral membrane 
surface charge is preferred to limit the adsorption of particles to the membrane, since 
the natural organic macromolecules in water and waste water are commonly 
negatively charged (Cardew and Lee, 1998). 
 
The membrane separations depend on the membrane ability to permit one component 
from the feed mixture. The pore size of the membrane is large enough to allow some 
molecules to pass through, and too small to permit the others (Figure 2.4). The 
removal of trace contaminants in the Water Industry may be achieved by using RO or 
NF membranes in a water recycling plant. The combination of advanced water 
treatment systems such as ultrafiltration (UF) and microfiltration (MF), followed by 
reverse osmosis (RO), has become industry standard practice for the reclamation of 
municipal wastewater for industrial and indirect potable reuse applications. 
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Figure 2.4: Pore sizes for different type of membranes relative to various water 
quality concerns. (USEPA, 2001) 
 
 
 
Organic pollutants could be removed partially or totally in wastewater treatment 
plants; while it is not sufficient to remove all micro-contaminants, some treatment 
processes are clearly more effective than others at reducing the concentration of a 
broad range of trace contaminants. Research study has reported that the capability of 
NF/RO membranes to reject organic micropollutants such as endocrines, 
pharmaceuticals and others was incomplete (Golet et al., 2002; Kimura et al., 2003; 
Schäfer et al., 2003; Kimura et al., 2004; Nghiem et al., 2004).  
 
The performance of membrane separation has been estimated in order to predict the 
mass balance through membranes (Williams et al., 1999; Bowen et al., 2002). The 
removal efficiencies for organic constituents is much more difficult than for inorganic 
compounds since the physico-chemical properties and interactions with the membrane 
properties significantly affect the compound’s mass transfer (Williams et al., 1999; 
Van der Bruggen and Vandecasteele, 2002).  
2.6 Kuwaiti pharmaceutical consumption and disposal 
Most of the studies recorded on the detection of, and quantifying the fate of, 
pharmaceutical waste in the environment are done in cold or wet countries, but with 
very little undertaken in hot dry countries such as Kuwait.  
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Different factors may affect the pharmaceutical compounds; these factors could be 
physical or chemical, such as radiation, humidity and temperature. Photo-chemical 
(photolysis) reactions may transform the pharmaceuticals to a toxic form or degrade 
them into less harmful compounds, which this study aims to investigate.  
 
The disposal method and quantity of unused or expired pharmaceuticals in Kuwait 
and other Arab countries are currently not known. They dispose of the 
pharmaceuticals together with other municipal waste in the same landfill. 
Inappropriate disposal methods may cause health problems (e.g. mixing dangerous 
pharmaceuticals such as those used in treating cancer with other volatile compounds).  
 
The Kuwaiti government spent approximately 298 million US dollars on pharmacies 
in 2008. Government health centres provide for the majority of the population in 
Kuwait while private pharmacies provide for a smaller proportion of people. Because 
of the free medication provided by the government, the high proportion of public 
health system derived pharmaceuticals could be a reflection that this is where most 
patients obtain their pharmaceuticals. 
A study on Arabian Gulf countries’ households in 2001 established that 25% of 
pharmaceuticals are held in the home until they expire (Abu Auda, 2003). The same 
scenario may occur in Kuwait where the cost of expired pharmaceuticals can be 
estimated at around 74 million dollars annually. Thus, this increases the caution about 
the pharmaceutical waste in Kuwait, where pharmaceuticals expired with an average 
value of 25 dollar per person for 3 million populations. In the United Kingdom, a 
study in 1996 estimated that £37 million of unused pharmaceuticals were held in 
households (Hawksworth et al., 1996), where in the United States the value of unused 
pharmaceuticals was over $1 billion per year for mature patients alone (Morgan, 
2001) and in Texas it is estimated that pharmaceutical waste is valued at $106 million 
per year (Garey et al., 2004). 
A survey was conducted to determine the pharmaceuticals most commonly used 
annually in Kuwait collected from the Ministry of Health in November 2008; the 
study of the monthly consumption of commonly used pharmaceutical drugs during the 
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year 2008 in Kuwait and data was also collected from four different hospitals in 
Kuwait in April 2009. These results can help us to understand the usage behaviour of 
these drugs during the year and excitants in the environment.    
 
In this study, pharmaceutical drugs were selected on the basis of the availability of 
eco-toxicity data of the most commonly used of these drugs in Kuwait (Table 2.2), 
such as Metformin, Paracetamol, Amoxicillin, Ranitidine HCL, Metronidazole and 
CO-Trimoxazole. Paracetamol is a common analgesic used by humans. Secondly, 
antibiotic drugs that are used in large quantities, such as Amoxicillin. It is used to 
treat many different types of infections caused by bacteria. Other antibiotic drugs used 
extensively for treating infections caused by anaerobic bacteria and protozoans such 
as Trichomonasvaginalis and Giardia lamblia are Metronidazole, where Co-
trimoxazole is a Sulphonamide antibacterial combination of Trimethoprim and 
Sulphamethoxazole used in the treatment of a variety of bacterial infections. Most of 
these drugs are non-biodegradable or not easily degradable (Richardson and Bowron, 
1985; Perez et al., 2005) nor soluble in water, so they are not typically removed 
during conventional sewage treatment meaning they are likely to accumulate in the 
aquatic environment (Kummerer, 2001).  
Lastly, Ranitidine hydrochloride is a histamine H2-receptor antagonist that inhibits 
stomach acid production. It is commonly used in the treatment of peptic ulcer disease 
and gastroesophageal reflux disease. Ranitidine is also used in other antihistamines 
for the treatment of skin conditions such as hives. 
These pharmaceutical drugs have a toxic effect on humans and ecosystems; for 
example, Metronidazole along with other antibacterial and anticoccidial drugs with a 
Nitroimidazole ring structure are suspected of being carcinogens and mutagents 
(Revankar and Vedavathi, 2014). These drugs may be found in the wastewater due 
their excretion. Studies must be done to detect these drugs and enhance the 
degradation process in the wastewater biological treatment or physical chemical 
treatment. 
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A survey done to estimate the monthly use of the most common pharmaceuticals in 
Kuwait (Figure 2.5) revealed different consumption rates of pharmaceuticals during 
the year. Antibiotics are mostly used in the seasonal sick period, where Metronidazole 
is largely used in summer due to food poisoning. Paracetamol consumption 
substantially increases then stabilizes from May to the end of the year.  
 
Table 2.2: Total of most pharmaceutical drug used in Kuwait* 
Pharmaceutical Product group Weight g 
Metformin Diabetic 2 40748210 
Paracetamol Analgesic 38610781 
Amoxicillin Antibiotic 18209596 
Ibuprofen Anti-inflammatory 7149200 
Cephalexin Antibiotic  3622675 
Ranitidine  HCL Antagonist 3213629.5 
Acetyl salicylic acid (Aspirin) Analgesic 2999300 
Mefenamic acid Anti-inflammatory 2456700 
Metronidazole Antibiotic 2218960 
CO-Trimoxazole (Trimethoprim 
+ Sulphamethoxazole) 
Antibiotic 2190336 
Bezafibrate Hormones  1143090 
* Taken from Ministry of Health (2009), Health & Vital Statistics Division, Department of 
Statistics & Medical Records.
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Figure 2.5: The consumption of commonly used pharmaceutical drugs during the year 2008 in Kuwait (Taken from Ministry of Health (2009), 
Health & Vital Statistics Division, Department of Statistics & Medical Records).
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2.7 Sulaibiya wastewater treatment plant 
 
2.7.1 Plant Description 
 
The Sulaibiya wastewater treatment plant was opened in 2005 as the world’s 
largest membrane-based water reclamation facility utilizing ultra-filtration (UF) 
and reverse osmosis (RO) systems. It serves a domestic population of 
approximately 1370650 with a capacity of 375,000 m
3
.d
-1
 (Alhumoud et al., 
2010). As well as domestic wastewater, the plant receives effluent from 18 
different hospitals with a patient capacity of 4744 beds.  
 
Figure 2.6 shows that the preliminary treatment at Ardiya consists of particulate 
and grit removal, as well as fat, oil and grease removal. The wastewater is then 
pumped to Sulaibiya. Biological removal of nitrogen and phosphorus are the first 
stage in the Sulaibiya WWTP, where anoxic and aerobic systems are used in 
addition to secondary clarifiers with a nominal HRT of 14hours. The water 
reclamation facility (Figure 2.6) receives secondary-treated municipal 
wastewater, which is pre-filtered with micro-filters and then fed into the 
ultrafiltration (UF) system. UF permeate feeds a RO plant, and UF retentate is 
recycled to the WWTP. The UF system receives almost 100% of the effluent 
from the biological treatment plant since UF retentate is recycled. The RO plant 
is constructed for 85% water recovery and, therefore, the production rate is 
expected to be 318,750 m
3.
d
-1
.  
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Table 2.3 Statistics of hospitals in Kuwait describing the number of beds and 
patients*.   
Hospitals Beds Inpatient Outpatient Emergency Operations 
Sabah 438 18631 112481 341865 3378 
Amiri 394 11010 131287 153579 2009 
Mubarak 437 17515 163240 283471 4487 
Farwania 633 26263 318401 650701 6310 
Al Razi 267 6107 162615 116434 6985 
Phys. Med Rehab 78 339 50115 0 0 
Maternity 375 20914 27034 17532 5678 
Chest Diseases 131 6744 89930 0 1073 
Infectious Diseases 151 3340 14285 17410 0 
Psychological 
Med. 
749 3058 55962 6610 0 
Ibnsina 363 10918 244055 150824 13769 
Kuwait Cancer 
Control Centre 
112 2124 41460 0 1118 
Kuwait Allergy 
Centre 
128 1031 89212 0 0 
Al Mowasat 88 6852 188452 0 4657 
Hadi 101 11979 377996 0 7364 
Dar–Al Shefa 88 12230 233595 0 5698 
Al Rashid 84 3306 87000 0 2541 
Al Salam 127 9355 186890 0 6723 
Total 4744 171716 2574010 1738426 71790 
* Taken from Ministry of Health (2009), Health & Vital Statistics Division, Department of 
Statistics & Medical Records. 
 
 
2.7.2 Ultrafiltration System (UF) 
Since RO systems require pre-treatment to protect the RO membranes from 
fouling, UF was selected to provide appropriate pre-treatment of the secondary-
treated municipal effluent before being fed to the RO. The UF technology is 
robust, has favourable life cycle costs, and provides better quality water to the 
RO membranes (Alhumoud et al., 2010). The characteristics of the UF system 
used in this plant are presented in Table 2.4. In terms of its operation, each UF 
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unit can be operated individually. These units are regularly backwashed to ensure 
removal of suspended matter being retained and held by the membranes. The 
backwash water is pumped back upstream of the WWTP to receive appropriate 
treatment and achieve the maximum total water recovery for the plant. The 
influent to the UF first passes through a micro-filter and subsequently, a small 
amount of coagulant (ferric chloride at 1 – 2 mg.L-1) is added to coagulate fine 
particulates and possibly allow some TOC removal to facilitate the operation of 
the plant. The silt density index (SDI) of the UF product is consistently below 2, 
which is the key standard for RO plant performance (Gagne, 2002). 
 
2.7.3 Reverse Osmosis System (RO) 
The characteristics of the RO system adopted in the Sulaibiya plant are shown in 
Table 2.4. This system is used to desalinate the wastewater effluent to 100 mg.L
-1
 
TDS and to provide an additional barrier to bacteria and viruses. The average 
salinity of the secondary-treated effluent is 1,280 mg.L
-1
 TDS, with a maximum 
value of 3,014 mg.L
-1
. The RO system modules are arranged in a train of 4:2:1 
array, forming three stages of RO treatment. The first stage recovers 50%, the 
second stage recovers 50% and the third stage recovers 40% of the flow. The RO 
system is limited to recover 85% by the calcium phosphate precipitation, which 
can often be a limiting factor for the recovery of water in membrane desalination 
systems in municipal wastewater (Gagne, 2002). Reverse osmosis effluent passes 
through the stripper unit to remove the CO2 and adjust the pH with a minimum 
addition of caustic soda prior to distribution, and then the product is chlorinated 
before leaving the plant. The system’s brine is disposed of in the Arabian Gulf. In 
order to minimize fouling of the membranes they are regularly cleaned with CIP 
comprising surfactants, sulfuric acid, biocide and sodium hydroxide. 
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Figure 2.6: Flow diagram of treatment processes at Sulaibiya WWTP (Alhumoud et al., 2010) 
Sand Filter 
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Table 2.4. Characteristics of membrane systems employed at Sulaibiya 
water reclamation plant 
Membrane 
System 
Membrane 
Type 
Membrane 
Configuration 
Membrane 
Arrangement 
Membrane 
Area 
Ultrafiltration 
( UF ) 
Norit’s X Flow 
Cross Flow, 
The 
Netherlands. 
 
(Model XIGA 
SXL-225). 
Polyvinyldene 
Fluoride 
Capillary 
hydrophilic 
hollow fibers 
Membranes are packed 
in 20 x 152 cm 
membrane elements (35 
m
2
 /element), 4 
membrane elements are  
placed inside a 
membrane housing. 
There are 68 skids, each 
with 32 membrane  
housings for a total of 
8,704 membrane 
elements (4 x 32 x 68).  
8,704 x 35 m
2
 = 
304,640 m
2 
 
Reverse 
Osmosis 
( RO ) 
Toray of  
America. 
(Model TML 
20-400). 
Polyamide 
composite. 
Spiral wound Membrane modules of 
42 identical skids in a 
4:2:1        array (train) 
of modules. Each 
module contains about  
504 RO elements (72 
pressure vessels x 7 RO 
element/ vessel) for a 
total of 21,168 
membrane elements (7 x 
72 x 42). 
21,168x 37 m
2
 = 
783,216 m
2 
 
 
 35 
 
3. Development of Analytical Methods 
 
Wastewater treatment plants (WWTPs) have been identified as a major point 
source of pharmaceuticals waste in the environment as they receive continuous 
inputs of these compounds either as the parent compound or as an array of 
metabolites (Daughton & Ternes, 1999). Pharmaceuticals are persistent 
contaminants that can be harmful to the environment, even at trace levels. 
Researchers are always attempting to develop more sophisticated analytical tools 
and sensitive techniques for their detection in water samples.  The diversity of 
pharmaceuticals and the complexity of environmental matrices, as well as the 
ultra-trace detection limits required, make chemical analysis a difficult task for 
researchers. 
For the purpose of this study, it was necessary to develop analytical methods 
which were accurate, precise and practical. Furthermore, such methods had to be 
quick, relatively inexpensive, require simple tools, and use the minimum of 
hazardous reagents. 
 
3.1 Selection and development of pharmaceutical measurement method 
 
There were two options for analytical methods to be used in this study. The first 
option was to use methods described in published papers, while the second option 
was to develop new analytical methods. Criteria for the selection of new 
analytical methods were as follows: 
1. Simplicity: An analytical method required in this research should not be too 
complicated.  
2. Availability of the instruments: So as to facilitate the sample analysis, the 
instruments required for sample preparation and analysis need to be available 
near the sample collections points. This criterion was set not only for making 
the analytical step as convenient as possible but also for minimising the cost 
and reducing sample change during transportation and storage. 
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3. Methodical detection limits: pharmaceuticals in the environment are 
commonly found at very low concentrations (ng.L
-1
). Thus, the detection 
limits of a selected analytical method should meet the requirements.  
4. Selectivity and sensitivity: these are the most important factors in the 
selection of analytical methods for the achievement of the desired detection 
limits.  
 
3.2 Validation of Analytical Methods and Procedures 
 
Method validation is the process used to confirm that the analytical procedure 
employed for a specific test is suitable for its intended use. Results from method 
validation can be used to judge the quality, reliability and consistency of the 
analytical method; it is an integral part of any good analytical practice.  
The development of sensitive analytical techniques provides detailed information 
on the structure of metabolites and transformation products (TPs) of 
pharmaceuticals in extracts of environmental samples such as gas 
chromatography with mass spectrometry (GC-MS) or with tandem MS (GC-
MS2) and Liquid chromatography–mass spectrometry (LC-MS) or (LC-MS2). 
They are many of the analytical techniques applied to the quantification of 
pharmaceuticals in samples of wastewater, which is a complex matrix containing 
many different organic molecules. 
 
3.3 Application of GC-MS and LC-MS 
 
Advanced analytical techniques (GC-MS, GC-MS2, LC-MS and LC-MS2) are 
common in pharmaceutical analysis, because they can provide compound 
confirmation and detailed information on the structure of the compounds 
analysed, and give separation and detection of compounds having the same 
molecular mass but different product ions. 
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As a result, there is growing interest in the application of these techniques, GC-
MS2, LC-MS and LC-MS2, for the analysis of pharmaceuticals as they can 
provide low limits of detection (LODs) in wastewater and can be useful to obtain 
further information about new compounds, which can be metabolites or TPs of 
pharmaceuticals, which have not yet been identified. 
After efforts to improve these technologies, progress has been made in recent 
years in equipment (Horimoto et al., 2002; Diaz-Cruz et al., 2005) as well as 
sample preparation, derivatization and clean-up procedures (Stumpf et al., 1999; 
Moder et al., 2000; Sacher et al., 2001; Jux et al., 2002; Andreozzi et al., 2003; 
Ollers et al., 2001; Renew et al., 2004; Balakrishnan et al., 2006). In order to 
obtain lower LODs the selective ion monitoring (SIM) mode of MS detection has 
been used for pharmaceuticals. On the other hand, the scan mode is also required 
for searching for the presence of unknown metabolites in samples for 
pharmaceutical analysis (Gomez et al., 2007; Zuccato et al., 2008; Pavlovic et al., 
2007; Hao et al., 2007). 
A significant disadvantage of GC-MS and GC-MS2 analysis is the requirement 
for derivatization of polar pharmaceuticals, which can affect the accuracy of the 
method, as losses of analytes can occur or the derivatization reaction can be 
incomplete. Thus, to avoid derivatization, LC-MS or LC-MS2 analysis is being 
used widely with good results (Castiglioni et al., 2005; Balakrishnan et al., 2006; 
Hao et al., 2007). However, analytical problems have also frequently occurred, 
especially during the analysis of wastewater, so that sensitivity has decreased 
(Fatta et al., 2007). In order to solve these analytical problems in both GC and LC 
analytical procedures, a clean-up step is added prior to analysis of the final 
extract. 
The analytical methods considered in this study were selected to determine five 
pharmaceuticals in wastewater, namely Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine. 
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3.4 Development of liquid chromatography–mass spectrometry analysis 
 
3.4.1 Chemicals and reagents 
 
Methanol, acetonitrile, and water were HPLC grade obtained from Sigma–
Aldrich (Steinham, Germany). Dichlorodimethylsilane, Sodium thiosulphate, and 
Toluene were also purchased from Sigma–Aldrich. Pharmaceutical standards 
were of a high purity ≥95%. Trimethoprim, Sulphamethoxazole, Metronidazole, 
Paracetamol, Ranitidine, and internal standard Metronidazole-
13
C2,
15
N2  were 
purchased from Sigma–Aldrich. 
Stock solutions 100 mg.L
-1
 of each analyte were prepared in HPLC grade 
methanol and stored at 4 ◦C in the dark for increased stability. Supelco C18 (500 
mg/3 mL) used for solid phase extraction was purchased from Phenomenex 
(United Kingdom). Sterile membrane filters 0.45 µm were obtained from Gelman 
Sciences, while glass microfibre filters (934-AH) were purchased from Whatman 
(United Kingdom). 
 
3.4.2 Solid phase extraction 
 
Supelco C18 (500 mg/3mL) was investigated for sample pretreatment and analyte 
preconcentration. Samples were first filtered through sterile membrane filters 
0.45 µm to remove any microorganisms and solid particulates, and were adjusted 
to pH 4 using sulphuric acid. Samples were then divided into aliquots of 500 mL 
for solid phase extraction (SPE). A Phenomenex extraction manifold was used 
for SPE. Cartridges were first conditioned with 6 mL of methanol followed by 6 
mL of water (HPLC grade). Following this, samples were percolated over the 
cartridge under vacuum at a pressure of −10 kPa. The sorbent was washed with 5 
mL of water after sample addition and dried under vacuum for 30 min. The 
sorbent was then eluted with 10 mL of methanol, dried under a stream of nitrogen 
and reconstituted in 0.5 mL of methanol. This provided a measuring 
concentration factor of 10
3
, from raw sample to methanol extract. 
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3.4.3 Instruments 
 
The LC-MS analytical method was used to monitor selected mass ions of each 
pharmaceutical compound with high sensitivity. The significance of these 
methods is to evaluate good selectivity and sensitivity so as to permit fast 
analytical separation and achieve sensitive sample detection. Samples were 
prepared from different pharmaceuticals (Metronidazole, Trimothoprim, 
Sulphamethoxazole, Paracetamol, and Ranitidine) dissolved in methanol. 
 
The LC analyses were performed using a Thermo LCQ fleet with Surveyor 
HPLC, APCI mode equipped with a SGE Wakosil C-18RS column (250mm × 
4.6 mm) 5µm particle size. The HPLC pump (P4000, Spectra system, Thermo 
Finnigan, San Jose, CA, USA) was used to generate a gradient from two mobile 
phase solvents at a flow rate of 0.6 ml/min and temperature of 25°C. As a number 
of compounds were to be analysed by different separation methods, different 
elution gradient mixtures of the mobile phases, such as methanol and water with 
0.1% formic acid, were examined in varying ratios as shown in Table 3.1.  
The ion trap mass spectrometer (LCQ Fleet, Thermo Finnigan) was equipped 
with an atmospheric pressure chemical ionization (APCI) ion source, and the 
heated capillary temperature was set at 275°C. The MS parameters were 
optimised semi-automatically using LCQ internal software. The sheath and 
auxiliary nitrogen gas flows were 40 and 10 (arbitrary units), respectively, and 
the source voltage was maintained at a constant 3.10 kV for all analytes. The 
capillary voltage (36V) and the collision energy (for fragmentation in MS/MS) 
were individually optimised for each substance.  
 
Metronidazole-
13
C2,
15
N2  internal standard (I.S.) was determined together with 
the different analytes. The time required to analyse one sample using this 
approach varied depending on the retention time. All the separated 
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pharmaceuticals compounds were detected using APCI -MS/MS in positive ion 
mode. Quantification was achieved using the internal standard calibration 
method. A five-point calibration curve was prepared for each substance, using 
values from approximately 1µg.L
-1
to 100 µg.L
-1
, based on analyte/I.S. peak area 
ratios. Levels of the internal standards used in native wastewater samples were 
monitored in order to avoid underestimation of analyte concentrations.  
 
All the literature reported m/z-values of the selected pharmaceutical’s parent and 
daughter ions were used for MS detection. For instance, the characteristic parent 
ions were Metronidazole (m/z 172), Trimethoprim (m/z 291), Sulphamethoxazole 
(m/z 254), Paracetamol (m/z 152), and Ranitidine  (m/z 315), and daughter ions 
were Metronidazole (m/z 82.5, 111), Trimethoprim (m/z 261), 
Sulphamethoxazole (m/z 156), Paracetamol (m/z 107), and Ranitidine  (m/z 176) 
(Hartig et al., 1999; Lindsey et al., 2001; Benotti, 2002; Cronly et al., 2009; 
Zeleny et al., 2009; Langford & Thomas 2009). Additional daughter ions of 
Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol, and Ranitidine 
(m/z 128, 230, 188.0, 110, and 176), respectively, were also monitored (Benotti, 
2002; Andreozzi et al., 2003; Lindberg et al., 2004) using the same instrument 
(Table 3.2.) 
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Table 3.1: Elution gradient used in the method of separation of different 
pharmaceutical in LC-MS 
Compound  Gradient Programme  
 
Metronidazole 
 
Time (min) Flow 
(ml/min) 
Methanol 
(%) 
H2O (%) 
0 0.4 30 70 
14 0.4 90 10 
16 0.4 30 70 
20 0.4 30 70 
 
Trimethoprim
 
Time (min) Flow 
(ml/min) 
Methanol 
(%) 
H2O (%) 
0 1 60 40 
6 1 60 40 
 
Sulphamethoxazole 
 
Time (min) Flow 
(ml/min) 
Methanol 
(%) 
H2O (%) 
0 0.4 30 70 
15 0.4 95 5 
18 0.4 30 70 
20 0.4 30 70 
 
Paracetamol 
 
Time (min) Flow 
(ml/min) 
Methanol 
(%) 
H2O (%) 
0 0.4 40 60 
13 0.4 90 10 
15 0.4 40 60 
20 0.4 40 60 
 
Ranitidine 
 
Time (min) Flow 
(ml/min) 
Methanol 
(%) 
H2O (%) 
0 1.2 90 10 
6 1.2 90 10 
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Table 3.2: Monitored ions of pharmaceuticals and internal standards 
Compound  m/z parent ion Collision 
energy (%) 
m/z daughter 
ion 
Metronidazole 172 
 
23 128  
Trimethoprim 291 34 230.1  
Sulphamethoxazole  254  27 188 
Paracetamol 152 24 110 
Ranitidine  315 28 270 
Metronidazole-
13
C2,
15
N2  (I.S.) 
176 23 132 
 
3.4.4 Recovery 
 
The extraction recovery process in each different sample was evaluated using 
internal standards. This was determined by spiking mixed pharmaceuticals in 
different samples (distilled water, tap water, and synthetic wastewater) at 
concentrations 1 µg.L
-1
. Sodium thiosulphate was used at concentration 100 
mg.L
-1
, to remove the chlorine present in tap water. Calculation of the recovery 
of the pharmaceuticals was based on their standard concentrations. 
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3.4.5 Effect of chlorine on extraction 
 
Chlorine is commonly used in the disinfection of drinking water and in the 
WWTP final step. The presence of chlorine may have a strong effect on the 
adsorption of organic compounds to adsorbents (Suffet & Wable, 1995; Gilloly et 
al., 1998). Therefore, the presence of residual chlorine may affect the adsorbent 
coating fiber of SPE. Furthermore, because chlorine is a strong oxidant, a 
reaction between chlorine and the analytes may also occur during the extraction 
process changing their chromatographic properties. 
In this study, the effect of chlorine on the recovery using SPE analysis of the 
pharmaceuticals was investigated. Finally, to reduce the deleterious impact of 
chlorine during the SPE analysis, chlorine was removed to evaluate its effect on 
the extraction process. This experiment used different samples (distilled water, 
tap water, 1 mg.L
-1
 of chlorine in wastewater, and wastewater). Sodium 
thiosulphate was used to remove the chlorine. Three different tests were 
conducted: 
A- Sample with only pharmaceuticals at concentration 1 µg.L-1. 
B- Add pharmaceuticals at concentration 1 µg.L-1 then after 5 min add 
Sodium thiosulphate at concentration 100 mg.L
-1
. 
C- Add Sodium thiosulphate at concentration 100 mg.L-1 then after 5 min 
add pharmaceuticals at concentration 1 µg.L
-1
. 
 
3.5 Results and discussion 
 
3.5.1 Standard stability 
 
The stability of analytes standards during their storage is crucial when 
determining trace concentrations in wastewater samples, or any other matrix. 
Therefore, individual stock standard solutions of each analyte were stored in the 
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dark at 4°C, and tested over a period of three months. No significant degradation 
of any of the pharmaceuticals was observed during this period. However, in order 
to increase the rigour of the laboratory work, mixed standards of the analytes, in 
suitable solvents, were often made. Figure 3.1 shows the separation and detection 
peak of pharmaceuticals in the extracted sample from spiked wastewater.   
 
3.5.2 Calibration and limits of quantification 
 
Table 3.3 and Figure 3.1 presents data showing individual substance retention 
times, linearity of the calibration curves, limits of quantification, and recovery 
yields following extraction.  
Calibration curves were prepared for each compound by plotting the average total 
ion peak area versus the analyte concentration. A sample with no analyte peaks 
was used as a blank for the calibration curves. Linearity was tested in the range 
1–100 µg.L-1 depending on the type of pharmaceutical, and all showed R2 values 
>0.99, indicating a good linearity with high correlation. Variance of the method 
was investigated by determining the short-term and long-term relative standard 
deviations (RSDs) under identical conditions. The RSDs were obtained by 
analysing three replicates of samples at 10 µgL
-1
. Intra- and inter-day variance 
were found to be lower than 10% for all compounds. Limits of detection (LODs) 
calculated as the signal-to-noise ratio (S/N) of 3:1, ranged from 1 to 5 ng.L
-1
, 
depending on the compound spiked in the effluent wastewater (Table 3.3). The 
relative standard deviation (RSD) of the slope of the calibration curve was less 
than 10% for each of the individual substances, based on fresh calibration 
solutions that were made and injected on three different days. The limits of 
quantification (LOQ) were in the range of 7–10 ng.L-1 depending on the analyte 
(pharmaceutical) injected. These values were determined by spiking 
pharmaceuticals in wastewater and extraction using SPE, then the extract was 
injected in LC-MS until the signal-to-noise ratio for any signal analyte reached a 
value of 10:1.    
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The SPE procedure was evaluated using standards prepared in distilled water, 
influent wastewater, synthetic wastewater, and tap water, with the studied 
compounds. Recoveries as evaluated in spiked distilled water, as well as in 
spiked real samples, are shown in Figure 3.2. The recoveries of the analytes from 
the samples spiked with pharmaceutical at a concentration of 100  ng.L
-1
wasthe 
highest for distilled water and synthetic wastewater ranged from 87 to 99 %;  
with real wastewater samples giving moderate recoveries ranging from 77 to 
94%. However, the lowest recoveries were for tap water (34 to 64%), due to the 
chlorine effect, except Ranitidine which showed the highest recovery level at 
91%. This observation gives a high uncertainty in the quantification of 
pharmaceuticals at very low concentrations, but allows for their reliable 
detection, presence or absence, even at low concentrations.  
 
Table 3.3: Limits of detection, limits of quantification and linearity of 
calibration curve of pharmaceutical compounds. 
Compound R
2
 Average 
R.S.D 
(%) 
limit of 
Detection 
(LOD) 
ng.L
-1
 
limits of 
quantification 
(LOQ) ng.L
-1
 
Metronidazole 0.9989 4.778 5 8 
Trimothoprim 0.9993 2.24 5 7 
Sulphamethoxazole 0.9989 6.838 1 10 
Paracetamole 0.9993 4.63 5 10 
Ranitidine 0.999 5.75 5 10 
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RT: 0.00 - 24.73
0 2 4 6 8 10 12 14 16 18 20 22 24
Time (min)
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
0
50
100
13.08
4.83
5.04
16.03
7.56
7.271.07 5.57 7.80 12.63 15.149.40 16.423.05
1.69
12.98
NL: 7.25
m/z= 127.50-128.50 F: ITMS + c APCI corona 
SRM ms2 172.10@cid23.00 [127.50-128.50]  MS 
IS+Metro10ppbAPCI1
NL: 2.05E1
m/z= 229.50-230.50 F: ITMS + c APCI corona 
SRM ms2 291.10@cid34.00 [229.50-230.50]  MS 
is+trimetho10ppbapcinew_100104175550
NL: 4.98
m/z= 187.50-188.50 F: ITMS + c APCI corona 
SRM ms2 254.10@cid28.00 [187.50-188.50]  MS 
is+sulfa50ppbapcinew
NL: 3.16E1
m/z= 109.50-110.50 F: ITMS + c APCI corona 
SRM ms2 152.00@cid24.00 [109.50-110.50]  MS 
is+para50ppbapcitest
NL: 8.07
m/z= 269.50-270.50 F: ITMS + c APCI corona 
SRM ms2 315.10@cid27.00 [269.50-270.50]  MS 
is+rani25ppbapci5
NL: 1.08E2
m/z= 131.50-132.50 F: ITMS + c APCI corona 
SRM ms2 176.10@cid24.00 [131.50-132.50]  MS 
IS+Metro10ppbAPCI1
Metronidazole
Tri ethoprim
Sulphamethoxazole
Pa acetamole
Ranitidine 
Internal standard
 
Figure 3.1: Chromatograms of standards: Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamole, Ranitidine, and IS on 
different LC-MS runs each compound at specific ion monitoring (SIM).
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Figure 3.2: Recoveries of pharmaceutical compounds in spiked distilled water, tap water, synthetic wastewater, and real 
wastewater, with the standard solution (ST).
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3.5.3 Effect of chlorine on pharmaceutical extraction efficiency 
 
Figure 3.3 shows the analytical extraction results for Metronidazole, 
Trimothoprim, Sulphamethoxazole, Paracetamol, and Ranitidine using SPE. The 
relative concentrations (concentration compared to that without residual chlorine) 
of the laboratory samples at different free chlorine concentrations, are compared. 
The residual chlorine substantially reduced the observed concentrations of 
pharmaceuticals.  
Depending on the pharmaceuticals and solvent nature, reductions of recovery 
between 10–80% were found. Reductions were found with tap water, whereas the 
lowest reductions were found with tab water and chlorinated wastewater. The 
effect of free chlorine in the chlorinated wastewater showed a reduction in the 
recovery of pharmaceuticals approaching 0%, as in the Ranitidine, whereas 
Trimethoprim had the lowest recovery in tap water due to the presence of free 
chlorine. 
In chlorine removal experiments, samples with different pharmaceuticals were 
reacted with 1.0 mg.L
-1
 of sodium hypochlorite. Sodium thiosulfate was then 
used to reduce any remaining free chlorine. As shown in Figure 3.3, the 
analytical results for the dechlorinated samples were very close to those without 
any free chlorine addition. A significant increase was observed in the recovery of 
pharmaceuticals from tap water and chlorinated wastewater when sodium 
thiosulphate was added prior to addition of the pharmaceuticals. These results 
confirm that the addition of sodium thiosulfate effectively eliminates the negative 
effect of chlorine on the extraction using SPE. 
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Figure 3.3: Effect of chlorine on the recovery of pharmaceutical compounds spiked in distilled water, tap water, wastewater, and 
chlorinated wastewater revealed by sodium thiosulphate treatment.
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3.5.4 Matrix interferences 
 
There are many studies reported in the literature on interferences between the co-
elution of matrix components and the target analyte in LC-MS/MS, commonly 
referred to as ion suppression effects (Jemal et al., 2003; Schuhmacher et al., 2003).  
These effects may influence both the precision and accuracy of a method. Here the 
precision was compared between analyte and internal standard ratios in both pure 
standard solutions and spiked extracts of distilled water, tap water, synthetic 
wastewater, and real wastewater. The recovery of repeated injections (n = 3) of a 
pure standard solution and a spiked extract (Figure 3.2) showed relatively small 
differences in recoveries were obtained between pure a standard solution and a 
spiked extract, irrespective of the matrix. The only exception was that widely 
lowering recoveries were observed for different pharmaceutical in tap water. 
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4. MATERIALS AND METHODS 
 
4.1 Fate of pharmaceuticals in Sulaibiya wastewater treatment plant 
 
4.1.1 Methodology 
 
This study uses 12 months of complete monthly measurements of quantitative data 
from Sulaibiya WWTP for the period 1 September 2010 to 31 August 2011. A flow 
diagram with sampling points for analytical measurements is shown in Figure 4.1. 
Wastewater samples for analysis of pharmaceuticals were usually collected monthly 
in amber glass containers, which had been pre-cleaned with reagent water and 
organic solvents such as methanol and acetone. Both discrete and composite samples 
were sampled, but it is more appropriate to collect composite samples to evaluate the 
performance of a WWTP. UF backwash and RO brine were also sampled for 
investigation. To prevent any bacterial activity wastewater samples were filtered 
using 0.45 µm membrane filters (Gelman Sciences), sulphuric acid added to reduce 
the pH to 3, and stored up to 7 days at 4ºC until extraction. 
4.1.2 Calculation of Concentration Factor 
 
The concentration factor of a membrane filter is a ratio of the average concentration 
of a compound in the backwash and brine compared to the UF and RO feed 
respectively, which depends on the recovery of water and retention of individual 
compounds. It can be represented as shown in Equation 4.1. 
  
  
  
                                                             (4.1) 
where CF and Cc are the solute concentrations in the feed and in the backwash or 
brine, respectively. 
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The process variables analysed from the database of Sulaibiya WWTP were flow 
rate, temperature, total organic carbon (TOC) and physicochemical parameters (e.g., 
pH, electrical conductivity (EC), suspended solids (SS), total dissolved solids (TDS), 
chemical oxygen demand (COD), biological oxygen demand (BOD) and coliform 
bacteria ( measured as total coliforms). 
4.1.3 Trace of pharmaceuticals Analysis 
 
The samples were filtered through sterile membrane filters 0.45 µm (Gelman 
Sciences), adjusted to pH 2-3, and extraction was carried out using SPE. Extracts 
were analysed by LC-MS-MS for detection of Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine (See section 3.4). 
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Figure 4.1: Diagram indicating the sampling points at the WWTP. 
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4.2 The removal of pharmaceuticals by chlorination and ozonation treatment 
processes 
 
To identify any removal of pharmaceuticals by chlorine, a study was carried out on 
the chlorination of the pharmaceuticals at laboratory scale. In addition, other 
treatments also found in water reclamation plants such as ozonation were 
investigated. Several treatment processes such as chlorine and ozone concentration 
were tested to compare their removal efficiency of spiked pharmaceuticals at 
concentration 100 µg.L
-1 
in different sample media such as synthetic wastewater, real 
wastewater and tap water. Chlorination and ozonation test of the five 
pharmaceuticals were performed in order to assess their degradability. A bench scale 
experiment was conducted using a 500 ml sample in a stirred beaker spiked with 
pharmaceuticals at concentration 100 µg.L
-1
 treated for 30 minutes with 5 and 10 
mg.L
-1
 chlorine from commercial Clorox sodium hypochlorite bleach and 5, 10 and 
15 mg.L
-1
 ozone by ozone generator (Reef Scientific Ozoniser, UK). 
 
4.3 Fate of pharmaceuticals in batch experiments 
 
4.3.1 Methodology 
 
Batch tests were carried out using the return activated sludge (RAS) taken directly 
from the aeration tank of the WWTP. This batch study was divided into two parts. 
One was a batch test to determine the effect of pharmaceutical concentration on 
organic removal, and the other was to examine the kinetic rates of organic removal 
in the activated sludge process. Batch experiments were performed using a 
continuously stirred tank reactor (CSTR) (Figure 4.2.) Each tank CSTR contained 2L 
of wastewater, and spiked pharmaceuticals (Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol, and Ranitidine) in separate experiments with 
initial concentrations of 0.1, 1, and 10 mg.L
-1
. The synthetic wastewater was added 
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as the sole organic carbon source at TOC 400 mg.L
-1
. These batch experiments were 
conducted with activated sludge inoculums at pH 6.8, 25 °C, and activated sludge 
concentration of ≈2.56 g MLSS .L
-1
.  
Three CSTR investigated different concentrations of pharmaceuticals, while the 
fourth was used as a control (without pharmaceutical). Air diffusers were installed at 
the bottom of the reactor giving a flow of 96 L.h
-1
, so that the dissolved oxygen (DO) 
concentration was maintained above 2 mg.L
-1 
in each reactor. Each batch experiment 
was run for five days.  
 
 
Figure 4.2: Photograph of the continuously stirred tank reactors. 
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4.3.2 Batch analysis test 
 
10 ml samples were collected from each batch in order to evaluate batch 
performance. Parameters analysed in this study were pH, temperature, DO, MLSS, 
TOC, and individual pharmaceutical (according to Section 4.5).  
 
4.3.3 Isolation of bacteria from a CSTR 
 
The stock minimal media solutions of 1M, 20X fold phosphate buffer at pH 7.2 (86.6 
g.L
-1
 Na2HPO4 and53 g.L
-1
 KH2PO4), 54 g.L
-1
 NH4Cl, 204 g.L
-1
 MgSO4, and 44 g.L
-1
 
CaCl2 were separately prepared and sterilized by autoclaving. 1000X fold trace 
elements at pH 6.7 (1.5 g.L
-1
 FeCl2.4H2O (dissolve in conc. HCl), 70 mg.L
-1
 ZnCl2, 
100 mg.L
-1
  MnCl2.4H2O, 200mg.L
-1
 CoCl2.6H2O, 20 mg.L
-1
 CuCl2.2H2O, 20 mg.L
-1
 
NiCl2.6H2O, 40 mg.L
-1
 Na2MoO4.2H2O and 20 mg.L
-1
 H3BO3), and 1000X fold 
vitamins (100 mg.L
-1
 Cyanocobalamine (B12), 300 mg.L
-1
  Pyridoxamine-2HCl (B6), 
100 mg.L
-1
 Ca-D (+)Pantothenate, 200 mg.L
-1
 Thiamine dichloride (B1), 200 mg.L
-1
 
Nicotinic acid, 160 mg.L
-1
  4-Aminobenzoic acid and 20 mg.L
-1
 D (+) Biotin), were 
sterilized by filtration using 0.22 µm (Nalgene) and kept protected from light 
(Gilbert et al., 1998).  
For preparation of 1 L of working minimal media, the following solutions were 
mixed together: (50 ml of potassium phosphate buffer (1M), 10 ml NH4Cl (1M), 1 
ml MgCl2 (1M), 1 ml CaCl2 (0.3 M), 1 ml of trace elements, and 1 ml of vitamins, 
then completed to 1L by distilled H2O). The pH of the medium was adjusted to be 
7.4.  
Activated biomass was collected from a CSTR that contained pharmaceuticals at 
concentration 1 mg.L
-1
 after each run. One litre of suspended sludge was collected, 
and allowed to settle. The supernatant was discarded and the biomass was pooled. 1 
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g of aliquots sample were collected in sterile 50 ml tubes with 10 ml of wastewater, 
and preserved at 4 ºC. The sample was centrifuged and the biomass suspended in a 
sterile 10 ml phosphate buffer (8 g NaCl, 0.2 g KCl, 1.44 g Na2HPO4 and 0.24 g 
KH2PO4, in 1 L of distilled water, pH 7.4). 1 ml of the suspension was inoculated in 
a flask containing 100 ml of minimal media, 10 mg.L
-1
 yeast extract and 1 mg.L
-1
 
pharmaceutical. The flask was incubated at 37 ºC under agitation (120 rpm) for a 
period of 3 d. Inoculations on 10 % LB agar plates containing minimal media, 10 
mg.L
-1
 yeast extract and 1 mgL
-1
 pharmaceutical. The plates were incubated at 30 ºC 
for 3 d and the colonies were picked at random, and sub-cultured three times with 
LB agar plates. Randomly selected isolates colonies were used for DNA isolation 
using Genomic DNA Purification Kit (Promega), according to the method described 
in Appendix B. 
 
4.4 Fate of pharmaceuticals in continuous flow bioreactors 
 
This section describes details of the experiments conducted using a bench-scale 
membrane bioreactor (MBR) and sequencing bioreactor (SBR), including the study 
of the effects of the concentration of pharmaceuticals on the removal efficiency. 
Details of the experimental setup, reactor start- up procedure and characteristics of 
the synthetic wastewater used in the experiment are given below.  
4.4.1 Membrane bioreactor (MBR) 
 
MBRs were constructed from PVC flexible pipes (1.5m x 0.3m internal diameter), 
coated with rubber and equipped with submerged A4 Kubota membranes (cartridge 
type 203), made from chlorinated polyethylene with a nominal pore size of 0.45 μm 
and an effective surface of 0.3 m
2
. They had a working volume of 8 L Figure 4.3a. 
The MBRs were operated in a sequencing batch mode, comprising periods of Fill, 
React, and Draw (Table 4.1). The MBRs were fed with wastewater by peristaltic 
pump (MANOSTAT - division of Barnant Company, Simon varistaltic pump, USA) 
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with a 3 L.h
-1
 flow rate, controlled by a timer switch and a level control switch to 
ensure that no spillage occurred during the fill step.  Oxygen required for both 
aerobic bacteria and membrane surface scouring, was provided by compressed air 
via air diffusers controlled by timer switch. Membrane permeate was drawn out by 
peristaltic pumps (MANOSTAT - division of Barnant Company, Simon varistaltic 
pump, USA) with a flow rate 1.5 L.h
-1
, controlled by a timer switch (Figure 4.4). 
Each MBR was seeded with activated sludge inoculums at pH 6.8, 25 °C, to achieve 
a starting concentration of ≈2.56 g MLSS .L
-1
. The MBR system operation is described 
fully in Table 4.1.   
 
4.4.2 Sequencing bioreactor 
 
The SBR system was built from rigid PVC pipes (1.5m x 0.2m internal diameter) 
and a working volume of 8 L. The SBR was operated according to a conventional 
laboratory-scale cycle, comprising periods of fill, react, settle and draw (Table 4.1). 
The reactor was fed with wastewater by peristaltic pump (MANOSTAT - division of 
Barnant Company, Simon varistaltic pump, USA) with a 3 L.h
-1
 flow rate, controlled 
by a timer switch and a level control switch (Figure 4.3b), to ensure that no spillage 
occurred during the fill step.  Oxygen required for both aerobic bacteria and 
membrane surface scouring, was provided by compressed air via air diffusers 
controlled by a timer switch. Treated wastewater was drawn out by solenoid valve 
with flow rate 6 L.h
-1
, controlled by a timer switch (Figure 4.4). Each SBR was 
seeded with activated sludge inoculums at pH 6.8, 25 °C, to achieve a starting 
concentration of ≈2.56 g MLSS .L
-1
.  The SBR system operation is described fully in 
Table 4.1.   
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Table 4.1: Summery operating conditions for the MBR and SBR 
Reactor Process phase order Duration Pharmaceutical 
concentration 
Duration 
 Fill  Aeration  Draw  
MBR 
(control) 
 
Fill 
Aerobic 
Draw 
on 
off 
off 
off 
on 
off 
off 
off 
on 
2 h 
18 h 
4 h 
 
No addition of 
pharmaceutical 
 
63 day 
SBR 
(control) 
Fill 
Aerobic 
Settle 
Draw 
on 
off 
off 
off 
off 
on 
off 
off 
off 
off 
off 
on 
2 h 
18 h  
2 h 
2 h 
No addition of 
pharmaceutical 
 
63 day 
MBR1  Fill 
Aerobic 
Draw 
on 
off 
off 
 
 
off 
on 
off 
 
 
off 
off 
on 
 
 
2 h 
18 h  
4 h 
 
No addition 
1µg.L
-1
 in synthetic WW 
1mg.L
-1
 in synthetic WW 
10mg.L
-1
 in synthetic WW 
1mg.L
-1
 in real WW 
10 day 
29 day 
10 day 
7 day 
9 day 
MBR2 Fill 
Anoxic 
Aerobic 
Draw 
on 
off 
off 
off 
off 
off 
on 
off 
off 
off 
off 
on 
2 h 
2 h 
16 h  
4 h 
No addition 
1µg.L
-1
 in synthetic WW 
1mg.L
-1
 in synthetic WW 
10mg.L
-1
 in synthetic WW
 
1mg.L
-1
 in real WW 
10 day 
29 day 
10 day 
7 day 
9 day 
SBR1 Fill 
Aerobic 
Settle 
Draw 
on 
off 
off 
off 
off 
on 
off 
off 
 
off 
off 
off 
on 
 
2 h 
18 h  
2 h 
2 h 
No addition 
1µg.L
-1
 in synthetic WW 
1mg.L
-1
 in synthetic WW 
10mg.L
-1
 in synthetic WW 
1mg.L
-1
 in real WW 
10 day 
29 day 
10 day 
7 day 
9 day 
SBR2 Fill 
Anoxic 
Aerobic 
Settle 
Draw 
on 
off 
off 
off 
off 
off 
off 
on 
off 
off 
off 
off 
off 
off 
on 
2 h 
2 h 
18 h  
2 h 
2 h 
No addition 
1µg.L
-1
 in synthetic WW 
1mg.L
-1
 in synthetic WW 
10mg.L
-1
 in synthetic WW 
1mg.L
-1
 in real WW 
10 day 
29 day 
10 day 
7 day 
9 day 
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Figure 4.3: Schematic diagram of the reactor setup and reactor dimensions (a) MBR 
(1.5m x 0.3m internal diameter) and (b) SBR (1.5m x 0.2m internal diameter). 
(a) MBR 
(b) SBR 
1.5 m 
0.3 m 
1.5 m 
0.2 m 
Break tank  
Break tank 
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Figure 4.4: Photograph of the MBR (right) and SBR (left) reactors showing 
floor-standing reactors, suspended tanks and peristaltic pumps. 
 
4.5 Preparation of synthetic wastewater 
 
The synthetic wastewater used in this study was prepared by dissolving the following 
substances in 1 litre of distilled water to make a stock concentrate.  
Peptone       16g 
Meat Extract       11g 
Urea        3g 
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Sodium Chloride (NaCl)     0.7g 
Calcium Chloride dihydrate (CaCl2.2H2O)   0.4g 
Magnesium Sulphate Heptahydrate (MgSO4.7H2O)  0.2g 
di-Potassium Hydrogen Phosphate (K2HPO4)  2.8g 
This stock synthetic wastewater is a 100-fold concentrate of that described in the 
OECD, 1976, but with the addition of di-potassium hydrogen phosphate for 
improved buffering. Immediately after preparation, the stock synthetic wastewater 
was autoclaved at 120ºC for 15min and then stored in the dark at 4ºC for no longer 
than one week. Before each use, the stock solution was diluted 40 times with tap 
water, to yield approximately 600-700 mgCOD.L
-1
, which is equivalent to a medium 
strength synthetic wastewater in terms of COD (Metcalf and Eddy, 2003). 
 
4.6 Analytical methods 
 
Performance parameters were pH, dissolved oxygen (DO), total organic carbon 
(TOC), mixed liquor suspended solids (MLSS), mixed liquor volatile suspended 
solids (MLVSS), and chemical oxygen demand (COD). 
4.6.1 pH 
Samples were measured for pH using the glass electrode pH meter (JENWAY 3310, 
Jenway Limited, Essex, U.K.) according to standard methods 4500H
+
 (APHA, 
1998).   
4.6.2 Dissolved oxygen (DO) 
DO of the reactor content was detected by the microprocessor logging dissolved 
oxygen meter (HANNA instruments, HI 91410). This meter utilised the membrane 
probe and could measure temperature to automatically compensate for temperature 
changes. The DO was taken from the laboratory bioreactors by reading directly from 
the screen according to standard methods 4500-O G (APHA, 1998).  
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4.6.3 MLSS and MLVSS 
To measure the MLSS, a suitable volume of sample was filtered through glass 
microfiber filters (934-AH) (Whatman, England), which was subsequently dried at 
105⁰C in an oven for one hour. This filter paper was weighed using an analytical 
balance after cooling in the desiccator. To determine the MLVSS, the same filter 
paper was then ignited at 550ºC in a muffle furnace for 15 minutes and cooled in a 
desiccator before being weighed using an analytical balance. MLSS and MLVSS of 
samples were calculated using the following equations (4.2 and 4.3). 
 
MLSS (mg/l) = 
1000*
V
WW ifo 
                                              (4.2) 
where: Wfo = weight of the filter paper after being dried at 104ºC in an oven (mg) 
 Wi = weight of the filter paper with 105⁰ residue (mg) 
 V = volume of sample (ml)  
MLVSS (mg/l) = 
1000*
V
WW fffo 
                                           (4.3) 
where: Wff = weight of the filter paper with residue after ignition at 550ºC in a 
furnace (mg) 
4.6.4 Total organic carbon (TOC) 
Samples were filtered using the glass microfiber filter papers (934-AH) before 50 µL 
was injected in triplicate into the total organic carbon analyzer (TOC-5050A, 
SHIMADZU, Japan), and the average result was taken, the sample was diluted if 
necessary to be calculated in the calibration curve range. The instrument was 
calibrated with standard solutions of hydrogen potassium phthalate with three point 
concentrations between 1-100 mg.L
-1
. Firstly CO2 produced was detected by the 
analyzer when phosphoric acid was added into a portion of the sample giving the 
inorganic carbon (IC) value. Then, the total carbon (TC) was measured from the 
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amount of CO2 produced when another portion of the same sample was ignited. TOC 
measurement of a sample was the result of IC subtracted from TC, which was 
directly given by the analyzer.     
4.6.5 Chemical oxygen demand (COD) 
COD was measured by using the standard method involving potassium‐dichromate 
oxidation for the analysis; standard test tubes (Lovibond) were used at two ranges, 
low range (0-150 mg.L
-1
) and medium range (0-1500 mg.L
-1
) from Orbeco-Hellige. 
1ml from the filtered sample was added to the standard reagent test tubes, and then 
was heated at 150⁰C for 2 hours by the COD digester (Lovibond, ET 108). The COD 
values were measured after cooling to room temperature with a COD photometer 
(Lovibond PCCheckIt) at wave length 254 nm. Blank filtered distilled water samples 
were also treated similar to the unknown sample to reset the photometer to zero 
value.    
 
4.7 Pharmaceutical concentration analysis 
The samples were collected and filtered through sterile membrane filters 0.45 µm 
(Gelman Sciences), adjusted to pH 2-3 with sulphuric acid, and the extraction was 
carried out using SPE to follow the degradation of the pharmaceutical. Extracts were 
analysed by LC-MS-MS for detection of Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine. Full details of the experimental 
method have been described previously in Section (3.4). 
 
4.8 Removal rate and the specific removal rate 
To evaluate and compare the performance of different bioreactors during different 
operating conditions in the same reactor, the removal rate and the specific removal 
rate were determined. The removal efficiency was defined as a percentage of the 
ratio of the removed substance compared to the initial amount of substance, and was 
calculated using Equation 4.4. 
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Removal efficiency = 
100
 
t
ttt
C
CC
             (4.4) 
where: t
C
= concentration of a parameter at time t (mg/l) 
 tt
C  = concentration of a parameter at time t+Δt (mg/l) 
 
The specific removal rate is a relatively important parameter because it shows the 
relationship between removal rate and mass unit of microorganisms. 
  
Specific removal rate (g removed.g MLVSS
-1
.d
-1
) = MLVSSV
QCC ittt

  )(
              (4.5)  
where: i
Q
= influent flow rate (m
3
/d) 
  V = reactor volume (m
3
) 
4.9 Microbial diversity study 
Microscopic analysis was used to study major physiological changes of the microbial 
communities at different pharmaceutical concentration conditions. To study the 
microbial diversity in more detail, the molecular technique, polymerase chain 
reaction-denaturing gradient gel electrophoresis (PCR-DGGE), was utilised. 
 
4.9.1 Microscopic analysis 
MLSS samples were taken directly from the bioreactor at the end of the reaction 
phase to ensure that the contents inside the bioreactor were completely mixed and 
the sample was representative of the bioreactor biomass. After the sludge was 
allowed to settle, one drop of the settled sludge was placed directly on a microscope 
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slide, and covered with a cover slip before being viewed (×100 magnification) under 
an Olympus BX51 microscope (Olympus Optical Co, Ltd., Tokyo, Japan). Four 
fields of view per slide were observed and pictures were taken using a digital camera 
Olympus DP12. 
 
4.9.2 PCR-DGGE 
Sludge samples for the MBRs and SBRs in experiment 4.3 were fixed to retain the 
morphological integrity of microorganism cells before the DNA extraction was 
carried out.  5 ml of the MLSS sample was taken and transferred to the sterile plastic 
universal bottle, which was pre-filled with 5 ml absolute ethanol. The sample was 
stored at -20ºC before conducting the DNA extraction (see Appendix C).  
The obtained DGGE band patterns were analysed using the Bionumerics software 
version 3.5 (Applied Maths, Sint-Martens-Latem, Belgium). This software comprises 
steps which allow the defining of different lanes, background subtraction, and 
marker assisted normalisation, which includes compensating for intensity difference 
between the lanes, and assigning the different bands in each lane. The DGGE 
compares the DNA bands of isolated pure culture bacteria in experiment 4.2 with the 
DNA bands of MBRs and SBRs in experiment 4.3.  
 
4.10 Statistical analysis 
The data was processed qualitatively and quantitatively by using computer analytical 
programmes such as Microsoft Excel 2007. The data was analysed statically using 
the ANOVA MINITAP. In each comparison, the confidence level is indicated where 
results are presented, to minimise the effects of the possibly unequal variances of 
each population in the one-way ANOVA analysis.  
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4.1.1 Analysis of Variance (ANOVA) 
The implications of each of the independent factors and their interactions on the 
responses were analyzed using ANOVA which was carried out with the aids of 
MINITAB (Version 16). As a result of such analyses is the p-value is determined which 
refers to the significance of the factor in affecting the response. A smaller p-value refers 
to a higher significance level of the factor affecting the response. It can determine the 
level of confidence through the application of equation (3):  
  
Confidence level = (1 - p-value) x 100                                                       (3) 
4.1.2 Correlation Analysis 
The correlation between the pharmaceutical concentration and performance parameters 
was determined. The responses were selected based on how significant is the effect of 
pharmaceutical concentration. These parameters are TOC and COD removal, TOC and 
COD biodegradation rate, MLSS concentration, pharmaceutical removals, and 
pharmaceutical degradation rate. The regression test was chosen to determine the 
correlation keeping in mind that the correlation coefficient R
2
 value higher than 90% 
indicates high correlation. Figures show the correlation between the concentration and 
each of the selected responses. All of these quantitative correlations corresponded with 
the qualitative correlations between the pharmaceutical concentration and each of 
biomass concentrations and removal efficiencies.  
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5. Results and Discussion 
 
5.1 Fate of pharmaceutical waste in Sulaibiya wastewater treatment plant 
 
5.1.1 Physicochemical Characterisation of Influent 
The inflow of the wastewater was monitored during the period between September 
2010 and August 2011. This data showed that the inflow of the wastewater ranged 
between 271000 and 298400 m
3
/day. The physicochemical parameters of the 
influent during the sampling period exhibited large variations. The wastewater 
temperature values varied from 23 °C in winter to 35 °C in summer. The values of 
pH, nitrogen, phosphorous, chemical oxygen demand (COD), electrical conductivity 
(EC) and suspended solids (SS) fluctuated during the sampling period (see Appendix 
D). 
 
5.1.2 Performance of wastewater treatment processes of Sulaibiya WWTP 
The physicochemical properties of the effluent are presented in Appendix D. The 
total phosphorus content decreased from 6.3 mg.L
-1
 in the influent to 1.6 mg.L
-1
 in 
the effluent and the total Kjeldahl nitrogen content of the influent 43.5 mg.L
-1
 
decreased to 2.5 mg.L
-1
 in the effluent.  Phosphorus and nitrogen are normally 
known as limiting nutrients for eutrophication in the natural balance of aquatic 
ecosystems; therefore, careful management of their discharge is important to prevent 
excessive algal growth (Andersen et al., 2006). The primary and secondary 
treatments of the wastewater effectively reduced the phosphorus and nitrogen by 
75% and 94%, respectively compared to influent levels. The final effluent had a 
better quality with regard to the nitrogen and organic content due to the efficiency of 
the activated sludge process in the WWTP where average COD removals were 93%. 
The suspended solids in the secondary effluent were much lower than the influent 
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and showed typically 95% removal. During the primary and secondary treatments, 
the cation concentrations did not change significantly, which can be seen by only a 
small change in the electrical conductivity between the influent and effluent, with an 
average reduction of 17%. 
 
5.1.3 Occurrence of pharmaceuticals in wastewater influents 
The concentrations of the target pharmaceuticals in the influent over the year-long 
sampling period at Sulaibiya are summarized in Figure 5.1.1. Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine were always found in influent 
samples, whereas Metronidazole was not detected in October and November. 
Metronidazole detection ranged between 4 ng.L
-1
 in December and 58 ng.L
-1
 in 
April, these both being lower than other reported values (Rosal et al., 2010). 
Trimethoprim and Sulphamethoxazole were found in the influent within the range of 
61 - 1814 and 11 - 1669 ng.L
-1
, respectively. The highest concentration of 
Trimethoprim was found in August, and the lowest was found in April, whereas the 
highest concentration of Sulphamethoxazole was found in October, and the lowest in 
February. 
Trimethoprim was reported at 290 ng.L
-1 
in raw influent wastewater in Switzerland 
(Goebel et al., 2005), and at relatively high concentrations 2100 – 7900 ng.L-1 in the 
USA (Batt et al., 2007). On the other hand, Sulphamethoxazole has been previously 
reported at a high concentration of 6000 ng.L
-1
 (Giger et al., 2003), but a 
concentration of 1669 ng.L
-1
 was the upper limit in the current study. Paracetamol 
and Ranitidine were found in the influent at concentrations substantially higher than 
the other target drugs, all of which were among the top ten pharmaceuticals 
dispensed in Kuwait. Paracetamol was detected in all the wastewater samples at 
concentrations ranging from 101 - 2086 ng.L
-1
 with the highest concentration in 
November 2010 and the lowest concentration in February 2011. These 
concentrations were, to some extent, lower than those reported previously (Pham and 
Proulx, 1997; Ternes, 1998; Blanchard et al., 2004). On the other hand, Ranitidine 
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ranged from 365 - 2009 ng.L
-1
, so is fairly consistent with other studies which have 
reported 580 ng.L
-1
 (Kolpin et al., 2002) and 1700 ng.L
-1
 (Gomez et al., 2006). 
 
The temperature fluctuated during the sampling between summer and winter. This 
fact might indicate that the concentrations of pharmaceuticals in the influent may be 
related to higher consumption during the winter periods of the year when more 
seasonal illnesses occur. 
 
Figure 5.1.1: Variation of concentration of various target compounds (ng.L
-1
) in 
the influent, with each point representing one monthly detected sample. 
 
5.1.4 Removal of pharmaceuticals during the primary and secondary treatment at 
Sulaibiya WWTP 
The removal rates of pharmaceuticals during the sampling period are shown in 
Figure 5.1.2 (a,b,c,d,e). Paracetamol was removed efficiently by the secondary 
2100 1800 1500 1200 900 600 300 0 
Metronidazole 
Trimethoprim 
Sulphamethoxazole 
Paracetamol 
Ranitidine 
ng.L-1
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treatment, at an average of 97.5%, with the highest removal reaching 99.9%, and the 
lowest removal being 86.1%. Trimethoprim was removed less effectively than 
Paracetamol, with an average removal of 86.1%, where the highest removal was 
96.1%, and the lowest removal was 63%.  Removal efficiency of Metronidazole 
during secondary treatment was at an average of 83.4%, with the highest removal at 
93.9%, and the lowest removal at 59.4%. Sulphamethoxazole and Ranitidine showed 
the lowest removal efficiencies with an average of 77.5% removal, where the highest 
removal of Sulphamethoxazole was 98.7%, and the lowest removal was 31.3%, 
while the highest removal of Ranitidine was 99.2%, and the lowest removal was 
47.4%. 
 
 
 
Figure 5.1.2.a: Concentration of Metronidazole (ng.L
-1
) in the influent and the 
removal percentage after secondary treatment processes of Sulaibiya WWTP 
between 2010 -2011.  
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Figure 5.1.2.b: Concentration of Trimethoprim (ng.L
-1
) in the influent and the 
removal percentage after secondary treatment processes of Sulaibiya WWTP 
between 2010 - 2011.  
 
Figure 5.1.2.c: Concentration of Sulphamethoxazole (ng.L
-1
) in the influent and 
the removal percentage after secondary treatment processes of Sulaibiya 
WWTP between 2010 - 2011.  
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Figure 5.1.2.d: Concentration of Paracetamol (ng.L
-1
) in the influent and the 
removal percentage after secondary treatment processes of Sulaibiya WWTP 
between 2010 - 2011.  
 
 
Figure 5.1.2.e: Concentration of Ranitidine (ng.L
-1
) in the influent and the 
removal percentage after secondary treatment processes of Sulaibiya WWTP 
between 2010 - 2011.  
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 In general, the removal efficiencies found in this study were consistent with other 
WWTPs using primary treatment and secondary treatment with activated sludge. For 
example, a 75% removal rate was observed for Diclofenac in Germany (Ternes, 
1998; Stumpf et al., 1999), up to 90% removal of Ibuprofen  being reported in Spain 
(Santos et al., 2007), and greater than 90% removal efficiency was observed for 
Aspirin, Ibuprofen, and Thymol  in Japan (Nakada et al., 2006). The removal 
efficiency for a single compound can vary greatly from one WWTP to another 
depending on the type of treatment (e.g. biological and physicochemical) and the 
residence time of wastewater in the primary sedimentation tank (Santos et al., 2007). 
 
Removal efficiency of Metronidazole has been reported with a large variability range 
of 65 - 80% in Spain (Gros et al., 2010). On the other hand, Trimethoprim has been 
reported to show incomplete removal during conventional treatment by several 
studies (Gobel et al., 2007; Jelic et al., 2011), while Gros et al. (2010) reports 65 - 
80% removal efficiency in treatment plants with longer hydraulic retention times. 
Similar observations were made by other researchers for the removal efficiency of 
Sulphamethoxazole and Ranitidine with reported removal efficiencies of 30 - 92% 
and 50 - 98%, respectively (Gros et al., 2010). In Germany, Paracetamol was found 
to be removed efficiently at 95% due to its biodegradability, and was detected in less 
than 10% of all WWTP effluent (Ternes et al., 1998; Kolpin et al., 2004; Roberts and 
Thomas, 2006).  
 
Concentrations of the target pharmaceuticals detected in the WWTP effluent were in 
the range 1 - 1000 ng.L
-1
, and are presented in Figure 5.1.3 (a, b, c, d, e). This is in 
agreement with Ternes et al. (1998), who reported that many pharmaceuticals were 
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detected in the effluents and measured at high concentrations due to incomplete 
removal in German sewage treatment plants. 
 
The efficiency of modern wastewater treatments has increased the removal of 
pharmaceuticals from the influent with the introduction of the activated sludge 
process. Elimination of pharmaceuticals in the activated sludge process occurs due to 
several processes, adsorption, biological or chemical degradation and 
biotransformation. Ternes et al. (1998) suggested that the activated sludge process 
removes higher amounts of pharmaceuticals than other treatments, most likely due to 
the bacterial activity in the activated sludge. The results of the current study showed 
that there was incomplete elimination of trace levels of pharmaceuticals in the 
effluent. Therefore, implementing other technologies such as membrane systems 
would be necessary for more complete removal of these trace quantities. 
 
5.1.4.1 Effect of temperature on the removal efficiencies of secondary treatment 
Although the total concentrations of target compounds in the influent samples 
fluctuated throughout the year-long sampling period, the removal process in the 
WWTP appeared to work as efficiently during the summer months than during the 
winter months; therefore, the effect of temperature was analysed statistically using 
ANOVA. The increase in temperature was correlated to an increase in the removal of 
COD, BOD, organic nitrogen, TKN, MLVSS, and target pharmaceuticals, and was 
highly significant (p < 0.05). This conclusion agrees with other researchers who have 
found that the removal processes in wastewater treatment plants were higher in 
summer than in winter (Vieno et al., 2005). They suggested that the reason was the 
lower biodegradation in the plant because of the low temperatures in winter.  
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5.1.4.2 The correlation of pharmaceutical concentrations with the removal 
efficiencies of WWTP 
The correlation of pharmaceutical concentrations with the removal parameters of the 
WWTP (COD, BOD, organic nitrogen, TKN, MLVSS and pharmaceutical) was 
highly significant (p < 0.05), except for Sulphamethoxazole, which had a significant 
correlation with COD, BOD, organic nitrogen, and TKN removal (p< 0.1), and had 
highly significant correlation with MLVSS and Sulphamethoxazole removal 
efficiency (p< 0.05).  
The primary and secondary wastewater treatment stages gave moderate to high 
removal efficiencies for all pharmaceuticals. However, the secondary effluent still 
had considerable concentrations of some pharmaceuticals in the range 1 - 1000 ng.L
-
1
, with most pharmaceuticals present in the influent being found in the effluent, 
which indicates the need for further treatment stages for complete removal of these 
pollutant compounds. 
 
5.1.5 Physical removal of pharmaceuticals at Sulaibiya WWTP 
 
5.1.5.1 Physicochemical Characteristics 
The physicochemical characteristics of the feed and permeate from the ultrafiltration 
process at Sulaibiya WWTP during the sampling period are presented in Appendix 
D. The average value of the physicochemical characteristics at the inlet of the 
ultrafiltration stage was pH (7.04), TSS (8.68 mg.L
-1
), TDS (437.1 mg.L
-1
), COD (24 
mg.L
-1
), BOD (4.07 mg.L
-1
), total iron (1.38 mg.L
-1
), and total coliforms (426261 
CFU/100ml).   
 
The average removal efficiencies for the TSS, total iron and total coliforms by the 
ultrafiltration process were 98%, 95% and 99%, respectively, while there was no 
significant change in the TDS measurements (Appendix D). The concentrations of 
 76 
 
COD were measured for ultrafiltration feed and permeate. Results did not show high 
removal of trace organic contaminants through the filtration processes, indicated by 
an average removal of COD of 42% while the BOD was 72%. Thus, the 
ultrafiltration process provides an essential pre-treatment for the RO by removing 
particulate and colloidal material from the feed (such as iron precipitates), but the 
removal is limited to particles larger than the membrane pore size (Van der Bruggen 
et al., 2003). 
 
The average removal efficiencies of the RO process for the TSS and total coliforms 
measurements were 68% and 99%, while there was a highly significant removal in 
the TDS measurements with an average removal of 96% (Appendix D). 
Furthermore, the concentration of BOD in the RO feed and the permeate shows high 
removal of trace organic contaminants through the RO filtration processes with an 
average removal of 90%.  
 
Trace organic compounds including pharmaceuticals, may be completely or partially 
degraded in the WWTP, with degradation taking place mostly in the activated sludge 
process. Pharmaceuticals fluctuate in their degradation in various wastewater 
treatment processes; however, remaining pharmaceuticals may be removed by 
ultrafiltration to RO systems. 
 
Pharmaceutical compounds were detected in the RO feed that was derived from the 
WWTP. Variations in concentration were a result of annual fluctuations of 
compounds in the raw wastewater, in addition to other processes involved in 
wastewater treatment. Most of the pharmaceuticals, namely Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol, and Ranitidine, were found in all 
samples from the RO inlets during the sampling year. The average concentrations of 
these compounds found in the RO inlets were 4 ng.L
-1
, 61 ng.L
-1
, 47 ng.L
-1
, 8 ng.L
-1
, 
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and 210 ng.L
-1
for Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol, 
and Ranitidine  respectively (Figure 5.1.3 (a,b,c,d,e)). The highest removal 
efficiency of these compounds was 97% for Ranitidine, 92% for Sulphamethoxazole 
and Paracetamol, and 86% for Trimethoprim. Lastly, the lowest removal efficiency 
of 56% found for Metronidazole was probably due to the low starting concentration 
found in the RO inlets.  
 
 
Figure 5.13a: Concentrations of Metronidazole (ng.L
-1
) detected in the RO inlet, and the 
removal percentage by RO process in the Sulaibiya WWTP during the year. 
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Figure 5.1.3b:Concentrations of Trimethoprim (ng.L
-1
) detected in the RO inlet, and the 
removal percentage by RO process in the Sulaibiya WWTP during the year. 
 
Figure 5.1.3c: Concentrations of Sulphamethoxazole (ng.L
-1
) detected in the RO inlet, and the 
removal percentage by RO process in the Sulaibiya WWTP during the year. 
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Figure 5.1.3d: Concentrations of Paracetamol (ng.L
-1
) detected in the RO inlet, and the removal 
percentage by RO process in the Sulaibiya WWTP during the year. 
 
Figure 5.1.3e: Concentrations of Ranitidine (ng.L
-1
) detected in the RO inlet, and the removal 
percentage by RO process in the Sulaibiya WWTP during the year. 
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membrane. In general, concentrations of these compounds in the brine were 16 times 
that in the feed for Metronidazole; twice for Trimethoprim, Sulphamethoxazole and 
Paracetamol; but it was totally removed from the feed and no traces found in the 
permeate for Ranitidine, and the concentration factor was found very small in the 
brine. Different concentration factors were found in the chosen pharmaceuticals, the 
reason behind that could be explained due to the different physical and chemical 
properties of these pharmaceuticals.    
The solubility of these pharmaceuticals varies; some are moderately soluble such as 
Sulphamethoxazole and Trimethoprim where the solubility was 281 mg.L
-1
 and 400 
mg.L
-1
, respectively; some are highly soluble like Ranitidine, Paracetamol and 
Metronidazole where the solubilities were 24.7 g.L
-1
, 14 g.L
-1
and 10 g.L
-1
, 
respectively. Log Kow values of these pharmaceuticals ranged between -0.02 and 
0.92. The correlation of log Kow with removal efficiency is shown in Figure 5.1.5, 
the solubility and log Kow did not correlate with the behaviour of these 
pharmaceuticals in the RO stage; however, Tolls, (2001) has suggested that log Kow 
may not be a good indicator of the behaviour of pharmaceuticals in the environment. 
It has been reported that the removal efficiency of solutes by ultrafiltration and RO 
can be affected by different parameters such as pH, solute charge, molecular weight 
and geometry, polarity and hydrophobicity, as well as the membrane surface charge 
(Van der Bruggen et al., 1998; Van der Bruggen et al., 1999; Kiso et al., 2000; Kiso 
et al., 2001; Ozaki and Li, 2002; Kimura et al., 2003b; Kimura et al., 2004).  
Investigations carried out previously on the removal efficiency of RO compared to 
other types of membranes showed a great advantage in using RO in producing high 
quality recycled water. According to Lopez-Ramirez et al. (2006), reclaimed 
wastewater with RO membranes widely exceed the drinking water standards and RO 
membranes achieve highly reduced levels of pollutants in the permeate. Furthermore, 
microorganisms were removed from the RO permeate, which would allow safe reuse 
of water in agriculture. 
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Figure 5.1.4:Concentration of Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol 
and Ranitidine (ng.L
-1
) in RO feeds, permeate and brine for December 2010. 
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Figure 5.1.5:Plot of the octanol water coefficient (log Kow) of pharmaceuticals against permeate removal efficiency. 
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5.1.5.2 Effect of temperature and pH on removal efficiencies by the RO process 
As with biological treatment, temperature affected the removal processes in the RO 
system. The concentrations of target pharmaceuticals in the RO inlet samples during 
the sampling year fluctuated during the summer and winter months. Therefore, the 
effect of temperature and pH was also analysed statistically using ANOVA. The 
correlation of temperature and pH with the removal of BOD, TSS, TDS, total 
coliforms and all target pharmaceuticals was highly significant (p< 0.05).  
In this study, comparison between the removal of pharmaceuticals and the other 
removal parameters tested, such as TSS, TDS, BOD, and total coliforms in the RO 
streams were tested, found that regression analysis did not show any correlation 
between the removal efficiency of pharmaceuticals with the removal of TSS, TDS, 
BOD, and total coliforms. This might be due to the complexity of the RO feed in 
WWTP, and to a broad range of rejection of the RO membrane. Therefore, it is very 
difficult to associate these operating parameters with the removal rates of the 
pharmaceuticals. 
 Due to the wide range of variability, and limitations in the data, it was not possible 
to determine any relationship between the removal of pharmaceuticals and their 
molecular weight and molecular size. According to Kimura et al. (2003) there was a 
linear relationship between molecular weight of the non-charged compounds and 
their removal. However, in the current study, there was a relationship between the 
molecular weight and the removal of Metronidazole, Trimethoprim and Ranitidine, 
as observed by the linear regression analysis, but for Sulphamethoxazole and 
Paracetamol there was no relationship (Figure 5.1.6). The physicochemical 
characteristics of the pharmaceuticals tested in this study differ from each other. 
Thus, a relationship between any of the removal trends could possibly be described 
by different physicochemical characteristics such the charge, shape and polarity of 
the compounds. Steric hindrance is the main removal mechanism of RO membranes, 
as well as electrostatic interaction and hydrophobic interaction between compounds 
and the membrane (Bellona et al., 2004). The removal efficiency of RO has been 
investigated by many researchers, and suggests that the removal may be influenced 
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by the dipole moment of compounds, and the hydrophobicity of compounds as 
represented by Kow,and molecular size (Ozaki and Li, 2002; Van der Bruggen et al., 
2003). Positive correlation between hydrophobicity of non-phenolic compounds (log 
Kow) and their removal by nanofiltration was reported by Kiso et al., 2000. On the 
other hand, hydrophilic compounds tended not to adsorb to the membrane polymeric 
matrix (Alturki et al., 2010). According to Snyder and co-workers (2007), some 
compounds are able to pass through the RO membrane, thus no clear and consistent 
relationship between molecular structure and membrane permeability has been 
established. Penetration of molecules through the RO membrane could be as a result 
of diffusion into and through the membrane, short-circuiting of the membrane, or 
supporting media failure. The removal of micropollutants by RO is influenced by 
complex interactions of electrostatic and other physical forces acting between the 
specific solute, the solution and the membrane. Furthermore, electrostatic attraction 
or repulsion forces can affect the removal of some micropollutants by RO 
membranes due to their negative surface charge (e.g. repulsion of 
Sulphamethoxazole due their negative charge) (Bellona et al., 2005).  
 
 
Figure 5.1.6: The relationship between the molecular weight and the removal efficiencies of 
Metronidazole (M), Trimethoprim (T), Sulphamethoxazole (S), Paracetamol (P) and Ranitidine 
(R) by the RO process. 
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The concentrations of the pharmaceuticals were reduced as they passed through the 
ultrafiltration systems in the water reclamation plant so that Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine were detected in the 
effluent at maximum concentrations of 13, 190, 73, 15, and 236 ng.L
-1
, respectively.  
Other researchers have found high levels of pharmaceuticals in the effluents of 
WWTPs such as analgesics/anti-inflammatories at a concentration of 57 μg.L-1 
(Nakada et al., 2006; Roberts and Thomas, 2006; Gomez et al., 2007; Santos et al., 
2007). Therefore, the removal of pharmaceuticals is more effective in an advanced 
treatment plant using RO systems than in conventional treatment plants (Snyder et 
al., 2007).  
However, removal rates with RO membrane observed in the current study were high, 
which is in agreement with results obtained by other researchers (Alturki et al., 2010; 
Radjenovic et al., 2008; Reznik et al., 2011; Snyder et al., 2003; Dolar et al., 2012).  
In a pilot scale experiment using a MBR with RO membranes Dolar et al. (2012), 
observed that the majority of compounds present in the influent were completely 
removed in the permeate. Joss et al. (2011) reported that most organic 
micropollutants were removed or retained by RO to below their detection limit. 
Carbamazepine, Sulphamethoxazole, Metoprolol and Sotalol were removed with 
high removal rates (>98%) using RO membranes (Radenovic et al., 2008 and Gur-
Reznik et al., 2011).  
 
5.1.6 Effect of chlorination on pharmaceuticals during treatment at Sulaibiya 
WWTP 
The effluents of the RO process at Sulaibiya were treated further by chlorine 
oxidation before discharge. Most of the pharmaceuticals were able to pass through 
the RO system to some extent, so that trace levels were always detected in the RO 
effluent. The maximum concentration detected was 19 ng.L
-1
 and 15 ng.L
-1
 for 
Trimethoprim and Ranitidine, 7 ng.L
-1
, 5 ng.L
-1
, and 4 ng.L
-1
 for Metronidazole, 
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Sulphamethoxazole and Paracetamol, respectively. On the other hand, the lowest 
concentration detected in the RO effluents for Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol, and Ranitidine were 0.2 ng.L
-1
, 1 ng.L
-1
, 0.2 ng.L
-
1
, 1 ng.L
-1
, and 1 ng.L
-1
, respectively. The incomplete removal of these 
pharmaceuticals at wastewater treatment plants have permitted their spread 
extensively in surface waters (Boyd et al., 2003; Carballa et al., 2004; Kim et al., 
2007; Metcalfe et al., 2003; Okuda et al., 2008; Paxeus, 2004; Reemtsma et al., 
2006; Tauxe-Wuersch et al., 2005; Ternes et al., 1998), many of which are used as a 
source of raw water for drinking water.  
 
Sulaibiya WWTP was designed to treat the product water with chlorine before 
discharge. Samples were taken to follow the fate of these pharmaceuticals when 
treated with chlorine. Chlorine treatment allowed between 0 to 100% removal or 
transformation of these pharmaceuticals (Figure 5.1.7). However, most of the 
detected pharmaceuticals in the final effluent after chlorination were below 4 ng.L
-1
 
or completely removed below detection limits, indicating highly effective oxidation 
of the investigated pharmaceuticals in the presence of the free chlorine residual.  
 
 
 
 87 
 
 
Figure 5.1.7.a: Seasonal concentrations of Metronidazole (ng.L
-1
) detected in the RO outlet, and 
the removal percentage by chlorination process at Sulaibiya WWTP. 
 
 
Figure 5.1.7.b: Seasonal concentrations of Trimethoprim (ng.L
-1
) detected in the RO outlet, and 
the removal percentage by chlorination process at Sulaibiya WWTP. 
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Figure 5.1.7.c: Seasonal concentrations of Sulphamethoxazole (ng.L
-1
) detected in the RO outlet, 
and the removal percentage by chlorination process at Sulaibiya WWTP. 
 
 
Figure 5.1.7.d: Seasonal concentrations of Paracetamol (ng.L
-1
) detected in the RO outlet, and 
the removal percentage by chlorination process at Sulaibiya WWTP. 
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Figure 5.17.e: Seasonal concentrations of Ranitidine (ng.L
-1
) detected in the RO outlet, and the 
removal percentage by chlorination process at Sulaibiya WWTP. 
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include DBPs. Most products are more polar and of lower molecular weight than the 
parent pharmaceutical (halogenated, hydroxylated, cleaved rings), and many of 
which are isomeric and more persistent (Daughton, 2010). Other factors adding 
further complexity include the potential for certain reaction products to revert back 
to the original pharmaceutical, as reported for the N-chlorinated intermediate from 
sulphamethoxazole when free chlorine is insufficient (Dodd and Huang, 2004).  
 
The reaction intermediates and end products can sometimes express combined 
toxicity greater than the parent pharmaceutical (Radjenovic et al., 2009). The 
halogenated DBPs (those containing chlorine, bromine, or iodine) are of particular 
toxicological concern as many halogenated DBPs in finished drinking water occur at 
concentrations well above 1 μg.L-1 (Krasner et al., 2006). 
 
 
 
5.1.7 Overall removal of pharmaceuticals during wastewater treatment 
Modern WWTPs can effectively remove micro-pollutants, as well as microbial 
pollution. These WWTPs receive a large number of different trace organic polluting 
compounds, among them pharmaceuticals; however, conventional treatments have 
not been specifically designed to remove these pharmaceuticals (Suárez et al., 2008). 
Therefore, pharmaceuticals often occur in effluents because either they do not have 
the tendency to adsorb onto activated sludge, or their biodegradation is not possible 
within the hydraulic retention time. However, using further treatment such as 
filtration (ultrafiltration, nanofiltration and RO) and chemical disinfection (chlorine 
and ozone), further to conventional treatment, increased removal efficiency can be 
achieved by the WWTP. 
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Pharmaceuticals were followed through the overall treatment process to evaluate the 
removal process (see Methods Section 4.1). Box plots have been used to show levels 
of pharmaceuticals found in influent and the effluent of each process in the Sulaibiya 
WWTP (Figure 5.1.8).  
 
5.1.7.1 Biological removal 
Metronidazole concentration in the influent raw sewage was low compared to other 
pharmaceuticals, and at all sampling times the concentration was highly variable, 
with a median concentration of 15 ng.L
-1
 and a mean of 22.33 ng.L
-1 
(Figure 5.1.8). 
Statistical analysis of the data showed that biological removal of Metronidazole was 
highly significant, the median and mean concentration after biological treatment 
being 3 ng.L
-1
 and 6.28 ng.L
-1
, respectively. On the other hand, Trimethoprim 
concentration in the influent was high, and also highly variable with one point 
outside the box plot (Figure 5.1.8). The median concentration was 470 ng.L
-1
 and the 
mean concentration was 622 ng.L
-1
. The biological removal of Trimethoprim was 
also statistically highly significant, the median and mean concentration of the 
secondary effluent being the same at 107.5 ng.L
-1
. Similarly, Sulphamethoxazole 
concentration in the influent was high and moderately variable, with two points 
outside the box plot, and a median concentration of 241 ng.L
-1
 and a mean 
concentration of 365 ng.L
-1
. Highly significant biological removal of 
Sulphamethoxazole gave a median and mean concentration in the secondary effluent 
of 66.5 ng.L
-1
and 134.1 ng.L
-1
, respectively, with two points outside the box plot. 
Paracetamol concentration in the influent was also high and highly variable, with a 
median concentration of 740 ng.L
-1
 and a mean of 881 ng.L
-1 
(Figure 5.1.8). 
Paracetamol was very effectively removed by the activated sludge process with near 
100% efficiency, and statistically high significance; the median and mean 
concentration of the effluent was 10.5 ng.L
-1
 and 15.25 ng.L
-1
, respectively. Lastly, 
Ranitidine concentration in the influent was high and also highly variable, one point 
was outside the box plot, with a median concentration of 624 ng.L
-1
 and a mean 
concentration of 812 ng.L
-1 
(Figure 5.1.8). The biological removal of Ranitidine was 
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also statistically highly significant, with the median and mean concentration of the 
secondary effluent being 199 ng.L
-1
 and 320 ng.L
-1
, respectively, with one point 
outside the box plot. 
 
The treatment of secondary effluent at Sulaibiya WWTP with sand filtration is 
intended to remove suspended solids and turbidity that persists after clarification. 
Pharmaceutical degradation can also occur in these systems by further biological 
degradation by biofilms that develop on the filter media (Gobel et al., 2007). 
Adsorption to the filter solids is also possible. 
 
Metronidazole was removed by sand filtration during the sampling period by 50% 
where the mean and median concentrations in the sand filtration effluent were 3.56 
ng.L
-1 
and 1.5 ng.L
-1
, respectively (Figure 5.1.8), with one point outside the box plot 
(13 ng.L
-1
). Similarly, Trimethoprim was reduced by 53% by sand filtration, where 
the mean concentration was 61.3 ng.L
-1
 and the median concentration was 50 ng.L
-1
, 
with one point outside the box plot (253 ng.L
-1
). In contrast, Sulphamethoxazole was 
removed by only 31% with nearly constant concentrations in the effluent with a 
mean 47.2 ng.L
-1
 and median 46 ng.L
-1
 (Figure 5.1.8). Paracetamol was removed by 
57%, with mean and median concentrations in the sand filtration effluent of 8.58 
ng.L
-1
and 4.5 ng.L
-1
, respectively (Figure 5.1.8). However, Ranitidine showed 
minimal removal by sand filtration, with only a 16% reduction, and the mean and 
median concentrations in the effluent were 210.1 ng.L
-1 
and 166.5 ng.L
-1
, 
respectively (Figure 5.1.8), with one point outside the box plot (1057 ng.L
-1
), and the 
residual concentration being relatively high compared to the other pharmaceuticals.     
 
In summary, Metronidazole, Trimethoprim and Paracetamol reveal removal 
efficiencies ≥50%, while Sulphamethoxazole and Ranitidine removal efficiencies 
were 31% and 16%, respectively, when sand filtration is employed. Removal by sand 
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filters is attributable to biological activity or adsorption, and from the structural and 
physical properties of the pharmaceuticals it can be predicted which will be more 
susceptible to treatment. Although from the observations of sorption tendencies (i.e., 
correlation to Kow values), the highest removal efficiencies were obtained for 
pharmaceuticals previously identified as being efficiently removed during the active 
sludge process. Moreover, there are some influences of operational variables such as 
hydraulic residence time, hydraulic loading rate and bulk water quality 
characteristics on pharmaceutical removal during sand filtration. Gobel et al. (2007) 
found significant differences in the removal of Trimethoprim (15% versus 74%) in 
two sand filters with comparable hydraulic retention times and hydraulic loading 
rates (per biofilm surface area) in each case. Furthermore, Nakada et al. (2007) 
suggested the removal of 24 different pharmaceuticals during sand filtration. 
Similarly, Gobel et al. (2007) observed that some of the pharmaceuticals were 
eliminated to the greatest extent during the sand filtration stage. Therefore, sand 
filter could remove pharmaceuticals as it is reduced during the treatment.  
 
5.1.7.2 Pharmaceutical removal by membrane filtration 
Results show that pharmaceutical removal by UF and RO processes in wastewater 
treatment is more efficient compared to secondary treatment. The concentration of 
pharmaceuticals was low in the UF influent, with median concentrations 1.5, 50, 46, 
4.5 and 166.5 ng.L
-1
 for Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol and Ranitidine, respectively. The median removal by UF was low to 
moderate 0%, 44%, 64%, 77% and 74% for Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine, respectively. In contrast, 
pharmaceutical removal in the RO process was moderate to high compared to the UF 
process, with removal rates of 33%, 82%, 94%, 100% and 97% for Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine, respectively. RO 
therefore showed very high pharmaceutical removal efficiencies. However, some 
pharmaceuticals have been detected in RO permeate (Figure, 5.1.8) and their 
breakthrough cannot be rationalized by their physicochemical properties.  
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5.1.7.3 Pharmaceutical removal by chlorination 
Box plot analysis reveals that some of the pharmaceuticals can break through the RO 
membrane, and were detected at median concentrations ranging between 0.667 and 5 
ng.L
-1 
(Figure, 5.1.8). Chlorination of all effluents achieved further pharmaceutical 
removal greater than 86%, while the highest concentrations were 3, 3, 1, and 4 ng.L
-1 
for Metronidazole, Trimethoprim, Sulphamethoxazole and Ranitidine, respectively 
in chlorinated RO filtrate. Laboratory investigations by other researchers using 
model systems have demonstrated convincingly that chlorination of common 
pharmaceuticals can lead to the formation of known toxicants and probable 
carcinogens. Dodd and Huang (2007) found that chlorination reacted with 
Trimethoprim, and the products were predominantly multi-chlorinated and 
hydroxylated. Bedner and MacCrehan (2006) demonstrated that free chlorine doses 
typically used in water treatment could react with Paracetamol and led to the 
production of several products. 
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Figure 5.1.8: Box plot showing pharmaceutical removal efficiencies in Sulaibiya WWTP. Plots show 
the distribution of removal efficiencies, expressed in terms of fraction of pharmaceuticals remaining 
after each treatment compared to all before the treatment stage. The solid line in each box represents 
the median. 
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5.2 Removal of pharmaceuticals by chlorination and ozonation in laboratory 
investigations 
 
5.2.1 Effect of chlorination and ozonation on pharmaceuticals in laboratory 
investigations 
The removal percentage of each pharmaceutical at the end of a laboratory conducted 
experiment is shown in Figure 5.2.1 (a,b,c,d,e) and showed that removal varied: 
Metronidazole had the lowest removal and Ranitidine the highest by both 
chlorination and ozonation.  
Results showed that Metronidazole was affected by the doses of chlorine and ozone 
oxidants in different media such as synthetic wastewater, tap water and real 
wastewater. The removal gradually increased with the increase in oxidant dose. The 
highest removal was 96% in tap water that contained a chlorine dose of 10 mg.L
-1
 
while, in synthetic wastewater and real wastewater with the same doses of chlorine, 
59 and 58% removal was observed, respectively. On the other hand, the effect of 
ozone doses were similar, with the highest removal of Metronidazole occurring at 15 
mg.L
-1
 of ozone in synthetic wastewater 55%, and 51% being observed in tap water 
and real wastewater.  
 
Trimethoprim almost completely disappeared in tap water and real wastewater at the 
10 mgL
-1
 dose of chlorine, with 99% removal for both, while the removal rate at the 
same doses in synthetic wastewater gave 92% removal. On the other hand, the 
removal rate of Trimethoprim by ozonation was similar in synthetic wastewater, tap 
water and real water, with a removal rate >84% at the 15mg.L
-1
 ozone dose.    
 
Sulphamethoxazole was almost completely removed in the synthetic wastewater, tap 
water and real wastewater at all doses of chlorine, whereas the highest removal of 
95% was observed at 15 mg.L
-1
 dose of ozone. The removal of Sulphamethoxazole 
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in synthetic wastewater, tap water and real wastewater by 15 mg.L
-1
 of ozone was 
comparable, with removal rates of 90%, 92% and 95%, respectively. 
 
Paracetamol was removed from the synthetic wastewater, tap water and real 
wastewater at similar rates for the different doses of chlorine and ozone. The 
maximum removal was found at the 10 mg.L
-1
 chlorine dose, with a rate of >96%, 
while the removal rate at the 15 mg.L
-1
 ozone dose was 91%.  
 
Ranitidine was removed more effectively than the other pharmaceuticals, being 
almost completely removed at different doses of chlorine and ozone, except for the 5 
mg.L
-1
 ozone dose where the removal rate was 71%, 73% and 75% for synthetic 
wastewater, tap water and real wastewater, respectively.  
 
Chlorine and ozone are oxidation processes and have the potential to transform 
pharmaceuticals. Other researchers reported that Sulphamethoxazole, Trimethoprim 
and Paracetamol were efficiently removed by chlorination (Alum et al., 2004; 
Westerhoff et al., 2005). Ozone is known as a strong oxidant and is very effective in 
the transformation of Sulphamethoxazole, Roxithroymcin, Diclofenac, Naproxen and 
Steroids that can be oxidized at 90 ‐  99% (Ternes et al., 2002; Alum et al., 2004; 
Westerhoff et al., 2005; Huber et al., 2005). But in the current study it was found that 
chlorine is more effective than ozone for the chosen pharmaceuticals.  
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Figure 5.2.1.a: Effect of the initial chlorine and ozone dose on the Metronidazole removal or transformation in laboratory experiments performed at 
different doses (5mg.L
-1 
O3, 10mg.L
-1 
O3, 15mg.L
-1 
O3, 5mg.L
-1 
Cl2, and 10mg.L
-1 
Cl2) with synthetic wastewater, tap water and real wastewater. 
Figure 5.2.1.b: Effect of the initial chlorine and ozone dose on the Trimethoprim removal or transformation in laboratory experiments performed at 
different doses (5mg.L
-1 
O3, 10mg.L
-1 
O3, 15mg.L
-1 
O3, 5mg.L
-1 
Cl2, and 10mg.L
-1 
Cl2) with synthetic wastewater, tap water and real wastewater. 
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Figure 5.2.1.c: Effect of the initial chlorine and ozone dose on the Sulphamethoxazole removal or transformation in laboratory experiments performed 
at different doses (5mg.L
-1 
O3, 10mg.L
-1 
O3, 15mg.L
-1 
O3, 5mg.L
-1 
Cl2, and 10mg.L
-1 
Cl2) with synthetic wastewater, tap water and real wastewater. 
Figure 5.2.1.d: Effect of the initial chlorine and ozone dose on the Paracetamol removal or transformation in laboratory experiments performed at 
different doses (5mg.L
-1 
O3, 10mg.L
-1 
O3, 15mg.L
-1 
O3, 5mg.L
-1 
Cl2, and 10mg.L
-1 
Cl2) with synthetic wastewater, tap water and real wastewater. 
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Figure 5.2.1.e: Effect of the initial chlorine and ozone dose on the Ranitidine removal or transformation in laboratory experiments performed at 
different doses (5mg.L
-1 
O3, 10mg.L
-1 
O3, 15mg.L
-1 
O3, 5mg.L
-1 
Cl2, and 10mg.L
-1 
Cl2) with synthetic wastewater, tap water and real wastewater. 
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5.2.2 The degradation pathway of Chlorination 
 
The effective removal of pharmaceuticals from water by chlorination requires 
sufficient free chlorine concentration and contact time. Chlorination can degrade or 
transform chemical compounds via one of two pathways; firstly, by chlorine 
substitution or addition reactions, which may alter active functional groups; and 
secondly, chlorine radicals may oxidize (break down) the target compounds, such as 
pharmaceuticals, into smaller molecules, which may or may not possess the active 
properties (Crain and Gottlieb, 1935). 
 
A study by Gibs et al. (2007) on the effect of free chlorine on the transformation of 
some pharmaceutical compounds in drinking water during distribution, found 50%- 
80% removal for sulphonamides and 42% for Trimethoprim after one day, with 
complete removal after 10 days. At a concentration of 3.5 - 3.8 mg.L
-1
 of free 
chlorine, 90% to 99% removal was achieved for Sulphamethoxazole and 
Trimethoprim in river water after 24 h contact time (Westerhoff et al., 2005). HOCl 
and ClO2 oxidise Sulphamethoxazole at specific functional groups with high electron 
densities, such as neutral tertiary amines and aniline (Huber et al., 2005). On the 
other hand, rapid and substantial transformation of Trimethoprim to a wide range of 
chlorinated and hydroxylated products is expected to occur under typical conditions 
of wastewater and drinking water chlorination (Dodd and Huang, 2007). Therefore, 
chlorine appears to be effective at oxidising pharmaceuticals in the treated 
wastewater, but the formation of oxidative by-products appears to be likely toxic. 
 
5.2.3 The degradation pathway of ozonation 
 
Other researchers have reported the effective use of ozonation for the removal of 
pharmaceuticals in water and wastewater effluents (Adams et al., 2002; Ternes et al., 
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2003; Huber et al., 2005). Adams et al. (2002) found that ozonation removed more 
than 95% of several sulphonamides and Trimethoprim from river water within 1.3 
min contact time at an ozone dose of 7.1 mg.L
-1
. Huber et al. (2005) also observed 
that at doses >2 mg.L
-1
 of ozone, sulphonamides were oxidised 90% to > 99% in 
secondary wastewater effluents.  
 
Oxidative degradation of organic chemicals by ozone treatment can occur either by 
direct reaction with molecular ozone (O3) or indirectly via hydroxyl radicals 
(Staehelin and Hoigne, 1985). Dodd et al. (2006), through ozonation of wastewater, 
showed that many pharmaceuticals were predominantly transformed via direct 
reaction with the ozone. Furthermore, the oxidation reaction depended on the ratio of 
molecular ozone and hydroxyl radicals, the corresponding reaction kinetics, and 
presence of organic matter (Elovitz et al., 2000; von Gunten, 2003). Ozone and/or 
hydroxyl radicals deactivate the bactericidal properties of antibiotics by attacking or 
modulating their pharmaceutically active functional groups, such as aniline moieties 
of sulphonamides (Huber et al., 2005), and the phenol ring of Trimethoprim (Dodd et 
al., 2009). Highly effective removal (>90%) by ozonation was observed for those 
compounds with electron-rich aromatic systems, such as hydroxyl, amino (e.g. 
Sulphamethoxazole), acylamino, alkoxy and alkyl aromatic compounds, as well as 
those compounds with deprotonated amines (e.g. Trimethoprim) and nonaromatic 
alkene groups since these key structural moieties are highly vulnerable  to oxidative 
attack (Dickenson et al., 2009).  
 
Adams et al. (2002) found more than a 95% conversion of Trimethoprim by 
ozonation in a pre-filtered river water sample spiked with this antibiotic at an initial 
concentration of 50 mg.L
-1
. Similar reactivity of Trimethoprim and 
Sulphamethoxazole by ozonation has been found in wastewater (Ternes et al., 2003). 
Ternes et al. (2003) confirmed that 5 mgL
-1
 of applied ozone could completely 
remove 0.62 mg.L
-1
 Sulphamethoxazole present in biologically treated municipal 
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wastewater. Similar results were also reported elsewhere (Huber et al., 2003, 2005). 
Paracetamol was effectively degraded by ozone, which could degrade 0.8 g.L
-1
 
Paracetamol in 30 min with an ozone flow rate of about 72 g.h
-1
 (Andreozzi et al., 
2003). A number of degradation intermediates were found during the ozone 
treatment; these follow typical phenol ozonation pathways, such as hydroxylation of 
the phenol ring, anomalous ozonation to cleave the aromatic ring of hydroquinone, 
and decarboxylation by hydroxyl radicals (Andreozzi et al., 2003).  
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5.3 Fate of pharmaceuticals in batch experiments 
 
5.3.1 The effect of pharmaceutical concentration on TOC removal 
The effect of pharmaceutical concentration on the removal rate of organic substrates, 
as expressed by total organic carbon (TOC) and pharmaceuticals was investigated. 
Figure 5.2.1(a, b, c, d and e) shows that the decrease in TOC concentration with time 
was high during the first 10 hours, and gradually dropped between 10 to 25 hours 
before levelling off. This trend was observed in all cases, indicating a first-order 
kinetic model (Figure 5.3.2). Pharmaceutical concentration had a small effect on the 
degradation rate of TOC in the case of Metronidazole, Trimethoprim, and 
Sulphamethoxazole, but for Paracetamol and Ranitidine, the reduction in TOC 
concentration occurred more slowly for high drug concentrations compared to low 
drug concentrations. The effect of pharmaceutical concentration on TOC removal 
efficiency during batch experiments was highly significant for all pharmaceuticals 
(p<0.05, one-way ANOVA at a 95% confidence level).  
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Figure 5.3.1(a): TOC removal in a batch experiment with Metronidazole present at 
concentrations of 0.1mg.L
-1
, 1mg.L
-1
, 10mg.L
-1
, and control (0mg.L
-1
). 
 
Figure 5.3.1(b): TOC removal in a batch experiment with Trimethoprim present at 
concentrations of 0.1mg.L
-1
, 1mg.L
-1
, 10mg.L
-1
, and control (0mg.L
-1
). 
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Figure 5.3.1(c): TOC removal in a batch experiment with Sulphamethoxazole present at 
concentrations of 0.1mg.L
-1
, 1mg.L
-1
, 10mg.L
-1
, and control (0mg.L
-1
). 
 
Figure 5.3.1(d): TOC removal in a batch experiment with Paracetamol present at 
concentrations of 0.1mg.L
-1
, 1mg.L
-1
, 10mg.L
-1
, and control (0mg.L
-1
). 
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Figure 5.3.1(e): TOC removal in a batch experiment with Ranitidine present at concentrations 
of 0.1mg.L
-1
, 1mg.L
-1
, 10mg.L
-1
, and control (0mg.L
-1
). 
 
The removal of TOC in the activated sludge process can be presented by a pseudo-
first-order kinetic model as observed in Figure 5.3.1. Other researchers using batch 
experiments with activated sludge have reported that the removal of pharmaceuticals 
and other organic substances in the water phase can be described by a pseudo-first-
order reaction, as given in Equation (1) (Layton et al., 2000; Shi et al., 2004; Li et 
al., 2005).  
  
  
                                                                                 
where C is the concentration of the target substance in the water phase (mg.L
-1
), k is 
the first-order-rate constant (h
-1
) and t is the reaction time (h). Integration and 
rearrangement of equation (1), gives the following equation  
 
  
                                                                        
where C0 is the initial concentration of the target substance in the water phase (mg.L
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0
50
100
150
200
250
300
350
400
450
500
0 50 100
T
O
C
 (
m
g
.L
-1
) 
Time (h) 
Ranitidine 
Control 0.1 mg/l
1mg/l 10mg/l
(e) 
 108 
 
first-order rate constant k is obtained from the slope of the straight line. The term 
ln(C/C0) could be converted to log(C/C0) to give k to the base 10.  
 
The concentration profiles of TOC and pharmaceuticals as substrates in the first 
series of batch experiments plotted in the form of log(C/C0) versus t are shown in 
Figure 5.3.2(a, b, c, d, and e). Linear relationships between log(C/C0) and t were 
observed in all experiments, with a high correlation coefficient, confirming that the 
removal of organic substances in the current study followed the first-order kinetic 
model in Equation (1). The TOC removal rate constants obtained in the presence of 
each pharmaceutical at a concentration 1mg.L
-1
 over first 5 hours of reaction in 
Figure 5.3.2, were found to be 0.177, 0.166, 0.173, 0.170 and 0.176 (h
-1
)
 
for 
Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol, and Ranitidine, 
respectively. 
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Figure 5.3.2 (a): Kinetic plots of TOC reduction verses time during batch experiments for 
Metronidazole at concentration 1mg.L
-1
. 
 
 
Figure 5.3.2 (b): Kinetic plots of TOC reduction verses time during batch experiments for 
Trimethoprim at concentration 1mg.L
-1
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Figure 5.3.2 (c): Kinetic plots of TOC reduction verses time during batch experiments for 
Sulphamethoxazole at concentration 1mg.L
-1
. 
 
 
Figure 5.3.2 (d): Kinetic plots of TOC reduction verses time during batch experiments for 
Paracetamol at concentration 1mg.L
-1
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Figure 5.3.2 (e): Kinetic plots of TOC reduction verses time during batch experiments for 
Ranitidine at concentration 1mg.L
-1
. 
 
5.3.2 The Effect of Pharmaceutical Concentration on biomass growth (MLSS) 
The air flow rate to each reactor was kept constant at 96 L.h
-1
. This was sufficient to 
maintain DO concentration in each reactor above the 2 mg.L
-1
 required for aerobic 
biodegradation. The MLSS growth was increased steadily and rapidly for all 
pharmaceuticals at all concentrations in the first period; then, the MLSS 
concentration became steady, except for Ranitidine where MLSS decreased later for 
all concentrations as shown in Figure 5.3.3 (a, b, c, d and e).  
 
There was no clear effect of Metronidazole, Trimethoprim, Sulphamethoxazole, and 
Paracetamol concentration on the biomass concentration and biodegradation rate at 
different concentrations (0.1, 1 and 10 mg.L
-1
) (p>0.2 ANOVA). Since MLSS 
growth decreased with the increase of the Ranitidine concentration that may indicate 
an inhibitory effect on the microorganisms in the MLSS (p=0.11 ANOVA).  It can 
be seen that MLSS concentration has a great effect on the biodegradation rates 
(Figure 5.3.3) with the increase of MLSS concentration being attributed to the 
growth of microorganisms in the activated sludge, which then improved organic 
degradation. Furthermore, the increase in MLSS with the increase of pharmaceutical 
concentration could be explained by the utilisation of such pharmaceutical by 
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microorganisms as the sole carbon source. This might also contribute to the increase 
in the degradation rates of the pharmaceuticals (Table 5.3.1) with the increase of 
MLSS concentration.  
 
 
Figure 5.3.3 (a): The effect of Metronidazole concentration on MLSS growth in batch 
experiment. 
 
Figure 5.3.3 (b): The effect of Trimethoprim concentration on MLSS growth in batch 
experiment. 
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Figure 5.3.3 (c): The effect of Sulphamethoxazole concentration on MLSS growth in batch 
experiment. 
 
 
Figure 5.3.3 (d): The effect of Paracetamol concentration on MLSS growth in batch experiment. 
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Figure 5.3.3 (e): The effect of Ranitidine concentration on MLSS growth in batch experiment. 
 
5.3.3 Variations in pH 
At 25 °C approximately all pH values at the starting time for all batch reactors were 
within the range of 6 – 7, then pH decreased in relation to time to reach a minimum 
of pH 5.5 as shown in Figure 5.3.4 (a, b, c, d and e). The pH values were the same at 
all concentrations of each pharmaceutical compared with the control.  Nitrobacter 
and other types of bacteria may have been enriched causing a nitrification process in 
the batch reactor. Consequently, due to the nitrification process (release of H+), pH 
values decreased to less than 7 during the last 5 days of operation in all reactors, 
where the biomass concentrations stay steady (Figure 5.3.3).  
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Figure 5.3.4 (a): pH measurement during the batch experiment of Metronidazole at different 
concentrations. 
 
 
Figure 5.3.4 (b): pH measurement during the batch experiment of Trimethoprim at different 
concentrations. 
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Figure 5.3.4 (c): pH measurement during the batch experiment of Sulphamethoxazole at 
different concentrations. 
 
 
Figure 5.3.4 (d): pH measurement during the batch experiment of Paracetamol at different 
concentrations. 
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Figure 5.3.4 (e): pH measurement during the batch experiment of Ranitidine at different 
concentrations. 
 
5.3.4 The removal rate of pharmaceuticals during batch experiments 
In wastewater, pharmaceuticals exist at extremely low concentrations (ng.L
-1
), and 
many other organic compounds are present at much higher concentrations (mg.L
-1
). 
In this study, the initial concentrations of pharmaceuticals ranged from 0.1 to 10 
mg.L
-1
. The removal of pharmaceuticals during the batch experiments was high, and 
decreased with increasing concentration, except for Paracetamol where the removal 
% did not decrease (Figure 5.3.5). The effect of the pharmaceuticals’ concentration 
on its removal efficiency was highly significant (p<0.05, ANOVA). Pharmaceuticals 
could be immediately removed from the water phase to the sludge phase by sorption 
as a first step, and then further removal of the pharmaceutical progresses gradually 
with biodegradation.  
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Figure 5.3.5: Removal efficiency of pharmaceuticals after 5 days at concentration 0.1 mg.L
-1
, 1 
mg.L
-1
 and 10 mg.L
-1
in batch experiments. 
 
The % degradation of pharmaceuticals by microorganisms over 5 days depends on 
the initial concentration of the pharmaceutical. This is shown by a clear trend that 
generally exists between % degradation over 5 days of Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol, and Ranitidine and increases in the 
initial concentration of pharmaceutical in the range from 0.1 to 10 mg.L
-1
 (Table 
5.3.1). The biodegradation of pharmaceuticals increased with an increase in the 
initial concentration of these pharmaceuticals and the regression line having an R
2
 
value of > 0.99, except for Trimethoprim (R
2 
= 0.61), indicating no apparent 
inhibition of pharmaceuticals on their biodegradation (Figure 5.3.6).  These results 
suggest that the higher the initial pharmaceutical concentrations the greater the 
stimulatory effect on the microorganisms degrading them in activated sludge; there 
was no inhibitory effect at higher concentrations (p>0.2 ANOVA). The TOC 
biodegradation rate also increased with the increase of the initial concentration of 
pharmaceuticals (Table 5.3.1), indicating that the bacteria could utilize TOC more 
efficiently at higher initial concentrations of pharmaceuticals. Generally, the results 
show pharmaceuticals are readily degraded over a range of initial concentrations 
from 0.1 to 10 mg.L
-1
.  
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Table 5.3.1: Pharmaceutical concentrations and their effect on the specific TOC 
biodegradation rate and on the specific drug biodegradation rate. 
Drug  Pharmaceutical 
Concentration 
(mg.L
-1
) 
Specific TOC 
Biodegradation rate 
mgTOC.mgMLSS
-1
. d
-1 
Specific 
pharmaceutical 
Biodegradation rate 
mgPh.mgMLSS
-1
. d
-1 
Metronidazole Control 0.136 - 
0.1  0.136 2.56x10
-5
 
1 0.146 13.7x10
-5 
10 0.168 71.6x10
-5 
Trimethoprim Control 0.125 - 
0.1 0.122 1.3x10
-5
 
1 0.136 22.9x10
-5 
10 0.127 30x10
-5 
Sulphamethoxazole Control 0.120 - 
0.1  0.118 3.52x10
-5
 
1 0.124 15.8x10
-5 
10 0.127 79.3x10
-5 
Paracetamol Control 0.101 - 
0.1  0.115 3.6x10
-5
 
1 0.114 36.4x10
-5 
10 0.134 430.9x10
-5 
Ranitidine  Control 0.118 - 
0.1  0.146 3.75x10
-5
 
1 0.155 34x10
-5 
10 0.167 261.6x10
-5
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Figure 5.3.6 (a): The regression line comparing the Metronidazole concentration and the 
specific Metronidazole biodegradation rate (mgPh.mgMLSS
-1
. d
-1
). 
 
  
Figure 5.3.6 (b): The regression line comparing the Trimethoprim concentration and the 
specific Trimethoprim biodegradation rate (mgPh.mgMLSS
-1
. d
-1
). 
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Figure 5.3.6 (c): The regression line comparing the Sulphamethoxazole concentration and the 
specific Sulphamethoxazole biodegradation rate (mgPh.mgMLSS
-1
. d
-1
). 
 
 
  
Figure 5.3.6 (d): The regression line comparing the Paracetamol concentration and the specific 
Paracetamol biodegradation rate (mgPh.mgMLSS
-1
. d
-1
). 
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Figure 5.3.6 (e): The regression line comparing the Ranitidine concentration and the specific 
Ranitidine biodegradation rate (mgPh.mgMLSS
-1
. d
-1
). 
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5.3.5 Discussion 
The effect of Metronidazole concentration within the range 0.1 to 10 mg.L
-1
 on the 
TOC removal efficiency was negligible with an average TOC removal of 95% over 5 
hours (Figure 5.3.1a). Furthermore, the MLSS was similar at all concentrations 
which reveals that there are similar trends of microbial growth at all Metronidazole 
concentrations, while the Metronidazole removal efficiency decreased with an 
increased Metronidazole concentration with an average removal of 80%. On the 
other hand, the specific TOC biodegradation rate (mgTOC.mgMLSS
-1
.d
-1
) and the 
specific Metronidazole biodegradation rate (mgMetronidazole.mgMLSS
-1
.d
-1
) increased 
linearly with the increase of drug concentration with correlation coefficient (R
2
) of 
0.94 and 0.99 respectively. In contrast, Ingerslev et al. (2001) reported that the 
biological treatment to remove Metronidazole required long periods of treatment, 
and the Metronidazole removal efficiencies obtained were usually very low. A study 
by Kummerer et al. (2000) revealed that Metronidazole was not eliminated during 
batch experiments. On the other hand, Metronidazole reduction seems to be faster 
than reported by Ingerslev et al. (2001).  
 
Trimethoprim concentration within the range 0.1 to 10 mg.L
-1
 had little effect on the 
TOC removal efficiencies with an average removal of 94% over 5 hours (Figure 
5.3.1b). During the batch experiment, the MLSS concentration was almost similar at 
all Trimethoprim concentrations; however, the MLSS growth rate (Figure 5.3.7) 
increased with an increase in drug concentration with high correlation (R
2
 = 0.93). 
Furthermore, the Trimethoprim removal efficiency decreased with an increase in 
Trimethoprim concentration, achieving a maximum 92% removal after 24 hours. On 
the other hand, the specific TOC biodegradation rate (mgTOC.mgMLSS
-1
.d
-1
) remained 
constant with the increase in Trimethoprim concentration, while the specific 
Trimethoprim biodegradation rate (mgTrimethoprim.mgMLSS
-1
.d
-1
) increased sharply 
between 0.1 and 1 mg.L
-1
 and then, slowly increased up to the 10 mg.L
-1
 dose 
concentration. This is in agreement with results reported by Celiz et al. (2009) where 
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Trimethoprim was effectively eliminated by biological treatment at up to 97%. This 
compound has been observed to have a high biodegradation rate in conventional 
activated sludge systems, which involve a nitrification process (Batt et al., 2006). 
The removal of Trimethoprim by sludge adsorption can be considered to be 
negligible because of its high water solubility and very low log Kow. Consequently, it 
is likely that the high removal efficiency of Trimethoprim can be attributed to 
biodegradation. On the other hand, Pérez et al. (2005) and Yu et al. (2011) reported 
that Trimethoprim exhibited high adsorptivity and low biodegradability in the 
activated sludge process. They concluded that more than 40% of the substance was 
removed from the aqueous phase by bio-sorption or sorption, while there was only 
27% removal via biodegradation. 
 
 
   
Figure 5.3.7: regression line comparing the Trimethoprim concentration and MLSS growth rate 
(k). 
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MLSS concentration was almost the same at all concentrations which reveals no 
effect on increasing Sulphamethoxazole concentration, while at a dose concentration 
of 0.1 mg.L
-1 
the Sulphamethoxazole was removed to an undetectable concentration. 
However, the Sulphamethoxazole removal efficiencies remained high even with the 
increase in Sulphamethoxazole concentration, achieving 95% removal at the 10 
mg.L
-1
 dose. On the other hand, the specific TOC biodegradation rates 
(mgTOC.mgMLSS
-1
.d
-1
) sharply increased between 0.1 and 1 mg.L
-1
, then gradually 
increased to 10 mg.L
-1
 Sulphamethoxazole concentration; whereas, the specific 
Sulphamethoxazole biodegradation rates (mgSulphamethoxazole.mgMLSS
-1
.d
-1
) were 
increased linearly with an increase in Sulphamethoxazole concentration, with a 
R
2
correlation value of 0.99. These results are in agreement with those of Drillia et al. 
(2005) who found that Sulphamethoxazole removal efficiency was very high, even 
when Sulphamethoxazole concentration in the feed was increased up to 383 mg.L
-1
. 
Several studies reported that biodegradation of Sulphamethoxazole was the dominant 
removal mechanism in biological treatment systems (Batt et al., 2007; Abegglen et 
al., 2009; Wu et al., 2009; Li and Zhang, 2010). On the other hand, other researchers 
reported that Sulphamethoxazole was fairly well biodegraded and weakly sorbed to 
the bio-carriers and the removal efficiency via biodegradation of Sulphamethoxazole 
was 59% where the removal efficiencies via bio-sorption was 31% (Yu et al., 2011). 
 
Paracetamol concentration within the range 0.1 to 10 mg.L
-1
 exhibited a decreasing 
TOC removal efficiency with a minimum of 84% removal at 10 mg.L
-1
 dose over 5 
hours (Figure 5.3.1d). During the batch experiment, the MLSS growth rate gradually 
increased with an increase in Paracetamol concentration (correlation R
2
 = 0.99). 
Furthermore, the Paracetamol was removed effectively to undetectable levels at all 
concentrations studied. The removal efficiencies remained high, even with an 
increase in Paracetamol concentration, achieving almost 100% removal at all 
Paracetamol concentrations. On the other hand, the specific TOC biodegradation 
rates (mgTOC.mgMLSS
-1
.d
-1
) increased linearly with an increase in Paracetamol 
concentration (correlation R
2
 = 0.99), while the specific Paracetamol biodegradation 
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rate (mgParacetamol.mgMLSS
-1
.d
-1
) increased with an increase in Paracetamol 
concentration (correlation R
2
 = 1). Joss et al. (2006) reported similar results from 
batch biodegradation experiments, showing that biological degradation of 
Paracetamol removed the drug at 90% efficiency, and a kinetic biodegradation 
constant was greater than10 L.gss
-1
.d
-1
. Furthermore, Jones et al. (2006) found no 
adsorption of Paracetamol on activated sludge. The removal results of Paracetamol 
obtained in this study agree with those reported by Ivshina et al. (2006) and 
Takenaka et al. (2003). 
 
The effect of an increase in Ranitidine concentration on reactor performance was 
negligible within the range 0.1 to 10 mg.L
-1
. The TOC removal results were almost 
constant for all concentrations studied and reached 94% over 5 hours (Figure 5.3.1e). 
The MLSS concentration was similar at all concentrations of Ranitidine, which 
showed no effect of higher Ranitidine concentrations on MLSS concentrations, 
although the growth rate decreased gradually with an increase in concentrations 
(correlation R
2
 = 0.87). Furthermore, the removal efficiency of Ranitidine decreased 
from 100% to 88% with the increase in Ranitidine concentration (correlation R
2
 = 
0.90); whereas, the specific TOC biodegradation rates (mgTOC.mgMLSS
-1
.d
-1
) 
increased slightly with an increase in Ranitidine concentration, while the specific 
Ranitidine biodegradation rate (mgRanitidine.mgMLSS
-1
.d
-1
) gradually increased with 
increased Ranitidine concentration (correlation R
2
 = 0.99). Carucci et al., (2006) 
conducted SBR experiments operated with different sludge ages (8 and 14 days) to 
determine the removal kinetics of Ranitidine at several influent concentrations (2, 3 
and 5 mg.L
-1
) and the tests showed generally low removal efficiencies (17–26%), 
and a chronic inhibition on nitrification, whereas Barceló and Petrovic (2007) found 
that Ranitidine was rapidly eliminated (95% removal). 
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5.4 Fate of pharmaceuticals mixture in continuous flow bioreactors 
 
This phase of the study was conducted to compare the performance of membrane 
bioreactors (MBR) and sequencing batch reactors (SBR) treating synthetic 
wastewater containing a pharmaceuticals mixture (PM) of Metronidazole, 
Trimethoprim, Sulphamethoxazole, Paracetamol and Ranitidine in a continuous flow 
system to simulate full-scale wastewater treatment plants. Control MBR and SBR 
units were also operated in parallel to examine system performance during the 
treatment of synthetic wastewater in the absence of pharmaceuticals. The effect of 
PM concentration on the performance of the bioreactors, and the COD, TOC and PM 
removal efficiency, was examined. The influence of anoxic conditions on the 
removal of pharmaceuticals by MBR and SBR systems was also investigated. Details 
of the experimental conditions are described in Section 4.3. 
 
5.4.1 Performance of control MBR and SBR systems 
 
5.4.1.1 Variations in dissolved oxygen (DO) 
Figure 5.4.1 shows that the DO profile of the control MBR and SBR showed a 
similar response. The DO concentration dropped gradually at the beginning of the 
MBR operation, and remained fairly constant from day 10 until the end of the 
experiment. Similar effects were observed in the SBR. The operation of both systems 
was strictly aerobic since the DO concentration never dropped below 2 mg.L
-1
. 
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Figure 5.4.1: Changes in DO concentration in the control MBR and SBR.   
 
5.4.1.2 Variation of pH 
The average pH of the influent to both reactors was 7.77 (±0.33) and the average 
temperature was 22 (±3) °C (Figure 5.4.2). The effluent pH in the control MBR was 
stable with an average value of pH 5.96 (±0.24), while the average pH in the SBR 
was 5.74 (±0.32).  The effluent pH values were similar for both MBR and SBR 
during the first 5 days of operation, decreasing slightly each day.  During the next 10 
days the pH values remained at similar values with the lowest value of pH 5.55 for 
the MBR. The pH remained stable at around pH 6 (+ 0.23) from day 24 onwards. pH 
values for SBR also remained stable from day 24 to day 44 at an average of pH 5.93 
(+0.04), but after day 50 the pH started to decrease to reach the lowest pH value of 
5.14.    
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Figure 5.4.2: pH of influent and effluent synthetic wastewater in the control MBR and SBR.    
 
5.4.1.3 Variation of mixed liquid suspended solids and mixed liquid volatile 
suspended solids 
MLSS and MLVSS of the control MBR and SBR are presented in Figure 5.4.3. 
During the acclimation stage when the MBR was fed by the synthetic wastewater, 
the MLSS and MLVSS increased immediately (day 0 – day 4); however, MLSS and 
MLVSS then decreased gradually to reach a steady state from day 15 onwards, with 
3057 (+100) mg.L
-1
 and 2207(+89) mg.L
-1
, respectively. Furthermore, the MLSS and 
MLVSS in the control SBR followed a similar pattern, increasing in the first 5 days 
then decreasing to reach a steady state after 10 days, at levels of 2926(+69) mg.L
-1
  
and 2527(+66) mg.L
-1
, respectively. 
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Figure 5.4.3: Variation of MLSS and MLVSS in the control MBR and SBR with synthetics 
wastewater. 
5.4.1.4 Removal of COD and TOC in control MBR and SBR 
During operation of the control MBR and SBR systems, influent TOC was kept at 
360 (±45) mg.L
-1
, and influent COD at 674 (±34) mg.L
-1
. After the first 10 d of the 
acclimation stage, TOC removal in the MBR remained at a stable level of more than 
90% (Figure 5.4.4). Steady and high levels of TOC removal were also observed in 
the SBR. The COD showed a similar pattern to the TOC in both the MBR and the 
SBR. The COD and TOC removal, and the specific utilisation rates, are presented in 
Figure 5.4.5. Overall removal efficiency of the COD and TOC for the MBR and the 
SBR was maintained at greater than 90% throughout each experiment. The specific 
COD utilisation rate for the MBR and the SBR were in the same range (Figure 
5.4.5). The high COD and TOC removal efficiencies mean that the heterotrophic 
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bacteria and microorganisms responsible for decomposition of organic carbon were 
active under the operating conditions used in the control experiments.  
Figure 5.4.4: TOC and COD concentrations and removal in the control MBR and SBR. 
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Figure 5.4.5: Specific TOC and COD utilization rate of the control MBR and SBR. 
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5.4.2 Performance of MBR1 treating PM at three different concentrations under 
strictly aerobic condition 
 
The fate of PM was investigated under strictly aerobic conditions at different 
concentrations (Table 4.1) (see Section 4.3). The concentrations of PM treated in this 
experiment were 1 µg.L
-1
, 1 mg.L
-1
, and 10 mg.L
-1
. The MBR1 was operated at a 
hydraulic retention time (HRT) of 18 hours and a solids retention time (SRT) of 63 
d.  
 
5.4.2.1 Variation of dissolved oxygen (DO) 
Figure 5.4.6 shows the variation of DO in MBR1 at different pharmaceutical 
concentrations. The DO decreased from 4 mg.L
-1
 initially to 3.67 mg.L
-1
 at day 10 
before spiking with the pharmaceutical. After spiking 1 µg.L
-1
 of PM, DO decreased 
to 3.19 mg.L
-1
. The DO continued to decrease when the PM concentration was 
increased to 1 mg.L
-1
, and further decreased to reach 2.93 mg.L
-1
 when the PM 
concentration was increased to10 mg.L
-1
 on day 53. 
The DO concentration decreased (DO consumption) corresponded with the biomass 
growth, which increased more smoothly for the different PM concentrations than in 
the control. On the other hand, the DO consumption increased with the biomass 
reduction (Figure 5.4.8) until the end of first phase (1 µg.L
-1
). Then, the DO 
consumption became steady and started to increase at the beginning of the second 
phase (1 mg.L
-1
) until the last phase (10 mg.L
-1
) where changes were highly 
significant (ANOVA, p<0.05). This change was presumably due to the biomass 
adaptation to the high concentration of PM which took a longer time compared to the 
control. 
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Figure 5.4.6: Changes in DO concentration with different PM concentrations in MBR1.   
 
5.4.2.2 Variation of pH 
As shown in Figure 5.4.7, the influent of MBR1 was at pH 7.56 (±0.22) throughout 
the first 10 d of experiment while the effluent pH dropped to 6.19 (±0.22). Influent 
pH after spiking the PM at concentration 1 µg.L
-1
 was 7.8 (±0.32) and effluent pH 
was 6 (±0.22) for 30 d. On the other hand, influent pH increased to 8.27 (±0.35) and 
effluent pH 6.03 (±0.44) at a PM concentration of 1 mg.L
-1
, whereas, at a 
concentration of 10 mg.L
-1
, the influent pH was 7.97 (±0.28) and effluent pH was 
6.37 (±0.11). These pH values were very similar at all concentrations, and also 
similar to the control. 
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Figure 5.4.7: pH value of the influent and effluent of synthetic wastewater containing different 
PM concentrations in MBR1.    
 
5.4.2.3 Variation of mixed liquid suspended solids (MLSS) and mixed liquid volatile 
suspended solids (MLVSS) 
Figure 5.4.8 shows biomass growth as solids changed inside MBR1 during a period 
of 63 days. Before spiking with PM, MLSS increased from 2660 mg.L
-1
 initially to 
2750 mg.L
-1
 at day 5 and 2866 mg.L
-1
 at day 10. When the PM was spiked at 
concentration 1 µg.L
-1
 from day 10, MLSS gradually decreased to 2383 mg.L
-1
 at 
day 20, then MLSS become steady to the end of day 39 with MLSS 2198 mg.L
1
. The 
MLVSS varied similarly to MLSS, except the MLVSS reduced further from 2000 
mg.L
-1
 on day 39 to 1437 mg.L
-1
 at the end of day 53, which increased the gap 
between MLSS and MLVSS. This could have been affected by the high 
concentration of PM at 10 mg.L
-1
. The ratios of MLVSS/MLSS were similar at 
concentrations 1 µg.L
-1
 and 1 mg.L
-1
, but they were much lower at concentration 10 
mg.L
-1
. The effects of an increase in the PM concentration on MLVSS growth were 
highly significant (ANOVA, p<0.05). Since the MLVSS expresses the microbial 
biomass more accurately than MLSS, it could indicate that the biomass concentration 
reduced at a PM concentration of 10 mg.L
-1
 probably due to the partial inhibition of 
bacterial growth. 
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Figure 5.4.8: Variation of MLSS and MLVSS with change of PM concentration in MBR1.    
 
 
5.4.2.4 Removal of COD and TOC in MBR1 at different PM concentrations 
The COD removal efficiencies in MBR1 during the first 10 days before the PM 
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PM concentrations, namely 1 µg.L
-1
, 1 mg.L
-1
, and 10 mg.L
-1
, COD removal 
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respectively (p<0.05, ANOVA) (Figure 5.4.9). The TOC removal efficiencies 
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concentration of 10 mg.L
-1 
(p<0.05, ANOVA) (Figure 5.4.10). The highly significant 
effect of the PM concentration on COD and TOC removal efficiencies needs to be 
explained. The removal efficiencies of COD and TOC appear to be affected by the 
MLVSS reduction (Figure 5.4.8) as a result of PM concentration increase, while the 
specific COD utilisation rates do not change significantly with the change in PM 
concentration. The specific TOC utilisation rates were less than 50% of the specific 
COD utilisation rates for all PM concentrations except for concentration 10 mg.L
-1
 
where it increased to 66% of specific COD utilisation rates. It is to be noted that 
TOC expresses the concentration of the organic carbon whereas COD determines not 
only organic carbon but also other elements (e.g. N, P, S etc) in the substrate as gross 
parameters. 
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Figure 5.4.9: TOC and COD concentration and removal in MBR1 at different PM 
concentrations. 
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Figure 5.4.10: Specific TOC and COD utilisation rates for MBR1 at different PM 
concentrations. 
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88% were removed at concentrations of at concentration 1 µg.L
-1
, 1 mg.L
-1
, and 10 
mg.L
-1
, respectively (p>0.2, ANOVA) (Figure 5.4.11). Paracetamol was also 
removed efficiency in MBR1, decreased with increasing concentration, so that 88%, 
88% and 59%were removed at concentrations of at concentration 1 µg.L
-1
, 1 mg.L
-1
, 
and 10 mg.L
-1
, respectively (p>0.2, ANOVA) (Figure 5.4.11). Ranitidine was also 
removed efficiency in MBR1, increased with increasing concentration, so that 96%, 
99% and 99%were removed at concentrations of at concentration 1 µg.L
-1
, 1 mg.L
-1
, 
and 10 mg.L
-1
, respectively (p<0.05, ANOVA) (Figure 5.4.11). 
Figure 5.4.11: The removal efficiencies of pharmaceuticals in MBR1 at different PM 
concentrations. 
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pharmaceuticals removed in the MBR1 divided by the mass of microorganism (i.e. 
the specific pharmaceutical utilisation rate) was higher. To describe the specific 
utilisation rate of Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol, 
and Ranitidine at different initial concentrations, kinetic plots were determined and 
the data was found to fit the regression line R
2＞0.99 (Figure 5.4.12). The highest 
specific pharmaceutical utilisation rate was found in Ranitidine followed by 
Sulphamethoxazole, then Metronidazole and Paracetamol, and the lowest was 
Trimethoprim. The specific pharmaceutical utilisation rates (mgph.mgMLVSS
-1
.d
-1
) 
increased linearly with the increase of PM concentration at correlation coefficients 
(R
2
) of 1, 0.99, 0.99, 0.99, and 0.99 for Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol, and Ranitidine, respectively (p<0.05, ANOVA) 
(Figure 5.4.12).  
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Figure 5.4.12: Specific pharmaceutical utilisation rates at different PM concentrations in MBR1 with regression analysis.  
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5.4.3 Performance of MBR2 treating PM at three different concentrations under 
anoxic and aerobic conditions 
 
In this section the fate of the PM was investigated under the combination of anoxic 
and aerobic conditions using the operational schedule of MBR2 (Table 4.1) (see 
Section 4.3). The effect of the PM concentration was studied with an anoxic/aerobic 
cycle (anoxic period 2 hours, aerobic period 16 hours), a hydraulic retention time 
(HRT) of 18 hours, and a solids retention time (SRT) of 53 d. The PM 
concentrations used in this experiment were 1 µg.L
-1
, 1 mg.L
-1
, and 10 mg.L
-1
. 
5.4.3.1 Variation of dissolved oxygen (DO) 
The variation of DO in MBR2 under different PM concentrations is presented in 
Figure 5.4.13. The DO decreased from 4.1 mg.L
-1
 initially to 3.6 mg.L
-1
 at day 10 
before spiking with the PM. After spiking 1 µg.L
-1
 of PM the DO decreased to 2.99 
mg.L
-1
, but increased to 3.61 mg.L
-1
 when the PM concentration was increased to 1 
mg.L
-1
 and then decreased to 3 mg.L
-1
 at 10 mg.L
-1
 on day 53. The DO consumption 
increased correspondingly with the biomass growth, which increased in a similar 
pattern observed with MBR1. On the other hand, the DO concentration became 
steady and started to increase higher than that in MBR1 at the beginning of the 
second phase (1 mg.L
-1
).  
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Figure 5.4.13: Changes in DO concentration with different PM concentrations in MBR2.   
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Figure 5.4.14: pH value of the influent and effluent of synthetic wastewater containing different 
PM concentrations in MBR2.    
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Figure 5.4.15: Variation of MLSS and MLVSS with change of PM concentration in MBR2.    
 
5.4.3.4 Removal of COD and TOC in MBR2 at different PM concentrations  
The COD removal efficiencies in MBR2 were similar to MBR1 at different ranges of 
PM concentrations. The COD removal efficiency described in Figure 5.4.16 was 
94% (±1.3) before the PM had been spiked, at PM concentrations of 1 µg.L
-1
, 1 
mg.L
-1
, and 10 mg.L
-1
, COD removal efficiencies were changed less significantly to 
93% (±2), 88% (±4), and 91% (±3), respectively (p = 0.14, ANOVA). The TOC 
removal efficiencies in MBR2 were similar to those reported for MBR1 at a PM 
concentration range of 1 µg.L
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5.4.16), but TOC removal efficiency decreased at PM concentration 10 mg.L
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MBR1 (p<0.05, ANOVA) (Figure 5.4.17).   
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Figure 5.4.16: TOC and COD concentration and removal in MBR2 at different PM 
concentrations. 
 
 
 
0
10
20
30
40
50
60
70
80
90
100
0
200
400
600
800
1000
1200
1400
0 10 20 30 40 50 60
%
 R
e
m
o
v
a
l 
C
O
D
 m
g
.L
-1
 
Days 
MBR2 
Influent Effluent % Removal
1 µg.L-1 1 mg.L
-1 10 mg.L-1 Before 
spiking 
0
10
20
30
40
50
60
70
80
90
100
0
100
200
300
400
500
600
700
800
900
1000
0 10 20 30 40 50 60
%
 R
e
m
o
v
a
l 
T
O
C
 m
g
.L
-1
 
Days 
MBR2  
Influent Effluent % Removal
1 µg.L-1 1 mg.L
-1 
10 mg.L-1 Before 
spiking 
 148 
 
 
 
 
 
Figure 5.4.17: Specific TOC and COD utilisation rates for MBR2 at different PM 
concentrations. 
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5.4.3.5 PM removal efficiency in MBR2 at different concentrations  
Unlike the MBR1 the removal of PM spiked into MBR2 was somewhat different. 
There was less significant removal efficiency of Metronidazole (Figure 5.4.18), 
namely 80% at concentration 1 µg.L
-1
, 60% at concentration 1 mg.L
-1
 and 61% at 
concentration 10 mg.L
-1
 (p>0.1, ANOVA). Highly significant removal efficiencies 
of Trimethoprim in MBR2 were similar to MBR1, where the removal efficiency 
decreased with increasing Trimethoprim concentration; consequently, 69%, 49, and 
26% removal was seen in MBR2 at Trimethoprim concentrations of 1 µg.L
-1
, 1 
mg.L
-1
, and 10 mg.L
-1
, respectively (p<0.05, ANOVA) (Figure 5.4.18). 
Sulphamethoxazole was also removed effectively by MBR2, as it was in MBR1, 
with 91% removal at 1 µg.L
-1
 Sulphamethoxazole, 97% removal at concentration 1 
mgL
-1
, but only 67% removal at concentration 10 mg.L
-1 
(p>0.1, ANOVA).  The 
removal of Paracetamol in MBR2 was comparable with MBR1, with 82% removal 
efficiency at a concentration of 1 µg.L
-1
, 91% at 1 mg.L
-1
, and 67% removal at 10 
mg.L
-1 
(p>0.2, ANOVA). The removal of Ranitidine in the MBR2 showed the 
highest similarity to MBR1, with 98% removal at a concentration of 1 µg.L
-1
, 
increasing to 99% removal at 1 mg.L
-1
 and 10 mg.L
-1 
(p>0.2, ANOVA). 
 
Figure 5.4.18: The removal efficiencies of pharmaceuticals in MBR2 at different PM 
concentrations. 
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The specific utilisation rates of Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol, and Ranitidine in MBR2 were similar to those observed in MBR1, 
which generally increased with increasing concentration in the range of 1 µg.L
-1
, 1 
mg.L
-1
, and 10 mg.L
-1
 (Figure 5.4.19). This suggests a similar effect of the initial PM 
concentration on the microorganisms in the activated sludge of both MBR1 and 
MBR2. As shown in Figure 5.4.19, the specific utilisation rates increased with the 
increase of initial PM concentration, indicating no apparent inhibition of any 
pharmaceutical on its biodegradation. 
 
Potentially no effects of increases in PM concentration on the specific 
pharmaceutical utilisation rate were observed. The specific pharmaceutical 
utilisation rates (mgph.mgMLVSS
-1
.d
-1
) increased linearly with an increase in the PM 
concentration with a correlation coefficient (R
2
) of 0.99 for all pharmaceuticals 
(p<0.05, ANOVA) (Figure 5.4.19). The highest specific pharmaceutical utilisation 
rate for MBR2 was found in Ranitidine followed by Sulphamethoxazole, then 
Paracetamol and Metronidazole, and the lowest was Trimethoprim.  
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Figure 5.4.19: Specific pharmaceutical utilisation rates at different PM concentrations in MBR2 with regression analysis.  
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5.4.4 Performance of SBR1 treating PM at three different concentrations under 
strictly aerobic conditions 
 
The fate of the studied PM was also investigated under strictly aerobic conditions in 
the sequencing batch reactor (SBR1) at different PM concentrations range (1 µg.L
-1
, 
1 mg.L
-1
, and 10 mg.L
-1
) (Table 4.1) (see Section 4.3). The SBR1 was operated at a 
hydraulic retention time (HRT) of 18 hours every day for 53 d.  
5.4.4.1 Variation of dissolved oxygen (DO) 
The variation in DO in SBR1 under different PM concentrations was similar to those 
observed in the SBR control and MBR1 (Figure 5.4.20). The DO decreased from4.05 
mg.L
-1
initially to 3.45 mg.L
-1
at day 10 before spiking with the PM. After spiking 
with 1 µg.L
-1
 of PM the DO decreased to 3.05 mg.L
-1
. The DO remained steady and 
in the same range and was 3.05 mg.L
-1
 when the PM concentration increased to 1 
mg.L
-1
, and remained stable when the PM concentration was increased to10 mg.L
-1 
at 
day 53. 
 
Figure 5.4.20: Changes in DO concentration with different PM concentrations in SBR1.   
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5.4.4.2 Variation of pH 
The influent pH of SBR1 was similar to the influent of MBR1, and the effluent pH 
dropped in the first 10 d to 6.39 (±0.33) which was similar to MBR1 and the SBR 
control as it is 6.16 (±0.23) (Figure 5.4.21). The effluent pH remained steady after 
spiking with PM at concentration 1 µg.L
-1
 and 1 mg.L
-1
 and was recorded as 5.6 
(±0.29) and 5.57 (±0.36), respectively. When the PM concentration was increased to 
10 mg.L
-1 
the
 
effluent pH increased to 7.7 then decreased to 6.1.  
 
Figure 5.4.21: pH value of the influent and effluent of synthetic wastewater containing different 
PM concentrations in SBR1.    
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increased to 3280 mg.L
-1
 at day 20 at a PM concentration 1 µg.L
-1
 then decreased to 
2042 mg.L
-1
 at day 39. The MLVSS decreased with an increase in the PM 
concentrations to 1800 mg.L
-1 
and 1706 mgL
-1 
at PM concentrations of 1 mg.L
-1
 and 
10 mg.L
-1
, respectively. MBR2 is affected by the concentration of PM similarly to 
MBR1 from concentration 1 µg.L
-1
to 10 mg.L
-1
.  
 
Figure 5.4.22 Variation of MLSS and MLVSS with change of PM concentration in SBR1.    
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spiked and decreased to 92% (±5), 83% (±7), and 78% (±10) at PM concentrations 1 
µg.L
-1
, 1 mg.L
-1
, and 10 mg.L
-1
, respectively (p<0.05, ANOVA). 
Specific COD and TOC utilisation rates of SBR1 were similar to those observed in 
the SBR control and MBR1 during the increased PM concentrations, while  
insignificant changes of specific COD and TOC utilisation rates were observed with 
the increased PM concentration, except that the specific TOC utilisation rate 
increased to 0.142 mgTOC.mgMLVSS
-1
.d
-1
at PM 1 mg.L
-1
(Figure 5.4.24) (p>0.2, 
ANOVA). 
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Figure 5.4.23: TOC and COD concentration and removal in SBR1 at different PM 
concentrations. 
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Figure 5.4.24: Specific TOC and COD utilisation rates for SBR1 at different PM concentrations. 
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5.4.4.4 PM removal efficiency in SBR1 at different concentrations  
The removal of the PM spiked into SBR1 was different to that of MBR1. The 
removal efficiency of Metronidazole was 70% at a concentration of 1 µg.L
-1
, 57% at 
a concentration of 1 mg.L
-1 
and further decreased to 45% at a concentration of 10 
mg.L
-1
 (p>0.1, ANOVA) (Figure 5.4.25). The removal efficiencies of SBR1 for 
Trimethoprim were similar to MBR1 at a concentration of 1 µg.L
-1
 (67%) but 
decreased to 17% at a concentration of 1 mg.L
-1 
and 18% at 10 mg.L
-1 
concentration 
(p>0.1, ANOVA). Sulphamethoxazole showed a lower removal efficiency for SBR1 
compared to MBR1 with 70% removal at a concentration of 1 µg.L
-1
, 92% at 1 
mg.L
-1
,but decreased sharply to 47% at a concentration of 10 mg.L
-1 
(p>0.1, 
ANOVA).  Paracetamol removal in SBR1 was higher than MBR1, with 90% 
removal efficiency at a concentration of 1 µg.L
-1
 and 1 mgL
-1
, and 92% at 10 mg.L
-1 
(p>0.2, ANOVA). The removal efficiency of Ranitidine in the SBR1 was also the 
highest, as observed in MBR1, with 95% removal at a concentration of 1 µg.L
-1
 and 
99% at concentrations of 1 mg.L
-1 
and 10 mg.L
-1 
(p<0.05, ANOVA). 
 
 
Figure 5.4.25: The removal efficiencies of pharmaceuticals in SBR1 at different PM 
concentrations. 
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The specific utilisation rates of Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol, and Ranitidine in SBR1 were also similar to those in MBR1, generally 
increasing with an increase in initial PM concentration in the range of 1 µg.L
-1
, 1 
mg.L
-1
, and 10 mg.L
-1
 (Figure 5.4.26), indicating no apparent inhibition of the 
biodegradation of the pharmaceuticals. The specific pharmaceutical utilisation rates 
(mgph.mgMLVSS
-1
.d
-1
) increased linearly with the increase of pharmaceutical 
concentration with a correlation coefficient (R
2
) of 0.99 for all pharmaceuticals. The 
highest specific pharmaceutical utilisation rate for SBR1 was found for Ranitidine 
followed by Paracetamol, then Metronidazole and Sulphamethoxazole, and the 
lowest was Trimethoprim (Figure 5.4.26). The change of specific pharmaceutical 
utilisation rates with the increase of PM concentrations was highly significant for 
Metronidazole, Sulphamethoxazole, Paracetamol, and Ranitidine (p<0.05, ANOVA), 
but insignificant in Trimethoprim (p>0.2, ANOVA). 
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Figure 5.4.26: Specific pharmaceutical utilisation rates at different PM concentrations in SBR1 with regression.
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5.4.5 Performance of SBR2 treating PM at three different concentrations under 
anoxic and aerobic condition 
 
In the SBR2 the fate of PM was studied under a combination of anoxic and aerobic 
conditions using the sequencing batch reactor (SBR2) at different PM concentrations 
ranges (1 µg.L
-1
, 1 mg.L
-1
, and 10 mg.L
-1
). The effects of PM concentration were 
studied by the operational scheduled anoxic/aerobic cycle (anoxic period 2 hours, 
aerobic period 16 hours), a hydraulic retention time (HRT) of 18 hours, and a solids 
retention time (SRT) of 53 d (Table 4.1) (see Section 4.3).  
5.4.5.1 Variation of dissolved oxygen (DO) 
The variation of the DO in SBR2 under different PM concentrations was similar to 
MBR2 except that the DO increased further at a concentration of 10 mg.L
-1
 (Figure 
5.4.27). The DO decreased from 4.15 mg.L
-1 
initially to 3.49 mg.L
-1 
at day 10 before 
spiking the PM. The DO decreased to 2.67 mg.L
-1
 at the end run of 1 µgL
-1
 
concentration, then started to increase to 2.87 mgL
-1 
and 3.24 mgL
-1
 at a 
concentrations of 1 mgL
-1
, and 10 mgL
-1
, respectively. 
 
Figure 5.4.27: Changes in DO concentration with different PM concentrations in SBR2.   
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5.4.5.2 Variation of pH 
As shown in Figure 5.4.28, the first 10 d of the experiment the effluent pH dropped 
to 6.46 (±0.38) which was similar to MBR2 and SBR1 and comparable to the SBR 
control. The effluent pH, after spiking the PM at a concentration of 1 µg.L
-1
, 
decreased to 6.08 (±0.46) and remained steady even when the PM concentration 
increased to 1 mg.L
-1
, and increased to 8.17 (±0.32) at a concentration of 10 mg.L
-1
.  
 
Figure 5.4.28: pH value of the influent and effluent of synthetic wastewater containing different 
PM concentrations in MBR2.    
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concentration of 1 µg.L
-1
, then the MLVSS decreased to 2014 mg.L
-1
 at day 39, and 
it decreased further when the PM concentration increased (Figure 5.4.29). SBR2 is 
affected by the concentration of PM similarly to MBR1 from concentration 1 µg.L
-1 
to 10 mg.L
-1
.  
 
 
 
Figure 5.4.29: Variation of MLSS and MLVSS with change of PM concentration in SBR2.    
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(±0.51) for a concentration of 1 mg.L
-1
 and 10 mg.L
-1
, respectively (Figure 5.4.30). 
COD removal efficiency decreased with increasing PM concentration (p<0.05, 
ANOVA). The TOC removal efficiencies of SBR2 were 96% (±0.69) before PM 
spiked, and were steady similar to SBR1 when fed with PM at concentrations of 1 
µg.L
-1
l and 1 mg.L
-1
, decreased significantly to 93% (±3.1), 86% (±7.6), 
respectively, and decreased to 54% (±6.74) at a concentration 10 mg.L
-1 
(p<0.05, 
ANOVA) (Figure 5.4.30).  
The specific COD utilisation rates of SBR2 were relatively similar to SBR1, 
changing significantly with the increasing PM concentrations, except that it 
increased at a concentration of 1 mg.L
-1
 at day 45 (ANOVA, p=0.08) (Figure 
5.4.31). Furthermore, the specific TOC utilisation rates of SBR2 were also similar to 
SBR1, and the specific TOC utilisation rate changed less significantly with the 
increase of PM concentrations (ANOVA, p = 0.18) (Figure 5.4.31).  
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Figure 5.4.30: TOC and COD concentration and removal in SBR2 at different PM 
concentrations. 
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Figure 5.4.31: Specific TOC and COD utilisation rates for SBR2 at different PM concentrations. 
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concentration 1 µg.L
-1
compared with other reactors (MBR1, MBR2 and SBR1), and 
decreased significantly to 42% and 27% at a concentration of 1 mg.L
-1 
and 10 mg.L
-
1
, respectively (p<0.05, ANOVA) (Figure 5.4.32). Sulphamethoxazole removal 
efficiency in SBR2 was 81% at concentration 1 µg.L
-1
, then increased to 95% at a 
concentration of 1 mg.L
-1
 and decreased significantly to 32% at a concentration of 10 
mg.L
-1
(p<0.05, ANOVA) (Figure 5.4.32).  Insignificant changes were found in the 
removal efficiency of Paracetamol with the increase of PM concentrations in the 
SBR2, 87% removal at concentration 1 µg.L
-1
, which then increased to 93% and 
92% at concentrations of 1 mg.L
-1 
and 10 mg.L
-1
, respectively (p>0.2, ANOVA) 
(Figure 5.4.32). The removal efficiency of Ranitidine in the SBR2 was also high, 
97% at concentrations 1 µg.L
-1
 and 1 mg.L
-1 
and increased to 98% removal at a 
concentration of 10 mg.L
-1
, while the changes of removal efficiencies with the 
increase of PM concentrations was insignificant (p>0.2, ANOVA) (Figure 5.4.32). 
 
 
Figure 5.4.32: The removal efficiencies of pharmaceuticals in SBR2 at different PM 
concentrations. 
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The specific utilisation rates of Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol, and Ranitidine in SBR2 were similar to those of SBR1, which 
increased with increasing concentration in the range of 1 µg.L
-1
, 1 mg.L
-1
, and 10 
mg.L
-1
 (Figure 5.4.33). The specific utilisation rates increased with the increase of 
initial PM concentration, demonstrating that no apparent inhibition in the 
biodegradation of the PM studied. The specific pharmaceutical utilisation rates 
(mgph.mgMLVSS
-1
.d
-1
) increased linearly with the increase of the PM concentration 
with a correlation coefficient (R
2
) of 0.99 for all the pharmaceuticals studied. The 
effect of microorganisms in the activated sludge on each pharmaceutical was the 
same as in SBR1 at all concentrations. The highest specific pharmaceutical 
utilisation rate for SBR2 was found for Ranitidine followed by Paracetamol, then 
Metronidazole and Sulphamethoxazole, and the lowest was Trimethoprim. The 
increase in specific pharmaceutical utilisation rate changes were highly significant 
with increasing concentrations for Trimethoprim, Paracetamol, and Ranitidine 
(p<0.05, ANOVA), while it was significant in Sulphamethoxazole (p=0.07, 
ANOVA) and insignificant in Metronidazole (p>0.2, ANOVA). 
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Figure 5.4.33: Specific pharmaceutical utilisation rates at different PM concentrations in SBR2 with regression.
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5.4.6 Performance of bioreactors with real municipal wastewater 
 
Performance of the four reactors (MBR1, MBR2, SBR1, and SBR2) was tested with 
a real municipal wastewater feed spiked with PM at a concentration of 1 mg.L
-1 
to 
evaluate the removal efficiencies. Real municipal wastewater was used towards the 
end of the experimental study, and these treatability studies were conducted for 
comparison with the results of the synthetic wastewater studies. Comparisons of 
overall treatability of the four reactors on the actual municipal wastewater was based 
on effluent quality and pharmaceutical degradation patterns. 
The initial results had been obtained with synthetic wastewater as the sole organic 
carbon source, and this was highly removed in all the control reactors (without PM). 
The synthetic wastewater COD was also removed efficiently at PM concentrations of 
1 µg.L
-1
 (Figure 5.4.34). Analysis always detected remaining soluble COD at the end 
of each run, which mostly revealed the presence of PM, or residuals of low 
biodegradable products. The results suggest that the PM was probably adsorbed by 
the sludge, based on the assumption that they are practically non-biodegradable with 
short-term exposure to non-acclimated biomass. 
 
During the test of real municipal wastewater that contained 1 mg.L
-1 
of PM, the 
effluent pH increased to 6.8 (±0.56), 7.32 (±0.25), 7.26 (±0.28), and 7.41 (±0.13) for 
MBR1, MBR2, SBR1, and SBR2, respectively (Table 5.4.1). All the reactors using 
real municipal wastewater showed good COD removal of 79, 88, 86, and 82 % for 
MBR1, MBR2, SBR1, and SBR2, respectively, when compared with the COD 
removal for synthetic wastewater (Figure 5.4.34). On the other hand, the TOC 
removal efficiency with real municipal wastewater was less than that for synthetic 
wastewater at all PM concentrations, with TOC removal of 66, 62, 73, and 59 % for 
reactors MBR1, MBR2, SBR1, and SBR2, respectively. This can be explained by the 
relatively low concentration of easily biodegradable organic compounds present in 
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real municipal wastewater, which is only partially soluble and contains greater 
component of hard COD and complex molecules, unlike synthetic wastewater which 
contains highly soluble simple molecules as the organic matter. Consequently, the 
removal rates of COD for municipal wastewater were low in comparison with those 
found for the synthetic wastewater. A similar trend was observed for removal rates 
of TOC (Table 5.4.1). Furthermore, the DO concentration was relatively high in all 
reactors treating real municipal wastewater, being in the range 4.75 to 5.07 mg.L
-1
, 
indicating lower levels of microbial activity. Interestingly, the MLVSS was 
relatively high in the real municipal wastewater, where it decreased with increasing 
PM concentrations in synthetic wastewater. Furthermore, the specific COD and TOC 
utilisation rates were lower in municipal wastewater compared with synthetic 
wastewater at most pharmaceutical concentrations, with 0.059 to 0.074 
mgCOD.mgMLVSS
-1
.d
-1
 for COD, and 0.024 to 0.031 mgTOC.mgMLVSS
-1
.d
-1
 for TOC 
(Table 5.4.1).  
 
 
The observations from the current study are similar to results obtained from other 
studies conducted under aerobic conditions. Due to the acute inhibititory effect of 
PM observed in aerobic systems, the consumption of dissolved oxygen was 
significantly reduced upon first exposure to the PM. The study by Orhon et al. 
(2010), observed significant reductions in the amount of DO consumption due to the 
acute effect of 2,6-dihydrobenzoic acid on the biodegradation of a peptone mixture. 
Similarly, the acute effect of the same pharmaceutical on the biodegradation of 
organics in wastewater under aerobic conditions presented the same results in the 
reduction in the amount of oxygen consumed with the corresponding portion of the 
organic available in the experiments remaining unused (Cetecioglu, 2011; Ozkok et 
al., 2011). 
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Figure 5.4.34: The TOC and COD removal at all reactors at different PM concentrations in 
synthetic wastewater and real municipal wastewater. 
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Table 5.4.1: Summary of performance data from the four bioreactors at different PM concentrations and types of wastewaters. 
 Reactor     MBR1         MBR2         SBR1         SBR2     
 PM concentration 0 
1 
µg.L-1 
1 
mg.L-1 
10 
mg.L-1 
municipal  WW 
+ 1mg.L-1 
0 
1 
µg.L-1 
1 
mg.L-1 
10 
mg.L-1 
municipal  WW 
+ 1mg.L-1 
0 
1 
µg.L-1 
1 
mg.L-1 
10 
mg.L-1 
municipal  WW 
+ 1mg.L-1 
0 
1 
µg.L-1 
1 
mg.L-1 
10 
mg.L-1 
municipal  WW 
+ 1mg.L-1 
Influent pH 
7.56 
±0.22 
7.80 
±0.31 
8.27 
±0.03 
7.97 
±0.28 
7.61  
±0.32 
7.56 
±0.22 
7.80 
±0.31 
8.27 
±0.03 
7.97 
±0.28 
7.61  
±0.32 
7.56 
±0.19 
7.81 
±0.26 
8.28 
±0.11 
7.95 
±0.26 
7.61  
±0.32 
7.56 
±0.19 
7.81 
±0.26 
8.28 
±0.11 
7.95 
±0.26 
7.61  
±0.32 
Effluent pH 
6.19 
±0.22 
5.99 
±0.22 
6.03 
±0.44 
6.37 
±0.11 
6.80  
±0.56 
6.39 
±0.35 
5.63 
±0.24 
6.12 
±0.66 
7.38 
±0.32 
7.32  
±0.25 
6.39 
±0.33 
5.56 
±0.29 
6.28 
±0.88 
6.71 
±0.74 
7.26  
±0.28 
6.46 
±0.38 
6.08 
±0.46 
7.49 
±1.17 
8.19 
±0.35 
7.41  
±0.13 
DO 3.77 3.27 2.94 2.93 4.78 3.83 3.18 3.61 3 4.75 3.73 3.31 3.05 3 4.98 3.81 3.21 2.87 3.24 5.07 
MLSS 2758 2369 2396 2331 3195 3645 3241 2662 2388 2978 3636 3247 2218 2466 3031 3234 2964 2303 2209 2859 
MLVSS 2476 2198 1906 1437 2647 3113 2073 1741 1532 2442 2623 2706 1800 1706 2197 2264 2544 1627 1543 2290 
MLVSS/MLSS 89 92 79 61 82 85 64 65 64 82 72 83 81 69 72 70 86 70 69 80 
TOCinf 
346.3 
(±60) 
325 
(±48) 
308 
(±57) 
358 
(±37) 
138  
(±12) 
346 
(±60) 
325 
(±48) 
291 
(±57) 
358 
(±37) 
138 
 (±12) 
354 
(±48) 
327 
(±55) 
338 
(±65) 
376 
(±21) 
138  
(±12) 
354 
(±48) 
327 
(±55) 
338 
(±65) 
376 
(±21) 
138 
 (±12) 
TOCEff 
15  
(±7) 
31  
(±4) 
42 
(±12) 
58 
(±5) 
46 
(±6) 
18  
(±9) 
25  
(±6) 
29 
(±6) 
62 
(±27) 
51  
(±9) 
12  
(±3) 
21 
(±13) 
50 
(±11) 
77 
(±27) 
36  
(±7) 
11 
 (±2) 
19  
(±7) 
38 
(±10) 
173 
(±14) 
56  
(±24) 
% TOC Removal 
95 
 (±3) 
90  
(±1) 
84 
(±5) 
83 
(±2) 
66  
(±3) 
94  
(±4) 
92  
(±1) 
89 
(±1) 
81 
(±9) 
62 
 (±5) 
96 
(±0.8) 
92  
(±5) 
83 
(±7) 
77 
(±10) 
73  
(±4) 
96 
(±0.6) 
93  
(±3) 
86 
(±7) 
54 
(±6) 
59  
(±15) 
CODInf 
730  
±36 
698 
±104 
633 
±172 
671 
±132 
259  
±16 
730 
 ±36 
698 
±104 
633 
±172 
671 
±132 
259  
±16 
722  
±37 
687 
±108 
663 
±100 
677 
±114 
259  
±16 
722  
±37 
687 
±108 
663 
±100 
677 
±114 
259  
±16 
CODEff 
31  
(±7) 
48  
(±3) 
56 
(±39) 
82 
(±8) 
54  
(±21) 
38  
(±8) 
43 
(±13) 
67 
(±7) 
54 
(±10) 
29  
(±15) 
30  
(±3) 
34 
(±17) 
96 
(±24) 
99 
(±11) 
36  
(±12) 
28 
(±2) 
32  
(±9) 
69 
(±15) 
108 
(±4) 
44  
(±4) 
% COD Removal 
95  
(±1) 
92  
(±1) 
89 
(±9) 
87 
(±3) 
79  
(±6) 
94  
(±1) 
93  
(±2) 
88 
(±4) 
91 
(±3) 
88  
(±4) 
95 
(±0.6) 
95  
(±2) 
84 
(±6) 
85 
(±2) 
86  
(±3) 
96 
(±0.2) 
95  
(±1) 
89 
(±3) 
85 
(±0.5) 
82  
(±1) 
Spec. COD utilistion rate 
(mg.mgMLVSS
-1.d-1) 
0.216  0.208  0.168 0.224 0.059 0.169  0.214  0.189 0.222 0.07 0.203  0.194  0.199 0.199 0.074 0.234  0.21  0.338 0.265 0.067 
Spec. TOC utilistion rate 
(mg.mgMLVSS
-1.d-1) 
0.108  0.092  0.087 0.149 0.024 0.085  0.093  0.105 0.132 0.024 0.105  0.088  0.142 0.103 0.031 0.121  0.096  0.161 0.081 0.027 
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Results of the PM removal in the studied bioreactor configurations showed that the 
different treatment designs (MBR versus SBR) could also affect the removal of the 
PM since it fluctuated between bioreactors. In addition, correlations between 
removal efficiencies of the pharmaceuticals, and the removal efficiencies of general 
parameters, were observed. However, some similar trends were observed between 
the aerobic bioreactors and the anoxic-aerobic bioreactors. These results imply that 
the aerobic microorganisms are mostly responsible for the degradation of the 
pharmaceuticals. 
The overall removal of the pharmaceuticals by all the bioreactors under continuous 
PM loading was relatively steady over the experimental period of 63 days. It was 
observed that higher removal rates for Ranitidine occurred during the first day, 
suggesting that equilibrium was reached rapidly. Paracetamol was also seen to be 
removed more effectively with average elimination efficiencies of 88-93% by all 
bioreactors, whereas the average removal for Ranitidine ranged between 96-99%, 
indicating that Ranitidine is more biodegradable. On the other hand, 
Sulphamethoxazole also showed relatively high removal rates in all bioreactors, 
average elimination efficiencies being 70-97%, whereas the removal of 
Trimethoprim ranged between 18-69%, indicating that Trimethoprim is more 
resistant to biological treatment than the Sulphamethoxazole. However 
Metronidazole showed only moderate removal in all bioreactors, with average 
removal ranging between 29-83%.  
 
Figure 5.4.35 shows the removal of Metronidazole in the four different reactors. The 
removal of Metronidazole spiked in real municipal wastewater was very low 
compared with its removal in synthetic wastewater at similar conditions, real 
wastewater showing only 28, 53, 33, and 47 %  Metronidazole removal in MBR1, 
MBR2, SBR1, and SBR2, respectively. The low and highly variable removal of the 
Metronidazole is in good agreement with the report of Beier et al. (2010), and may 
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be attributed to the presence of a strong electron withdrawing group EWG nitro 
group in its structure. Metronidazole was not biodegradable in the laboratory-based 
batch experiment and is relatively hydrophilic according to Alexy et al. (2004). 
Because of these factors Metronidazole was not expected to be effectively removed 
during conventional wastewater treatment. On the other hand, an excellent removal 
of Metronidazole (95%) was observed with an MBR by Dolar et al. (2012).  
Similarly, the removal of Trimethoprim was also low in real municipal wastewater 
(Figure 5.4.36), but was higher than at PM concentration of 1 mg.L
-1
 in synthetic 
wastewater for all reactors (Figure 5.4.36). The removal of Trimethoprim was 
highest in MBR2 and SBR2 at 58%, followed by MBR1 at 57%, and lowest in SBR1 
(33%). A previous study by Batt el al. (2006) reported that enhanced biodegradation 
of Trimethoprim does occur in nitrifying activated sludge where the removals were 
approximately 20% in both nitrifying and inhibited nitrifying activated sludge 
reactors (Batt et al., 2006). On the other hand, research by Göbel et al. (2007) 
reported comparable elimination rates for SRTs of 16 and 33 days (30%), while 87% 
removal of Trimethoprim was obtained for SRTs in the range of 60–80 days in an 
MBR. In contrast, Tambosi et al. (2010) observed the highest removal efficiencies 
for Trimethoprim at 86% and 94% at 15 and 30 SRT respectively.  
In contrast, the removal of Sulphamethoxazole was relatively high compared with 
the previous pharmaceuticals but was degraded less efficiency in real municipal 
wastewater than in synthetic wastewater (Figure 5.4.37). The removal of 
Sulphamethoxazole in municipal wastewater was the highest in MBR2 at 87%, 
followed by MBR1 at 79%, and lowest in SBR2 and SBR1, at 52% and 28%, 
respectively. Göbel et al. (2007), who studied the elimination of Sulphamethoxazole, 
reported an elimination efficiency of around 80%. On the other hand, Tambosi et al. 
(2010) reported that Sulphamethoxazole was eliminated by 55% to 64% in the MBR 
treatment processes.  
The removal of Paracetamol in real municipal wastewater was relatively high for all 
reactors but still lower than that found in the synthetic wastewater (Figure 5.4.38). 
The highest removal of Paracetamol was in MBR2 at 85%, followed by SBR1 and 
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MBR1 at 82% and 81%, respectively. The lowest removal of Paracetamol was in 
SBR2 at 68%. The structure of Paracetamol allows the bacteria and enzymes to 
readily attack the molecule. This removal of Paracetamol could be attributed to 
biological conversion, resulting in quite stable transformation products which are 
conjugates of Paracetamol. These results are in agreement with other reported studies 
which obtained 99% Paracetamol removal during the treatment of municipal sewage 
in an MBR (Kim et al., 2007; Tambosi et al., 2010). 
The removal of Ranitidine from real municipal wastewater was the highest at 97% 
compared with other spiked pharmaceuticals and had the same level of removal in all 
reactors (Figure 5.4.39). Therefore, the effect of an increase in pharmaceutical 
concentration on the Ranitidine removal was negligible. High and steady Ranitidine 
removal of more than 80% in the MBR was observed by Radjenovic et al. (2007). 
Similarly, Dolar et al. (2012) observed a removal efficiency of Ranitidine in 
wastewater equal to 89%, whereas Radjenovic et al. (2009) observed a lower 
removal of Ranitidine of 44.2%.  
The mechanism of pharmaceutical biodegradation is well studied in the literature, 
mostly by enzyme analogy, and conveniently associating into two enzymatic 
mechanisms; firstly, competitive drugs which compete on the substrate for the same 
reactive site on the enzyme and secondly, non-competitive pharmaceuticals which 
can also bind with the enzyme and deactivate the bound enzyme sites (Campell and 
Farrell, 2007). In competitive or non-competitive experiment approaches, as in 
studies by Fountoulakis et al., 2008, the important point to consider in the results of 
this study is that the pharmaceutical impact is kinetic, slowing down the rate of 
different reactions for substrate utilisation. Thus, it would take more time for the 
completion of microbial activity ending with complete utilisation of available 
organic substrate, but the same stoichiometry would be observed at anytime along 
the pathway of biochemical reactions, (Campell and Farrell, 2007). The same would 
be true for a possible toxic effect of a pharmaceutical inactivating a part of the 
microbial community. However, remained substrate observed in the current study 
gives indication of a stoichiometric disturbance, as contrasted with the kinetic impact 
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reported for pharmaceutical effect studies. It is interesting to note that the results of 
Fountoulakis et al., 2008 related to the effect of ofloxacine on an organic substrate 
providing supporting experimental evidence as they showed the same disagreement 
between model simulation and experimental values.  
In this current study, the substrate was removed by microorganisms and the partially 
used pharmaceutical which could be interpreted from the substrate binding effect. 
The corresponding enzyme analogy probably has an uncompetitive effect, where the 
pharmaceutical could bind the enzyme substrate complex but not the free enzyme; 
this would correspond to the blocking of the substrate after enzymatic uptake, within 
the biomass. As previously mentioned, a similar binding effect of organic substrate 
by the same pharmaceutical at lower doses was also observed under aerobic 
conditions (Ozkok et al., 2011). 
Sorption onto sludge is one of the mechanisms which can be described as absorption 
and adsorption. According to Carballa et al. (2005), absorption is a hydrophobic 
interaction of the aromatic and aliphatic groups of a compound with the lipophilic 
cell membrane of the microorganisms, or with the sludge (depending on their Kow 
value), while adsorption is an electrostatic interaction of positively charged groups of 
dissolved chemicals with the negatively charged surfaces of the microorganisms 
(characterized by the dissociation constant pKa). Göbel et al. (2007) concluded that 
the removal of pharmaceuticals in an MBR and conventional activated sludge 
treatment by activated sludge adsorption was less than 6%. Therefore, the adsorption 
in the system was negligible, because this is within the analytical variance of the 
method. 
 
Physical retention of the membranes is another mechanism responsible for the 
removal of pharmaceutical compounds in the MBR. However, due to the molecular 
weight cut off of ultrafiltration MBR membranes are around 100–200 kDa which is 
much greater than the molecular weights of these pharmaceuticals (200-300 Daltons) 
and highly soluble at neutral pH (logD values < 2), the mechanism would not have 
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led to retention of the pharmaceuticals. The rejections were expected due to 
electrostatic interactions (attractive or repulsive) rather than size exclusion and 
hydrophobic interaction. The membranes are often negatively charged at neutral pH 
(Nghiem et al., 2005; Schafer et al., 2003; Simon et al., 2009), and thus negatively 
charged pharmaceuticals are rejected mainly through electrostatic repulsion; while 
the positively charged pharmaceuticals are removed by a combination of attractive 
electrostatic interaction with the membrane surface and Donnan equilibrium (Schaep 
et al., 2001; Verliefde et al., 2008).  
Metronidazole is a significantly hydrophilic compound and its removal was low to 
moderate in this study. This can be explained by the presence of one or more strong 
EWG (amide group and nitro group) or absence of strong electron donating group 
EDG in their structures. Our results regarding the removal efficiency of 
Metronidazole are in agreement with previous reports (Clara et al., 2005; Joss et al., 
2005; Radjenovic et al., 2007; Tadkaew et al., 2011). 
Sorption onto the membranes is also limited because of the available membrane 
surface area. Nhat LE (2011) found the amounts of Trimethoprim, which were 
partially positively charged at pH near 7, adsorbed to the membrane surface was 
2.93% while the adsorption of Sulphamethoxazole, which is mostly negatively 
charged at neutral pH, was much lower (less than 0.53%) and these figures reduced 
over the 4 hour experiment. This decrease in rejection rates may be due to the charge 
equilibrium occurring on the membrane surface.  
Sulphamethoxazole has a hydrophilic nature with two ionizable amine groups. As a 
result, in an aqueous solution, it can be present in positive, neutral and negative 
forms. At pH values between 1.4 - 5.8, the pKa value of Sulphamethoxazole is 
present predominantly as a neutral, while above pH 5.8 the pKa value becomes 
negatively charged. These properties indicate that in all reactors at pH 7.2 the sludge 
adsorption mechanism played a negligible role, due to electrostatic repulsion 
between the negatively charged Sulphamethoxazole and the negatively charged 
surfaces of the sludge. Therefore, biodegradation processes can be considered the 
main mechanism responsible for the removal.  
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One anomalous result obtained was the high removal of Ranitidine, despite 
containing a strong EWG (amide and nitro group) (Tadkaew et al., 2011). A possible 
explanation is that the presence of methyl groups (weak EDG) led to conversion of 
the methyl group to alcohol (Shaw and Harayama, 1992), bypassing the problematic 
amide conversion. In contrast, Paracetamol is a less hydrophobic compound (logD < 
3.2) containing a strong EDG hydroxyl group, and was consistently removed to a 
high degree, which agrees well with reports in other literature (Visvanathan et al., 
2005).  
 
 
Figure 5.4.35: The removal efficiencies of Metronidazole in four reactors at different PM 
concentrations with synthetic and real wastewaters. 
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Figure 5.4.36: The removal efficiencies of Trimethoprim in four reactors at different PM 
concentrations with synthetic and real wastewaters. 
 
 
Figure 5.4.37: The removal efficiencies of Sulphamethoxazole in four reactors at different PM 
concentrations with synthetic and real wastewaters. 
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Figure 5.4.38: The removal efficiencies of Paracetamol in four reactors at different PM 
concentrations with synthetic and real wastewaters. 
 
 
Figure 5.4.39: The removal efficiencies of Ranitidine in four reactors at different PM 
concentrations with synthetic and real wastewaters. 
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5.4.7 COD/TOC ratio 
 
The removal of TOC followed a similar trend to COD removal. The COD test 
consists of measuring all the organic materials that can be oxidized by a strong 
oxidizing agent, but the COD test has some restrictions and cannot oxidize some 
substances present in the wastewater such as sulfides, sulfites and ferrous iron. In 
addition, the COD test cannot completely oxidize some aromatic compounds. While 
the TOC test does not measure other organically bound elements such as nitrogen, 
hydrogen and inorganics that can be measured by COD, it also is independent of the 
oxidation state of the organic matter. Furthermore, the TOC test is not affected by 
the presence of organics that are difficult to oxidize completely.  
 
The most important observation made in the current study is that COD removal was 
high, but the amount of COD removal decreased depending on the dose of PM, 
which indicated that the pharmaceutical could be utilized in metabolic reactions 
(Figures 5.4.34). For this purpose COD with its soluble and particulate fractions, was 
measured for the pre-spiked PM, and measured for the additions of PM at different 
concentration runs. The decrease of the COD/TOC ratio in both the influent and the 
effluent with increasing PM in all reactors (Table 5.4.2) indicates the increase of the 
oxidative state of carbon in the organic solution and lower reactivity (Hsu et al., 
2004). In contrast, the increase in the COD/TOC ratio in the experiments carried out 
indicates a degradation pathway driven primarily by radical oxidation leading to 
different reaction intermediates. These results may be justified as COD utilization by 
biomass could be slightly changed during the different phases of the metabolic 
reactions. The ratio was the lowest with the municipal wastewater due to its 
complexity. However, the COD/TOC ratio of the effluent decreased as the PM 
concentration increased, and was the lowest in the case of real municipal wastewater 
except in the reactor SBR2.  
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Table 5.4.2: COD/TOC ratio in four reactors at different PM concentrations spiked in synthetic and real wastewater. 
                                                                Influent  
 
                                         Effluent 
 
0 1 
 µg.L
-1 
synthetic 
1 
mg.L
-1 
synthetic 
10 
mg.L
-1 
synthetic 
1 
mg.L
-1 
real municipal  
WW 
0 1  
µg.L
-1 
synthetic 
1  
mg.L
-1 
synthetic 
10  
mg.L
-1 
synthetic 
1 
mg.L
-1 
real municipal  
WW 
MBR1 
2.14 
(±0.3) 
2.24 
(±0.45) 
1.93 
(±0.15) 
1.78 
(±0.25) 
1.80 
(±0.2)  
2.13 
(±0.46) 
1.64 
(±0.08) 
1.32 
(±0.2) 
1.38 
(±0.05) 
1.13   
(±0.29) 
MBR2 
2.14 
(±0.3) 
2.24 
(±0.45) 
1.93 
(±0.15) 
1.78 
(±0.25) 
1.80 
(±0.2)  
2.38 
(±0.74) 
1.71 
(±0.31) 
1.84 
(±0.29) 
1.09 
(±0.23) 
0.52   
(±0.16)  
SBR1 
2.05 
(±0.19) 
2.1 
(±0.21) 
1.96 
(±0.08) 
1.79 
(±0.2) 
1.8 
(±0.2)  
2.46 
(±0.64) 
2.1 
(±0.63) 
1.76 
(±0.03) 
1.35 
(±0.48) 
0.96   
(±0.28) 
SBR2 
2.05 
(±0.19) 
2.1 
(±0.21) 
1.96 
(±0.08) 
1.79 
(±0.2) 
1.8 
(±0.2)  
2.52 
(±0.54) 
2.06 
(±0.81) 
1.61 
(±0.26) 
0.66 
(±0.1) 
0.87   
(±0.35) 
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5.5 MICROBIAL DIVERSITY ANALYSIS 
 
The analysis of microbial diversity present in each reactor during the experiment 
was carried out using the PCR-DGGE technique. This technique was used to 
characterise and understand how the stability and diversity of the microbial 
communities was influenced by the different concentrations of doses of the PM in 
the reactors, i.e. to investigate the effects of pharmaceutical concentration on 
microbial community structure.  
5.5.1 Analysis of DGGE profile 
DGGE profiles of bacterial 16S rRNA gene fragments from MBR1, MBR2, 
SBR1, and SBR2, and control reactors represented by MBR3 and SBR3, are 
shown in Figure 5.5.1. DGGE profiles of bacterial gene fragments reveal that 
different populations were present in the same reactor at different doses of PM, 
and there was a difference between the populations in different reactors even 
though differences in the overall patterns of bacterial populations in all reactors 
were clear, as evidenced by the loss and the appearance of some bands in the 
different phases of each reactor run. Moreover, there were some particular bands 
that obviously showed an increase and decrease in band intensity, indicating 
changes in the number of the predominant population at certain doses of a PM. 
These changes of band intensity were observed in MBR1, MBR2, SBR1 and 
SBR2.  
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Figure 5.5.1: DGGE profile of bacterial communities from MBR1, MBR2, SBR1, SBR2 and Control (MBR C and SBR C) (M = the marker band, run to correct for 
variation across different gels). 
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5.5.2 Effect of PM concentration on microbial diversity 
 The observations on the DGGE gel showed that for each dose of PM or different 
experiment diversity produced a different band pattern. The bands count and its change 
throughout the experiment showed that the change in PM concentration appears to affect 
the diversity of the microbial population. 
 
DGGE is a largely qualitative method, thus analysis was done on bands which clearly 
appeared, disappeared or changed in intensity relative to the control treatment. The 
DGGE analysis suggests that changes in microbial diversity may have occurred in the 
presence of PM as compared to the control. There was a significant change in microbial 
community for MBR1, MBR2, SBR1 and SBR2 (Figure 5.5.2) with an increase of the 
PM concentration (p< 0.05; ANOVA), where the number of bands decreased. The result 
was expected since the MLVSS decreased due to reduced microbial growth, and a 
reduction in COD removal was seen. Therefore, it is clear that the microbial diversity 
was affected by high doses of pharmaceuticals.  
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Figure 5.5.2: Microbial diversity changes shown by number of bands present in DGGE profile of 
different bioreactors, at different doses of PM concentration in synthetic and real municipal 
wastewater. 
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5.5.3 Similarities in microbial diversity 
Cluster analysis permitted a comparison of the levels of similarities between bacterial 
communities according to PM concentration and bioreactors operational design. This 
showed a small similarity between the samples according to the method of operational 
design and PM concentration. This similarity decreased with increasing PM dose (Figure 
5.5.3). The similarity between MBR1 and MBR2 at a concentration of 1 µg.L
-1
 of PM 
was 86.5%, whereas the similarity between SBR1 and SBR2 was 82.5%. All reactors at a 
concentration of 1µg.L
-1
 showed 73.5% similarity. The similarity decreased to 69.8% for 
all reactors when the PM concentration was increased to 1mg.L
-1
, where the similarity of 
sludge communities in MBR1 and MBR2 was 84%, and SBR1 and SBR2 was 83% at 
concentration 1mg.L
-1
. The similarity decreased to 57.5% in all reactors when fed by real 
municipal wastewater containing 1 mg.L
-1
 of PM. All these results showed that the 
concentration of PM and different conditions changed the diversity of bacterial 
communities according to the similarity profile.  
 
Figure 5.5.3: Dendogram for similarity of bacterial communities in different bioreactors at different 
PM concentrations in synthetic and real municipal wastewater. 
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5.5.4 Similarity of diversity of continuous batch bioreactors inoculated with isolated 
bacteria 
The microorganisms present in the activated sludge from the batch reactors experiment 
in Section 5.3 were isolated by both spread plate and streak plate method on selective 
media containing single a pharmaceutical such as Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine.  Different bacterial strains were 
isolated based on each pharmaceutical being the only carbon source in order to find the 
similarity of these isolated bacteria with non-inoculated bioreactors in Section 5.4. 
Figure 5.5.4 shows the visual comparison of the DGGE profiles of bacterial 16S rRNA 
gene fragments and reveals that isolated bacteria were present in the bioreactor during 
the experiments and there was a difference between different reactors (Figure 5.5.4). The 
loss and the appearance of some bands were still observed in the different phases of each 
reactor. Moreover, there were some particular bands that obviously showed an increase 
and decrease in band intensity, indicating changes in the number of the predominant 
population at different operating conditions. These changes in band intensity were also 
observed for some reactors with the isolated bacteria. The differences between the 
isolated bacteria were expected, as they grown in different pharmaceuticals. However, 
similarities were found between these isolated bacteria and bacterial communities of 
different reactors. 
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Figure 5.5.4: DGGE profile of bacterial communities from MBR1, MBR2, SBR1, and SBR2 
compared with the profile of specific isolated bacterial from Metronidazole (M), Trimethoprim (T), 
Sulphamethoxazole (S), Paracetamol (P) and Ranitidine (R). 
 
All bands were detected which clearly either appeared or disappeared when comparing 
treatments with pharmaceuticals at a specific concentration. However, all bands that 
were identified in the Metronidazole, Trimethoprim, Sulphamethoxazole, Paracetamol 
and Ranitidine showed increasing intensity in reactor communities with increasing 
concentration of PM (Figure 5.5.4). Furthermore, since other bands remained at similar 
intensities when comparing between different bioreactors and different concentration of 
PM, an increase in a specific band’s intensity could be explained by an increase in that 
species’ population and thus enrichment. 
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6. CONCLUSIONS 
1. Development of an analytical method  
An analytical method for the determination of Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine in wastewater at nano concentrations 
was successfully developed using LC-MS-MS after SPE extraction of samples. The 
method detection limits for the detection of Metronidazole, Trimethoprim, 
Sulphamethoxazole, Paracetamol and Ranitidine in wastewater were 5, 5, 1, 5 and 5 
ng.L
-1
, respectively.  
 
2. Removal of pharmaceuticals in Sulaibiya WWTP 
The results of raw wastewater analysis at Sulaibiya WWTP showed that the five target 
pharmaceuticals were always present, however, their concentrations varied throughout 
the year of study, depending on seasonal temperature variations, the prevalence of 
certain diseases intend to these use, and seasonal precipitation values. Generally, the 
concentration of pharmaceuticals found in the raw wastewater at Sulaibiya WWTP was 
lower than reported elsewhere around the world, which might indicate a lower level of 
their consumption in Kuwait compared to other countries.  
The effluent of the secondary treatment stage of Sulaibiya had a high quality removal 
regarding the organic and nitrogen contents due to the efficiency of the new technologies 
implemented, such as activated sludge processes in the wastewater treatment plant. 
Despite the high removal of organic compounds by the secondary wastewater treatment 
process, the removal efficiencies of pharmaceuticals fluctuated during the year, and that 
was considered to be mainly due to seasonal changes in temperature.   
The removal efficiency for trace organic compounds (TOC) was high as a result of 
implementing dual MF/ RO membrane systems at the Sulaibiya WWTP.  
The concentration of pharmaceuticals in RO permeate were very low levels, the 
maximum concentrations detected for Ranitidine and Trimethoprim being 15 and 19 
ng.L
-1
, respectively. The RO membrane served as a large reservoir for organic matter as 
well as trace organic compounds, such as pharmaceuticals, due to the adsorption of 
contaminants on the membranes and their likely release in the brine. The concentrations 
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of pharmaceuticals in the brine were at ng.L
-1
 levels, and the concentration factor ranged 
between one and six. Consequently, the disposal of this brine would cause a real 
pollution concern. 
The removal efficiency for conventional wastewater parameters was excellent, so that 
the product water could be used for various reuse applications. Chlorine was added to the 
product water as disinfectant to allow safe water reuse for irrigation of raw vegetables. 
Levels of pharmaceuticals remaining in the product water were either greatly reduced to 
very low concentrations or to undetectable levels or transform to by-product after 
chlorine treatment, which could cause environmental health problems.  
 
3. Chemical removal of pharmaceuticals by the oxidation processes indicated that 
chlorination removed pharmaceuticals more effectively than the ozonation process. 
Chlorination, at a concentration dose of 10 mg.L
-1
, removed pharmaceuticals by more 
than 92%, except for Metronidazole (58% removal). 
 
4. Studies on the effect of pharmaceutical concentrations on their removal in the batch 
reactors showed the TOC removal was fast and high during the first 5 hours at all 
concentration doses of every pharmaceutical. High removal of pharmaceuticals was 
observed at a concentration of 0.1 mg.L
-1
, then this decreased with increasing 
pharmaceutical concentration, except for Paracetamol which gave high removal for all 
concentrations doses.      
 
5. The removal efficiency of Metronidazole, Trimethoprim, Sulphamethoxazole, 
Paracetamol and Ranitidine was assessed in laboratory-scale MBR1, MBR2, SBR1 and 
SBR2 installed in parallel. Ranitidine showed the highest removal rate for all 
concentrations tested. Metronidazole was removed moderately in all reactors and the 
effect of increased pharmaceuticals mixture (PM) concentration on the removal 
efficiencies of Metronidazole was negligible in MBR1 and MBR2, and was significant in 
SBR1 and SBR2. The removal efficiency of Trimethoprim was similar to Metronidazole 
except that the effect of increased PM concentration on the removal efficiencies of 
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Trimethoprim was significant in all reactors. The removal efficiency of Paracetamol 
inSBR1 and SBR2 was much better than in MBR1 and MBR2, and the effect of 
increased PM concentration was negligible in SBR1 and SBR2, and was significant in 
MBR1 and MBR2. 
 
6. The effect of the PM concentration on the removal efficiency of the COD and the 
TOC in MBR1, MBR2, SBR1 and SBR2 was negligible at concentration 1 µg.L
-1
, 
compared with the control reactors. But the removal efficiency of the COD and the TOC 
started to decline with increased PM concentration at 1 and 10 mg.L
-1
 for all reactors. 
This was in agreement with the PCR-DGGE results, which showed the microbial 
diversities in MBR1, MBR2, SBR1 and SBR2 were lower at higher concentrations of the 
PM. The results of the PCR-DGGE analysis indicate the importance of microbial 
diversity on PM removal efficiency, higher removal efficiency of PM being observed in 
reactors containing higher microbial diversity and higher concentration of these 
microbial as in the increase in the intensity of DNA bands.    
 
Further Research  
There is further research needed to develop an analytical method in order to determine 
pharmaceuticals concentration lower than the ng.L
-1
 level. This would allow the removal 
of low level pharmaceuticals which were detected in the recycled water to be assessed. 
This research has focused on the analysis of the pharmaceutical parent compounds. 
Some of the pharmaceutical metabolites are also biologically active compounds which 
may also be excreted at high concentrations. Degradation products of pharmaceutical are 
also a potential source of persistent biologically active contaminants and it is important 
to identify metabolites and degradation products if the full input on the environment is to 
be known. 
There is still uncertainty about the fate of pharmaceuticals once they have become 
adsorbed to sludge, as this may be applied to farmland, incinerated, or occasionally 
disposed to landfill. Consequently, there is the potential for uptake by crops if used on 
agricultural land, which could be returned to the human food chain. Further research is 
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therefore required to establish the fate of pharmaceuticals when sludge is disposed to 
land. 
During the WWTP pharmaceutical could not be completely degraded though the 
treatment. Chlorine and ozone treatment may produce by-product compounds that cause 
environmental and health problem. Further research should be done in the persistence 
and toxicity of these by-products.  
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Appendix: A  
Calibration curve of authentic pharmaceutical in liquid chromatography Mass 
spectrometry (LC-MS-MS)  
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Appendix: B  
Isolating Genomic DNA from Gram Positive and Gram Negative Bacteria 
Materials to Be Supplied by the User 
• 1.5ml microcentrifuge tubes 
• water bath, 80°C 
• water bath, 37°C 
• isopropanol, room temperature 
• 70% ethanol, room temperature 
• water bath, 65°C (optional; for rapid DNA rehydration) 
• 50mM EDTA (pH 8.0) (for gram positive bacteria) 
• 10mg/ml lysozyme (Sigma Cat.# L7651) (for gram positive bacteria) 
• 10mg/ml lysostaphin (Sigma Cat.# L7386) (for gram positive bacteria) 
 
1. Add 1ml of an overnight culture to a 1.5ml microcentrifuge tube. 
2. Centrifuge at 13,000–16,000 × g for 2 minutes to pellet the cells. Remove the supernatant. 
For Gram Positive Bacteria, proceed to Step 3. For GramNegative Bacteria go directly to 
Step 6. 
3. Resuspend the cells thoroughly in 480μl of 50mM EDTA. 
4. Add the appropriate lytic enzyme(s) to the resuspended cell pellet in a total volume of 
120μl, and gently pipet to mix. The purpose of this pretreatment is to weaken the cell wall so 
that efficient cell lysis can take place. 
Note: For certain Staphylococcus species, a mixture of 60μl of 10mg/ml lysozyme and 60μl 
of 10mg/ml lysostaphin is required for efficient lysis. 
However, many Gram Positive Bacterial Strains (e.g., Bacillus subtilis, Micrococcus luteus, 
Nocardiaotitidiscaviarum, Rhodococcusrhodochrous, andBrevibacteriumalbidium) lyse 
efficiently using lysozyme alone. 
5. Incubate the sample at 37°C for 30–60 minutes. Centrifuge for 2 minutes at 13,000–16,000 
× g and remove the supernatant. 
6. Add 600μl of Nuclei Lysis Solution. Gently pipet until the cells areresuspended. 
7. Incubate at 80°C for 5 minutes to lyse the cells; then cool to room temperature. 
8. Add 3μl of RNase Solution to the cell lysate. Invert the tube 2–5 times to mix. 
9. Incubate at 37°C for 15–60 minutes. Cool the sample to room temperature. 
10. Add 200μl of Protein Precipitation Solution to the RNase-treated cell lysate. 
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Vortex vigorously at high speed for 20 seconds to mix the Protein Precipitation Solution with 
the cell lysate. 
11. Incubate the sample on ice for 5 minutes. 
12. Centrifuge at 13,000–16,000 × g for 3 minutes. 
13. Transfer the supernatant containing the DNA to a clean 1.5ml microcentrifuge tube 
containing 600μl of room temperature isopropanol. 
Note: Some supernatant may remain in the original tube containing the protein pellet. Leave 
this residual liquid in the tube to avoid contaminating the DNA solution with the precipitated 
protein. 
14. Gently mix by inversion until the thread-like strands of DNA form a visible mass. 
15. Centrifuge at 13,000–16,000 × g for 2 minutes. 
16. Carefully pour off the supernatant and drain the tube on clean absorbent paper. Add 600μl 
of room temperature 70% ethanol and gently invert the tube several times to wash the DNA 
pellet. 
17. Centrifuge at 13,000–16,000 × g for 2 minutes. Carefully aspirate theethanol. 
18. Drain the tube on clean absorbent paper and allow the pellet to air-dry for 
10–15 minutes. 
19. Add 100μl of DNA Rehydration Solution to the tube and rehydrate the DNA by 
incubating at 65°C for 1 hour. Periodically mix the solution by gently tapping the tube. 
Alternatively, rehydrate the DNA by incubating the solution overnight at room temperature 
or at 4°C. 
20. Store the DNA at 2–8°C. 
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Appendix: C 
DNA Extraction     
The FastDNA
®
 SPIN Kit for Soil (Q.BIOgene, USA.) was used and the DNA extraction 
technique carried out in this study was based on that detailed in the kit application manual, 
and summarised below. 
The procedure started by adding 978 µl of sodium phosphate buffer and 122 µl of MT buffer 
to the Lysing Matrix E Tube before 250 µl of completely mixed fixed sample was added to 
the same tube. The tube was then secured in the Ribolyser and processed at speed 6.5 for 30 
seconds before being centrifuged at 14,000×g for 10 minutes. Then, supernatant was 
transferred to a clean 2 ml Eppendorf tube (Eppendorf AG, Hamburg, Germany) and 250 µl 
of PPS reagent was added and mixed by inverting 10 times before centrifuging the tube at 
14,000×g for 5 minutes. The supernatant was again transferred to a new clean 2 ml 
Eppendorf tube and 1 ml of shaken DNA Binding Matrix solution was added. The tube was 
then inverted repeatedly by hand for 2 minutes before being left in a rack for 3 minutes to 
allow settling of silica matrix. 700-750 µl of supernatant was removed and discarded and the 
remaining Binding Matrix was resuspended again before approximately 600 µl of the mixture 
was transferred to a SPIN Filter and centrifuged at 14,000×g for 1 minute. The catch tube 
was emptied and the remaining mixture was transferred to the same SPIN Filter and 
centrifuged at 14,000×g for 1 minute, this step was repeated until all of the mixture was 
transferred. The SPIN Filter was then filled with 500 µl of SEWS-M and centrifuged at 
14,000×g for 1 minute. The flow-through was decanted and the SPIN Filter was replaced in a 
Catch tube before being centrifuged at 14,000×g for 2 minute to dry the residual SEWS-M 
wash solution. The SPIN Filter was removed and placed in a fresh kit-supplied Catch Tube 
with the cap opened to air dry the SPIN Filter for 5 minutes at room temperature. The DNA 
was eluted by adding 50 µl of DES and the matrix gently stirred using a finger flip before 
centrifuging at 14,000×g for 1 minute to transfer eluted DNA to a Catch Tube. This eluted 
DNA was ready to be used in the next step. 
 
Polymerase Chain Reaction 
The preparation of the polymerase chain reaction (PCR) mix and the general technique used 
for the different PCR reactions were based on the method described by Devereux and 
 217 
 
Willis(1995) with minor modifications. The sample preparation was carried out in the Bio2+ 
Class II Microbiological Safety Cabinet (Envair, Lancashire, England) in order to minimise 
contamination of the samples. 
 
The following reaction mix was prepared (volumes per sample). 
28 µl forward primer  
28 µl of reverse primer 
1316 µl Mega Mix Blue 
 
For each sample, 49 µl of reaction mix was transferred to the 1 ml Eppendorf tube followed 
by the addition of 1 µl of extracted DNA. A blank (same reagents, but no sample) was 
included with the PCR run, so as to check for contamination.   
The P×2 Thermal Cycler (Thermo Electron Corporation, USA) was used in the PCR 
amplification reactions. In this study the PCR was carried out targeting the whole eubacterial 
population). Sequences of the different primers utilised are shown in Table 4.4. 
 
Table : List of all the primers and respective sequences used for the PCR reactions, 
classified according to the oligonucleotide probe database (Alm et al., 1996).  
Primer Sequence (from 5'end to 3'end) Reference 
Vr ATTACCGCGGCTGCTGG Muyzer 
et al. 
(1993) 
Vf (CGCCCGCCGCGCGCGGCGGGCGGGGCGGGGGCACGGGGGG)
a
CCTACGGGAGGCAGCAG 
Muyzer 
et al. 
(1993) 
a
Added to the forward primer Vf was a high melting temperature GC-clamp  
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Eubacterial Specific PCR 
The primers used for revealing the whole bacterial population were the universal (eubacterial 
specific) primers Vr (reverse) and Vf (forward)(Muyzer et al., 1993). 
The program used in the PCR machine comprised the following steps. 
Initial Denaturation Step 95ºC 3 minutes  1 cycle 
Denaturation Step  95ºC 1 minute 
Annealing Step  65ºC 1 minute (to be reduced 1ºC every second cycle) 
Extension Step  72ºC 1 minute  (24 cycles) 
Denaturation Step  95ºC 1 minute 
Annealing Step  53ºC 1 minute  (15 cycles)  
Extension Step  72ºC 1 minute   
Final Extension Step  72ºC 10 minutes  1 cycle  
 
Agarose Gel 
The products of DNA extraction and of PCR reactions were examinedby agarose gel in order 
to check whether DNA was present in the samples and whether the correct gene fragments 
had been amplified. 1% agarose gels were prepared, where 1 g of agarose was added to 100 
ml of 1×TAE buffer (2 M Tris-Acetate, 0.05 M EDTA, pH 8.3, Eppendorf Scientific Inc., 
New York, USA). The agarose was, then, melted by heating the mixture on a hot plate. After 
the agarose was melted, the mixture was allowed to cool to about 60ºC and 2 µl of ethidium 
bromide were added. The gel was then poured into a plate and allowed to set for 30 minutes. 
The wells of the gel were loaded with 5 µl of sample and 2 µl of loading buffer. A reference 
DNA ladder was loaded in one of the wells of the gel to check the size of the DNA in the 
samples. For the samples from DNA extraction, Lambda DNA Hind III Digest (Sigma, 
Poole, UK) was used as the marker and 2 µl of this compound was added to 2 µl of loading 
buffer and to 3 µl of autoclaved deionised water. In the case of PCR products, the marker 
used was PCR 100 base pair ladder (Sigma, Poole, UK) (5 µl of marker and 2 µl of loading 
buffer). The gel was run for about 45 minutes using a Power Pac 300 power supply (Biorad, 
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Hemel Hempstead, UK) in a wide mini sub cell (Biorad, Hemel Hempstead, UK). The gel 
was then visualised using a dual-intensity transilluminator (UVP, San Gabriel, California). 
 
Denaturing Gradient Gel Electrophoresis (DGGE) 
The population fingerprinting method, denaturing gradient gel electrophoresis (Muyzer et al., 
1993) was used to analyse the bacterial diversity in the lab-scale bioreactors. The electric 
field of the gels used in this study is parallel to the denaturing chemical gradients which were 
formed with 10% (w/v) acrylamide stock solution (acrylamide-N, N'-
methylenebisacrylamide, 37:1), containing formamide and urea. PCR samples were directly 
applied onto a 10% polyacrilamide gel in 0.5×TE (20 mMTris acetate at pH 7.4, 10 mM 
sodium acetate, 0.5 mM Na2-EDTA) with a range of denaturants of 30-55% for the Vr/Vf and 
25-55% for the CTOs. The D-Gene system (Biorad, Hemel Hempstead, UK) was used to 
perform the DGGE analysis. Gels were run for 4.5 h at 200V constant voltage and at 60ºC 
and subsequently stained for 30 minutes in SYBR green I (Sigma, Poole, UK). Stained gels 
were viewed using an ultraviolet transilluminator (UVP, San Gabriel, California) and 
photographed with a Polaroid camera (CU-5, GRI, Great Dunmoor, Essex). 
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Appendix: D 
 
 
  
Temperature 
[°C]  
pH 
  
Conductivity  [µs/cm] 
  Total Suspended Solids  [mg/l] 
  
Volatile Suspended Solids 
[mg/l] 
  
  
Total Dissolved Solids [mg/l] 
  
DATE 
SULAIBIYA 
Raw wastewater 
ARDIYA Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
Sept 36.4 7.0 7.2 885.6 735.2 188.4 176.3 13.8 152.9 144.9 518.1 511.1 433.1 
Oct 34.7 7.0 7.2 867.7 730.7 258.5 133.1 14.1 215.2 111.0 509.2 510.6 430.3 
Nov 31.6 7.1 7.1 905.6 780.4 308.7 183.6 22.2 256.4 146.4 531.6 525.9 459.7 
Dec 29.5 7.1 7.1 901.5 737.0 262.4 188.4 27.4 210.8 155.9 529.2 512.3 431.6 
Jan 27.3 7.1 7.1 911.0 778.0 239.9 209.2 12.9 194.5 174.1 541.2 552.5 458.3 
Feb 27.3 7.2 7.2 901.7 736.3 322.2 210.9 7.8 273.9 175.8 529.3 516.2 433.7 
Mar 28.4 7.2 7.1 910.5 749.9 366.4 164.7 12.2 267.2 134.1 531.1 518.7 441.6 
April 30.7 7.2 7.1 908.0 747.4 351.3 227.1 15.9 279.4 177.4 533.1 521.2 440.3 
May 33.3 7.1 7.4 886.9 743.0 284.1 135.0 10.0 191.3 104.2 519.4 510.9 437.6 
Jun 35.2 7.0 7.4 798.7 656.5 192.1 150.3 12.3 153.3 123.3 469.2 478.1 386.6 
July 36.1 7.1 7.3 813.2 643.5 485.7 216.4 17.4 411.2 167.7 476.6 450.8 378.9 
Aug 37.0 7.0 7.2 762.9 592.3 208.8 167.5 7.7 172.4 136.1 447.8 412.1 348.7 
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Appendix: D 
 
  
  
COD [mg/l] 
  
  
BOD [mg/l] 
  
  
Total Phosphate [mg/l] 
  
  
Total Phosphorus [mg/l] 
  
Total 
Coliform-
Presumptive  
CFU/100ml 
DATE 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
SULAIBIYA 
Raw wastewater 
SECONDARY 
EFFLUENT 
ARDIYA Raw 
wastewater 
Sept 387.6 336.8 34.7 197.4 149.9 9.5 16.1 17.3 5.8 5.3 5.6 1.9 4.2E+07 
Oct 520.8 303.5 34.7 245.7 140.2 8.9 16.1 16.4 3.6 5.3 5.4 1.2 1.55E+08 
Nov 592.0 375.6 52.0 295.2 189.2 11.8 19.3 19.1 5.4 6.3 6.2 1.8 1.39E+08 
Dec 543.9 406.8 57.7 314.7 225.5 14.8 20.6 20.3 9.0 6.7 6.6 2.9 1.25E+09 
Jan 495.6 417.5 36.4 281.1 211.6 9.2 18.5 19.2 6.6 6.0 6.3 2.1 3.59E+08 
Feb 555.8 406.3 27.5 280.7 199.6 8.0 21.0 17.4 5.7 6.8 5.7 1.8 5.07E+08 
Mar 623.1 340.3 32.9 337.5 175.3 9.1 19.2 16.2 4.4 7.3 5.9 1.4 5.89E+08 
April 550.8 385.5 34.1 285.5 186.8 11.4 19.1 18.4 3.3 6.2 6.0 1.1 5.9E+08 
May 495.1 263.9 23.5 259.8 139.9 7.0 19.0 15.7 1.6 6.2 5.1 0.5 4.92E+08 
Jun 424.5 301.1 26.6 239.7 154.7 6.7 19.1 17.8 5.3 6.2 5.8 1.7 4.68E+08 
July 687.7 403.7 37.0 353.7 238.9 11.2 19.7 18.6 4.5 7.1 6.1 1.6 5.58E+08 
Aug 470.3 395.5 21.8 281.0 241.8 5.8 18.1 17.6 1.8 6.4 6.2 0.7 4.59E+08 
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Appendix:D 
 
 
  
  
Organic Nitrogen [mg/l] 
  
  
Nitrate Nitrogen [mg/l] 
  
  
Nitrite Nitrogen [mg/l] 
  
  
Total Kjeldahl Nitrogen [mg/l] 
  
  
Ammonia Nitrogen [mg/l] 
  
DATE 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
Sept 12.4 12.0 2.3 0.3 0.3 4.4 0.0 0.0 0.2 41.3 33.0 2.8 28.6 19.9 0.3 
Oct 16.0 10.5 2.2 0.4 0.3 5.7 0.0 0.0 0.2 43.1 32.2 2.6 26.1 20.9 0.2 
Nov 16.6 11.6 2.5 0.5 0.3 6.0 0.0 0.0 0.1 42.4 34.6 3.0 25.3 21.6 0.2 
Dec 16.8 13.1 3.4 0.4 0.4 6.9 0.0 0.1 0.2 43.5 35.9 3.9 26.5 22.0 0.2 
Jan 14.1 12.2 2.0 0.5 0.4 6.2 0.0 0.0 0.3 42.4 35.7 2.4 27.6 23.5 0.7 
Feb 16.4 11.2 1.3 0.5 0.4 6.2 0.1 0.0 0.3 46.7 35.7 1.6 29.0 23.6 0.7 
Mar 17.0 10.9 2.1 0.5 0.4 4.6 0.0 0.0 0.0 46.3 34.8 2.5 27.9 23.2 0.4 
April 16.2 11.9 2.2 0.4 0.3 5.5 0.0 0.0 0.1 47.2 36.5 2.4 28.7 22.6 0.2 
May 13.2 8.8 1.7 0.4 0.4 5.3 0.0 0.1 0.0 43.7 32.3 2.0 29.1 22.3 0.1 
Jun 12.4 10.3 2.0 0.4 0.3 5.5 0.0 0.1 0.1 41.3 34.5 2.2 28.1 23.1 0.2 
July 13.5 12.9 2.7 0.4 0.3 5.3 0.0 0.0 0.1 42.2 38.1 3.0 28.9 24.0 0.2 
Aug 12.9 10.6 1.3 0.4 0.3 4.1 0.0 0.0 0.0 41.5 32.3 1.4 28.2 20.8 0.1 
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Alkalinity CaCO3 [mg/l] 
  
 Chlorides [mg/l] 
  
Sulphates [mg/l] 
  
Sulphides [mg/l] 
  
  
Grease & Oil [mg/l] 
  
Settleable 
Solids  
[cm³/l/2hr] 
EFF 
Turbidity  
NTU 
Total Inflow 
S55  [m³/d] 
DATE ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
ARDIYA 
Raw 
wastewater 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
SULAIBIYA 
Raw 
wastewater 
SECONDARY 
EFFLUENT 
SULAIBIYA 
Raw wastewater 
Sept 219.8 219.4 73.9 83.1 100.6 91.7 107.7 12.0 0.006 23.4 10.3 0.0 3.1 5.6 286897.3 
Oct 200.7 219.0 66.5 69.9 102.7 88.6 107.2 5.1 0.008 22.3 10.4 0.0 5.2 6.1 287264.2 
Nov 198.2 223.2 59.0 79.5 112.6 115.1 118.0 6.2 0.015 18.1 7.9 0.0 6.2 12.0 281961.8 
Dec 192.5 218.7 53.1 88.1 105.0 112.5 114.1 4.7 0.017 18.1 13.9 0.0 4.9 17.8 278559.9 
Jan 190.8 206.7 54.8 107.2 114.7 109.3 112.3 3.2 0.010 15.0 11.7 0.0 4.1 6.4 271157.5 
Feb 195.2 203.7 53.8 100.7 108.3 117.8 113.4 3.6 0.006 16.5 12.1 0.0 6.6 3.5 275703.7 
Mar 222.8 205.2 61.3 82.7 101.4 114.9 118.0 3.5 0.004 13.7 8.9 0.0 6.0 5.0 285955.1 
April 204.9 215.6 66.5 66.6 108.1 97.2 109.1 5.8 0.006 28.0 18.7 0.0 6.3 7.0 287160.7 
May 196.1 202.2 65.3 88.2 104.0 95.4 111.4 6.9 0.006 35.7 21.4 0.0 3.6 3.6 290870.0 
Jun 186.7 188.6 62.4 90.2 86.2 68.2 86.4 4.1 0.008 27.7 17.8 0.0 2.8 4.8 271785.7 
July 191.0 185.7 62.0 96.0 86.0 65.7 86.6 5.3 0.012 291.3 21.5 0.1 6.6 7.7 274087.3 
Aug 170.1 158.9 59.7 86.9 77.2 68.5 83.5 4.7 0.006 81.2 32.5 0.1 3.1 3.7 298406.4 
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Appendix: D 
    
pH 
  
  
TSS (mg/l) 
  
  
TDS (mg/l) 
  
  
Total Coliforms (CFU/100 ml) 
  
  
BOD5 (mgO2/l) 
  
 
COD (mgO2/l) 
  
T 
otal Iron (mg/l as Fe) 
  
Date UF 
inlet 
Outlet UF 
and inlet 
RO  
Outlet UF 
inlet 
Outlet UF and 
inlet RO  
Outlet UF 
inlet 
Outlet 
UF and 
inlet 
RO  
Outlet UF inlet Outlet UF 
and inlet 
RO  
Outlet UF 
inlet 
Outlet UF 
and inlet RO  
Outlet UF 
inlet 
Outlet UF 
and inlet RO  
UF inlet Outlet UF 
and inlet RO  
Sept 7.06 6.62 7.50 9.9 0.136 0.036 438 453 19.8 216153 211 1 4.99 1.21 0.13 27.7 15.37 1.45 0.017 
Oct 7.02 6.62 7.45 9.13 0.283 0.048 442 449 20.2 600160 243 1 4.99 1.16 0.16 27.2 16.12 1.33 0.025 
Nov 6.98 6.62 7.38 12.7 0.170 0.076 464 508 17.8 772000 295 1 6.69 0.67 0.08 31.4 15.71 1.39 0.024 
Dec 6.91 6.63 7.44 13.3 0.15 0.093 445 451 16.6 1022105 334 1 6.05 1.11 0.05 36.0 13.99 1.58 0.034 
Jan 6.90 6.62 7.29 9.36 0.0961 0.058 464 473 16.0 340090 117 1 5.04 1.08 0.04 28.6 15.51 1.39 0.036 
Feb 6.97 6.67 7.36 6.18 0.240 0.0285 451 459 14.5 429411 278 1 2.01 0.57 0.06 17.9 12.14 1.17 0.166 
Mar 7.04 6.72 7.40 8.1 0.107 0.0225 455 461 16 304285 227 1 2.91 0.70 0.09 22.9 14.38 1.50 0.232 
April 7.04 6.73 7.36 8.30 0.08 0.0233 453 459 18.3 386666 235 1 3.33 0.65 0.09 21.7 12.69 1.25 0.017 
May 7.16 6.74 7.33 5.11 0.114 0.0354 456 465 20.5 306956 142 1 1.81 0.72 0.08 16.4 11.47 1.30 0.022 
Jun 7.11 6.78 7.35 8.22 0.126 0.03 397 402 18.1 229523 148 1 2.62 0.84 0.08 18.6 11.70 1.53 0.044 
Jul 7.17 6.74 7.43 9.67 0.088 0.0483 389 396 19.4 285971 167 1 4.32 1.0 0.11 24.5 11.57 1.49 0.048 
Aug 7.14 6.83 7.43 5.05 0.042 0 357 362 16.9 55500 37 1 3.45 2.14 0.05 16.6 11.10 1.29 0.053 
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